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Introduction to the thesis
Targeted cancer immunotherapy using ligands of the 
tumor necrosis factor super-family
(Cancer Letters 2011 Jan 5, Current Drug Targets 2009 Feb; 10(2):94-103.)
Potent systemic anticancer activity of adenovirally 
expressed EGFR-selective TRAIL fusion protein.
(Mol Ther. 2008 Dec;16(12):1919-26.)
Targeted delivery of a designed sTRAIL mutant results in 
superior apoptotic activity towards EGFR-positive tumor 
cells.
(Journal of Molecular Medicine 2008 Aug; 86(8):909-24.)
Melanoma-associated Chondroitin Sulfate Proteoglycan 
(MCSP)-targeted delivery of soluble TRAIL potently 
inhibits melanoma outgrowth in vitro and in vivo.
(Molecular Cancer 2010 Nov; 23(9):301.)
Cell surface delivery of TRAIL strongly augments the 
tumoricidal activity of T-cells
(Clin Cancer Res. 2011 Sep 1;17(17):5626-37.)
Treatment with TRAIL induces recruitment of the pro-
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Introduction
A major obstacle in the treatment of cancer is the occurrence of metastasis and therapy-
resistant disease relapse. A case in point here is cancer that originates from organs in the 
peritoneal cavity, such as ovarian carcinoma (OC). OC is the most deadly gynaecological 
malignancy with approximately 140,000 deaths worldwide per year [1]. Treatment of OC 
with curative intent typically consists of maximal surgical resection, followed by high dose 
chemotherapy. Unfortunately, many patients subsequently develop refractory relapses and 
ultimately succumb to extensive disseminated disease. These disease relapses are likely 
the result of several compounding factors, most notably the survival of a small subpopula-
tion of therapy-resistant cancer cells. After a period of minimal residual disease, these ther-
apy-resistant cells recapitulate the disease leaving few therapeutic options for intervention. 
Therefore, novel strategies that specifically eliminate ovarian cancer cells in disseminated 
and minimal residual disease are urgently needed. In this respect, the exploitation of cells 
and/or molecules of the human immune system is of particular interest.
In this thesis, the therapeutic concept of targeted delivery of the immune effector molecule 
TRAIL was evaluated in preclinical studies with an emphasis on eliminating cancer cells  in 
disseminated and minimal residual disease
Background
Already in the early nineteen hundreds Paul Ehrlich postulated that the immune system 
may play a key role in the suppression of cancer. In the 1950’s, this notion led Burnet and 
Thomas to formulate the so-called “cancer immune surveillance theory”. This theory states 
that immune cells act as sentinels in recognizing and eliminating continuously arising (pre-) 
cancerous cells. Since then, numerous scientific reports have provided evidence that im-
mune surveillance is a key defence mechanism that protects the host against the formation 
of tumours by maintaining normal cellular homeostasis (reviewed in [2]).
Understandably, considerable effort has therefore been spent on harnessing the immune 
system to treat or retard the progression of cancer, and several so-called immunotherapies 
have already made their way into clinical practice.
Arguably the most successful of these immunotherapeutic approaches thus far is the use 
of antibodies directed against cancer cell surface molecules. The beneficial effects of anti-
body-based therapies are largely attributable to their natural immune effector functions such 
as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity 
(ADCC). In addition, the selectivity of antibodies has also been exploited for the targeted 
delivery of toxic compounds to cancerous cells. Unfortunately, authentic tumour-specific 
target molecules for antibody-mediated therapy are very rare. In fact, most (if not all) of the 
clinically used monoclonal antibodies are merely directed at overexpressed tumour-asso-






enough to allow for the delivery of highly toxic agents at clinically relevant concentrations. 
This concern holds particularly true for the antibody-targeted delivery of intrinsically toxic 
compounds, such as bacterial toxins, cytolytic drugs, and radionuclides.
Ideally, therapeutic agents used for targeted approaches are therefore inactive while “en 
route” and gain full anti-tumour activity only after selective binding to malignant target cells. 
Particularly suited in this respect is the pro-apoptotic immune ligand “Tumour Necrosis 
Factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL)”. TRAIL is expressed as a type 
II transmembrane protein, but proteolytic processing or alternative splicing also yields a 
soluble form of TRAIL in vivo. This soluble form of TRAIL has been recombinantly repro-
duced in laboratories and has potent anti-tumour activity with no or minimal toxicity towards 
normal cells in numerous pre-clinical models. 
TRAIL exerts its anti-tumour effects via induction of programmed cell death, also known 
as apoptosis. One particularly attractive feature of TRAIL is that its pro-apoptotic activity 
appears to be largely restricted to cells that have undergone malignant transformation. 
However, (pre-) clinical work has identified several important limitations that might ham-
per the efficacy of TRAIL-based therapies. These include the ubiquitous expression of 
TRAIL-receptors (TRAILRs) throughout the body and the short serum half life of TRAIL that 
hampers its accretion at the tumour site(s). In addition, soluble forms of TRAIL (sTRAIL) 
are less efficient in triggering apoptotic signalling compared to the membrane-bound form 
of TRAIL. 
Outline of the thesis
In chapter 2, we highlight the rationale and perspectives of antibody fragment-based TRAIL 
fusion proteins for cancer immunotherapy. In this approach, sTRAIL is genetically fused to 
a recombinant antibody fragment directed against an overexpressed tumour-associated 
cell surface antigen. The resultant anti-tumour:TRAIL fusion protein has the capacity to 
selectively bind to the tumour cell surface and thereby convert sTRAIL into a membrane-
bound form of TRAIL, with fully reactivated pro-apoptotic potential. Of particular interest 
in this respect is the so-called dual signalling concept. Herein, an antibody fragment with 
inherent anti-tumour activity is incorporated into a TRAIL fusion protein. 
One prominent example of a scFv:sTRAIL fusion protein with dual signalling is the EGFR-
targeted TRAIL fusion protein designated scFv425:sTRAIL. ScFv425:sTRAIL binds to 
EGFR as overexpressed on the cell surface of tumour cells, thereby inhibiting EGFR-me-
diating oncogenic signalling activity and sensitizing cells to the apoptosis induced by its 
sTRAIL domain. Previous studies have identified that the dual anti-tumour signalling activ-
ity of scFv425:sTRAIL resulted in potent in vitro anti-tumour activity towards a broad panel 
of carcinoma cell lines, including ovarian cancer cell lines [3]. 
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In chapter 3, we expand on these promising data by evaluating the anti-tumour activity of 
scFv425:sTRAIL in an in vivo model for disseminated intraperitoneal cancer. Disseminated 
intraperitoneal cancers are frequently observed in advanced stage carcinomas such as OC 
and are a major burden for patients. After extensive disseminated tumour load had devel-
oped, mice were treated with either a high or low titre of a replication-deficient adenovirus 
encoding the gene for scFv425:sTRAIL (hereafter designated as Ad-scFv425:sTRAIL). High 
titre inoculation with Ad-scFv425:sTRAIL efficiently infected mouse livers, after which local 
production resulted in high serum levels of scFv425:sTRAIL. As a result, established intra-
peritoneal tumours were successfully eradicated. Inoculation of tumour-bearing mice with a 
low titre of Ad-scFv425:sTRAIL resulted in only moderate serum levels of scFv425:sTRAIL 
(<10 ng/mL). However, even these low serum levels of scFv425:sTRAIL were sufficient 
to completely halt further tumour growth. Together, these data highlight the potential of 
scFv425:sTRAIL for the treatment of intraperitoneal disseminated cancer.
In chapter 4, the scFv425:sTRAIL concept was modified by using a rationally-designed 
variant of sTRAIL with engineered enhanced binding affinity for TRAILR1. We speculated 
that the use of such a sTRAIL variant would further enhance the induction of apoptosis in 
cancer cells expressing TRAILR1 over TRAILR2. This novel fusion protein, designated 
scFv425:sTRAILmR1-5, showed superior anti-cancer activity in a broad panel of cancer 
cell lines, irrespective of the relative expression of TRAILR1 over TRAILR2. Moreover, the 
synergistic anti-tumour activity of scFv425:sTRAILmR1-5 was superior to scFv425:sTRAIL-
wt, when treatment was combined with cytostatic drugs. These data indicate that the use 
of rationally-designed sTRAIL mutants in the scFv:sTRAIL fusion protein concept results in 
an improved therapeutic activity.
 
Cancer patients that are diagnosed early with local cancer lesions usually have good pros-
pects for curative treatment. In contrast, patients diagnosed with metastatic disease will, 
even after seemingly complete tumour eradication, ultimately succumb due to occult meta-
static and refractory disease. A particularly important factor is the potential presence of 
circulating cancer cells that, after period of minimal residual disease, ultimately initiate 
formation of distant metastasis. Prevention and/or inhibition of metastases formation by 
circulating or occult cancer cells is therefore paramount to achieving curative treatment. 
Therefore, we hypothesized that a rationally-designed multi-functional scFv:sTRAIL fu-
sion protein that inhibits metastatic spread of circulating tumour cells while simultaneously 
inducing tumour cell-restricted apoptosis may have considerably enhanced therapeutic 
activity. To this end we used a scFv targeting domain that has intrinsic anti-metastatic 
potential in its own right. In chapter 5, this approach was evaluated in a model system for 







a novel anti-melanoma scFv:sTRAIL fusion protein, designated anti-MCSP:TRAIL, was 
constructed using a scFv antibody fragment derived from mAb 9.2.27. MAb 9.2.27 is di-
rected against the Melanoma Chondroitin Sulphate Proteoglycan (MCSP), an established 
melanoma-associated target antigen that is highly expressed on both primary tumours and 
metastatic lesions. Furthermore, previous reports indicated that MSCP signalling is impli-
cated in the metastatic potential of melanoma cells. Anti-MCSP:TRAIL potently induced 
apoptosis in a series of melanoma cell lines and inhibited outgrowth of melanomas both 
in vitro and in vivo. Interestingly, TRAIL-resistant melanoma cells were also effectively in-
hibited in their outgrowth. We speculated that the TRAIL-independent growth inhibition ob-
served for anti-MSCP:sTRAIL might be largely attributable to its inhibitory activity towards 
MCSP signalling. Previous reports indicated that treatment with the parental anti-MCSP 
monoclonal antibody mAb 9.2.27 resulted in the inhibition of pro-metastatic signalling path-
ways. Indeed, using kinase arrays, we demonstrated that treatment with anti-MCSP:TRAIL 
inhibited several kinases implicated in melanoma cell growth and metastasis. We conclude 
that fusion protein anti-MCSP:TRAIL has promising pre-clinical anti-melanoma activity that 
appears to result from combined inhibition of tumorigenic MCSP-signalling and concordant 
activation of TRAIL apoptotic signalling. 
The work presented in chapters 2 to 5 focuses on the direct delivery of TRAIL to the cell 
surface of tumour cells and establishes that the scFv:sTRAIL concept: 1. has in vivo activ-
ity towards solid cancers, 2. can be optimised by incorporating rationally-designed TRAIL 
mutants, 3. is effective at inhibiting metastatic features of cancer cells, and 4. has no or 
minimal activity towards normal cells.
In chapter 6, we evaluated a different approach in which TRAIL is targeted to the cell sur-
face of immune effector cells in an attempt to augment their TRAIL-mediated tumoricidal 
activity. As already detailed in chapter 2, TRAIL is an immune effector molecule that is 
expressed on the cell surface of natural killer (NK) cells, where it is essential for NK cell–
mediated tumour immune surveillance. In contrast, the expression of TRAIL on resting 
T lymphocytes (or T-cells) is typically very low. However, already a slight upregulation of 
TRAIL on the cell surface of T cells, as induced by e.g. ex vivo co-stimulation with anti-CD3 
antibodies and IFN-α, significantly increases their tumoricidal activity. This suggests that 
T-cells may substantially gain in tumoricidal potential when additional TRAIL is selectively 
delivered to their cell surface. This hypothesis was investigated by selectively delivering 
TRAIL to the T-cell surface molecules CD3 and CD7. To this end, we constructed two 
novel TRAIL fusion proteins, designated anti-CD3:TRAIL and K12:TRAIL, harbouring an 
anti-CD3 scFv and the CD7-ligand K12 respectively. Incubation of T-cells with these fu-
sion proteins resulted in an up to 500-fold increase of their in vitro tumoricidal activity 
towards a panel of cancer cell lines and towards primary patient-derived ovarian cancer 
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cells. Importantly, both anti-CD3:TRAIL and K12:TRAIL potently inhibited the outgrowth of 
disseminated intraperitoneal carcinoma xenografts in vivo. Together, these preclinical data 
indicate that targeted delivery of TRAIL to the cell surface of T-cells potently enhances their 
anti-tumour activity. Of note, this novel concept can easily be incorporated into current clini-
cally applied T-cell-based immunotherapeutic strategies.
As described above, TRAIL can be used to augment the anti-tumour activity of immune ef-
fector cells. Interestingly, TRAIL treatment may also have other immune stimulating effects. 
In this respect, it has been reported that treatment with certain pro-apoptotic agents, includ-
ing TRAIL, triggers translocation of the ER-resident chaperone protein calreticulin (CRT) to 
the tumour cell surface. Here, CRT appears to serve as an ‘eat me’ signal for phagocytes. 
It is well-established that the uptake of pre-apoptotic cells by conventional phagocytes 
is largely non-immunogenic. However, recently it was uncovered that CRT-exposing pre-
apoptotic cells are preferentially phagocytosed by dendritic cells, which may lead to the 
induction of an antitumor immune response. 
Recent in vitro findings, obtained by using an ELISA-type binding assay, indicated that CRT 
can directly interact with TRAIL. Therefore, in chapter 7, we evaluated the role of CRT in 
TRAIL-mediated cell death. We demonstrated that treatment of tumour cells with TRAIL in-
duced the rapid pre-apoptotic association of CRT with TRAIL and TRAILR2. Concurrently, 
CRT dissociated from its normal binding partner CD47. Of note, dissociation of CD47 from 
CRT has been reported to enhance clearance of apoptotic cells by phagocytes. Interest-
ingly, the association of TRAIL with CRT had no effect on the induction of apoptosis. In 
conclusion, association of TRAIL with CRT appears to alter cell surface distribution of CRT 
(and other immune molecules) and as such might have immunological implications for e.g. 
phagocytosis and immunogenicity of apoptotic tumour cells.
A summary of the work performed in this thesis is provided in chapter 8 along with per-
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Ideally, an immunotoxin should be inactive ‘en route’, acquire activity only after 
tumor cell surface binding and have no off-target effects towards normal cells. In 
this respect, antibody-based fusion proteins that exploit the tumor-selective pro-
apoptotic death ligands sFasL and sTRAIL appear promising. Soluble FasL largely 
lacks receptor activating potential, whereas sTRAIL is inactive towards normal cells. 
Fusion proteins in which an anti-tumor antibody fragment (scFv) is fused to sFasL or 
sTRAIL prove to be essentially inactive when soluble, while gaining potent anti-tumor 
activity after selective binding to a predefined tumor-associated cell surface antigen. 
Importantly, off-target binding by scFv:sTRAIL to normal cells showed no signs of 
toxicity. In this review, we highlight the rationale and perspectives of scFv:sTRAIL/
scFv:sFasL based fusion proteins for cancer therapy.
Introduction
Since the advent of targeted cancer therapy decades ago significant progress has been 
made in the development of drugs that display enhanced tumor-selective activity. Antibody-
targeted agents in particular have demonstrated potent activity both in pre-clinical and 
clinical studies and have had a positive effect on treatment outcome in several human 
malignancies [1]. In many cases, antibodies or fragments thereof are equipped with potent 
toxic effector moieties of bacterial or plant origin. An example worth mentioning is the im-
munotoxin Mylotarg, which comprises an anti-CD33 antibody chemically linked to the plant 
toxin calicheamicin. Mylotarg has been approved for a subgroup of Acute Myeloid Leuke-
mia patients and has yielded promising results [2]. Nevertheless, many forms of targeted 
therapeutics are hampered by dose-limiting toxicity towards healthy cells. Such toxicity can 
be due to a lack of tumor specificity of the antibody and/or a lack of tumor-selective activity 
of the cytotoxic effector molecule employed.
An attractive strategy to reduce toxicity towards normal cells and optimize therapeutic effi-
cacy of targeted therapy is to harness the body’s own effector mechanisms for the elimina-
tion of tumor cells. The immune system is equipped with potent tumoricidal molecules that 
may be exploited to effectively eliminate malignant cells with limited to no activity towards 
non-transformed cells. In this respect, members of the tumor necrosis factor (TNF) family 
and more specifically the subgroup of Death Inducing Ligands are of particular interest 
[3]. Of this small subgroup, the Fas ligand (FasL) and TNF-related Apoptosis Inducing 
Ligand (TRAIL) appear well suited for integration in antibody-targeted cancer therapy. As 
immune effector molecules, FasL and TRAIL are both primarily involved in the induction of 
programmed cellular death, better known as apoptosis, in virus infected and in malignant 
cells [4]. 







brane proteins. However, in vivo proteolytic processing or alternative splicing can also yield 
soluble forms of these death ligands [5]. These soluble ligands have a different activity 
profile than the corresponding membrane-bound form. The soluble form of FasL (sFasL) 
almost entirely lacks receptor activating potential for its agonistic receptor Fas [6-8]. The 
soluble form of TRAIL (sTRAIL) on the other hand retains receptor-activating potential for 
its agonistic receptor TRAIL-R1, but fails to efficiently activate the other agonistic receptor, 
TRAIL-R2 [9-12]. Intriguingly, sTRAIL has been found to specifically lack toxicity towards 
normal cells, whereas sFasL is largely inactive per se. An important finding that highlights 
the potential for use of these ligands for antibody-targeted therapy is the reacquisition 
of full membrane-like activity upon artificial oligomerization of sTRAIL and sFasL [13;14]. 
Previously, we and others reported on a novel class of anti-cancer agents in which a tu-
mor-selective single chain fragment of variable regions (scFv) antibody fragment is geneti-
cally fused to soluble sTRAIL and/or sFasL, yielding scFv:sTRAIL and scFv:sFasL fusion 
proteins, respectively. Upon tumor-selective binding, these largely inactive fusion proteins 
are locally converted to membrane-bound molecules with fully restored pro-apoptotic anti-
tumor activity. 
In this review, we will first briefly detail the basics of FasL and TRAIL–mediated apoptotic 
signaling events. Next, we will discuss the current status of non-targeted FasL and TRAIL 
in cancer therapy. Subsequently, we will highlight advances in the development of targeted 
FasL- and TRAIL-based therapeutic strategies to achieve optimal anti-tumor potential with 
minimal toxicity towards normal cells.
Apoptotic signaling
FasL and TRAIL eliminate cells by apoptosis, a pivotal homeostasis mechanism by which 
superfluous,  damaged, or dangerously altered cells are removed in a non-immunogenic 
manner [4]. At the heart of apoptotic signaling is the coordinated activation of a group 
of cellular cysteine proteases – the effector caspases – that cleave a variety of cellular 
substrates. These activated effector caspases ultimately induce apoptotic cell death. Ac-
tivation of effector caspases is carefully orchestrated by a subgroup of caspases known 
as initiator caspases. All caspases are produced as pro-enzymes that require proteolytic 
processing to unleash their catalytic activity. The initiator caspases can be activated via two 
main routes designated the Death Receptor (or extrinsic) pathway and the mitochondrial 
(or intrinsic) pathway (see Fig. 1 for overview). The Death Receptor pathway centers on 
the activation of cell surface expressed transmembrane Death Receptors (DR) by Death 
Inducing Ligands, such as FasL and TRAIL. Binding of TRAIL to its cognate agonistic re-
ceptor triggers the formation of a pro-apoptotic protein complex termed the Death Inducing 
Signaling Complex (DISC) at the cytoplasmic death domain (DD) of the Death Receptors 
[15]. The adaptor protein Fas-associated death domain (FADD), is subsequently recruited 
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Extrinsic pathway Intrinsic pathway
Figure 1. Molecular mechanisms of apoptosis. The extrinsic pathway of apoptosis is activated upon 
ligation of TRAIL or FasL to cell surface expressed transmembrane receptors TRAIL-R1 / TRAIL-R2 
and Fas, respectively. Binding of these death inducing ligands to their cognate receptors triggers the 
formation of a pro-apoptotic protein complex termed the Death Inducing Signaling Complex (DISC) at 
the cytoplasmic death domain (DD) of TRAIL-R1, TRAIL-R2 or Fas. A DD-containing protein, dubbed 
Fas-associated death domain (FADD), is subsequently recruited together with pro-caspase-8. In 
the DISC, initiator pro-caspase-8 is proteolytically activated, whereupon caspase-3 is proteolytically 
activated, leading to execution of apoptosis. The intrinsic pathway of apoptosis is activated upon 
signals of cellular stress or after stimulation with most apoptosis inducing chemotherapeutics. The 
hallmark of this intrinsic pathway is mitochondrial membrane depolarization, leading to the subsequent 
release of cytochrome C and activation of initiator caspase-9. Mitochondrial apoptosis is controlled by 
the Bcl-2 family, which consists of both pro- (Bid, Bax and Bak) and anti- (Bcl-2 and Bcl-XL) apoptotic 
proteins. In addition, a mitochondrial amplification loop can be activated by caspase-8-mediated 
cleavage of the BH3-only interacting domain death agonist (BID). Cleavage of BID into truncated BID 
(tBID) results in its mitochondrial translocation, where it associates with Bax and Bak and triggers 
mitochondrial depolarization.
to the DD of the receptor together with pro-caspase-8. In the DISC, initiator caspase-8 is 
proteolytically activated, whereupon the proteolytic caspase cascade is triggered, leading 
to execution of apoptosis [16].
The hallmark of the mitochondrial pathway of apoptosis is the depolarization of the mito-







initiator caspase-9. Caspase-9 in turn activates executioner caspase-3. The mitochondrial 
depolarization is governed by the Bcl-2 family, a family of proteins consisting of both pro- 
and anti-apoptotic proteins [17]. Most cellular stressors, including conventional chemother-
apeutics and radiation, induce apoptosis by shifting the balance towards the pro-apoptotic 
Bcl-2 family members, thereby triggering execution of the mitochondrial pathway of apop-
tosis. 
Crosstalk between the extrinsic and intrinsic apoptotic signaling pathways exist, as sig-
naling induced via Death Receptors can be amplified through a so-called mitochondrial 
amplification loop. This loop is activated by caspase-8 mediated cleavage of the BH3-only 
interacting domain death agonist (BID). Truncated BID (tBID) can then trigger mitochon-
drial depolarization and activation of caspase-9.
FasL and TRAIL biology
FasL signals apoptosis by binding to the trimeric receptor Fas (also known as CD95), after 
which Fas trimers reorganize into higher order molecular structures [18;19]. These receptor 
clusters are focal points for the formation of the above described DISC and form the start-
ing point for apoptotic signaling by Fas. In addition, FasL can also bind to Decoy Receptor 
3 (DcR3) [20]. DcR3 is a soluble receptor that lacks an intracellular DD and cannot recruit 
adaptor proteins required for apoptosis. Therefore, the main function of DcR3 appears to 
be inhibition of FasL-apoptotic activity [21]. Indeed, high circulating levels of DcR3 protect 
synovial fibroblasts against FasL signaling in rheumatoid arthritis [22].
TRAIL interacts with an elaborate receptor system comprising two agonistic receptors, 
TRAIL-R1 and TRAIL-R2, two antagonistic receptors, TRAIL-R3 and TRAIL-R4, and the 
soluble receptor osteoprotegrin (OPG) [23]. Both agonistic receptors TRAIL-R1 and TRAIL-
R2 contain a functional intracellular DD and can induce apoptotic signaling via DISC forma-
tion. The antagonistic receptor TRAIL-R3 is glycosyl-phosphotidylinositol (GPI)-linked and 
lacks an intracellular domain, whereas TRAIL-R4 only has a truncated and non-functional 
DD. These two receptors are, analogous to DcR3 for FasL, thought to function as decoy 
receptors that modulate TRAIL-sensitivity although the precise mechanism has yet to be 
characterized. Recent work suggests that TRAIL-R3 can bind and sequester TRAIL in lipid 
membrane microdomains [24]. TRAIL-R4 on the other hand appears to form heterotrimers 
with TRAIL-R2 and thereby disrupts TRAIL-R2 mediated apoptotic signaling [24;25]. Of 
note, the mechanism behind the resistance of normal cells to TRAIL remains unclear and is 
a subject of intense interest and debate for many researchers. It has been speculated that 
overexpression of antagonistic TRAIL-receptors, differential formation of heterotrimeric 
and inactive TRAIL-receptors, as well as cancer-specific post-translational modifications 
may be involved in the tumor-selective activity of TRAIL. The recently described correla-
tion between O-glycosylation of TRAIL-receptors and apoptosis induction following TRAIL-
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ligation may provide further clues [26]. As we will discuss further on, various aspects of this 
complex ligand/receptor system may be exploited to optimize the efficacy of TRAIL-based 
therapy.
Non-targeted sFasL for cancer therapy
Early studies with only partially characterized sFasL preparations and agonistic Fas anti-
bodies demonstrated potent apoptotic activity towards a host of tumor cell lines and primary 
human tumor cells [18]. In principle, this feature qualified FasL as an interesting candidate 
for cancer therapy. Unfortunately, systemic administration of these Fas agonists was asso-
ciated with severe liver toxicity in mice [27]. However, it is now well established that homog-
enous trimeric sFasL preparations that do not contain higher order molecular aggregates 
are largely inactive and in fact competitively inhibit the pro-apoptotic activity of membrane-
expressed FasL [6;7]. Of note, secondary cross-linking of trimeric sFasL to a hexameric 
state is already sufficient to largely restore its pro-apoptotic activity [13;14]. Of considerable 
interest in this respect is an engineered hexameric FasL variant, dubbed MegaFasL (MFL). 
MFL induced apoptosis in cell lines and primary cells from multiple myeloma (MM), acute 
myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and Burkitt’s lymphoma [14]. 
Furthermore, induction of apoptosis by MFL in gastro intestinal tumors (GIST) was potenti-
ated by co-treatment with the Bcr-Abl tyrosine kinase inhibitor imatinib [28]. Importantly, 
MFL did not induce apoptosis in normal hematopoietic progenitor cells [14]. Moreover, i.p. 
administration of therapeutic doses of MFL in a xenograft model of ovarian carcinoma re-
sulted in only mild and transient signs of liver toxicity. Histological analysis performed after 
cessation of therapy revealed that the liver damage was of reversible nature indicating that 
prudent development for clinical applications appears warranted [29].
Although highly active against a wide variety of tumor cell lines, resistance to FasL has 
been reported in various tumor types, e.g. prostate cancer. Specifically, prostate cancer 
cells with an androgen-independent phenotype appear to upregulate anti-apoptotic mol-
ecules like cFLIPL [30]. Therefore, combinatorial strategies that sensitize cells to the pro-
apoptotic activity of FasL are of particular interest. Interestingly, the inhibition of AMP-acti-
vated protein kinase (AMPK) was found to enhance cFLIP degradation in the proteasome 
thereby sensitizing prostate cancer cells to FasL-induced apoptosis [31]. In addition, many 
conventional chemotherapeutic agents like mitoxantrone and docetaxel potently enhanced 
FasL induced apoptosis in both cell lines and primary prostate cancer samples by, among 
others, increasing expression of Fas [32]. 
Targeted delivery of FasL for cancer therapy
As described above, a homogenous trimeric sFasL preparation is devoid of pro-apoptotic 







ably a promising candidate as effector molecule in antibody-targeted approaches. Antibody-
targeted sFasL, such as in our scFv:sFasL fusion protein format, remains inactive while 
en route but is converted to its fully active membrane-like form upon antibody-mediated 
binding to the tumor cell surface. The feasibility of this concept has been demonstrated by 
us and others. In a first report, targeted delivery of sFasL to the tumor stroma marker FAP, 
using an anti-FAP scFv resulted in a 1000-fold increase in specific activity to FAP-positive 
cells compared to untargeted sFasL [33] (see Table 1 for overview of reported scFv:sFasL 
fusion proteins). Importantly, this fusion protein remained inactive towards FAP-negative 
cells [33]. Similarly, targeted delivery of sFasL to the T-cell marker CD7, using the fusion 
protein scFvCD7:sFasL, induced potent CD7-restricted apoptosis in T-cell leukemic cell 
lines and primary patient-derived leukemic cells. In contrast, CD7-positive resting lympho-
cytes were fully resistant to prolonged treatment with the fusion protein scFvCD7:sFasL 
[34].
Of note, during the resolution phase of an immune response, activated T-cells are effec-
tively eliminated via a process called activation-induced cell death, a process in which FasL 
is a main pro-apoptotic cell surface molecule. In accordance with this physiological role, ex 
vivo activated T-cells were found to be highly susceptible to scFvCD7:sFasL mediated in-
duction of apoptosis. This feature might be of therapeutic interest in elimination of activated 
autoreactive T-cells in inflammatory diseases such as rheumatoid arthritis [35]. 
A promising strategy in the design of scFv:sFasL fusion proteins is the incorporation of a 
scFv fragment with intrinsic pro-apoptotic activity. The promise of this approach is illus-
trated by a recently generated fusion protein comprising a rituximab-derived antibody frag-
ment (scFvRit) and sFasL [36]. Rituximab binds to the B-cell antigen CD20 and is already 
in clinical practice with considerable success. In patients, rituximab exerts its effect partly 
through induction of apoptosis by crosslinking of the CD20 target molecule [37]. Interest-
ingly, we and others have previously identified that co-treatment of B-cell leukemic cell 
lines with rituximab and Fas-agonistic antibodies yielded a synergistic induction of apopto-
sis [38;39]. The CD20-directed fusion protein scFvRit:sFasL further capitalized on this co-
treatment approach which is evidenced by the superior levels of apoptosis this fusion pro-
tein induced in CD20-positive malignant cells compared to co-treatment with rituximab and 
FasL. In contrast, CD20-negative cells were not affected by scFvRit:sFasL. This superior 
apoptotic activity of scFvRit:sFasL suggests a unique cooperative effect of simultaneous 
CD20 crosslinking and Fas-activation. Considering the documented requirement for cross-
linking of both CD20 and Fas to achieve activation, it is conceivable that scFvRit:sFasL 
induces mutual spatial rearrangements in CD20 and Fas distribution, thereby enhancing 
pro-apoptotic signaling events.
Non-targeted TRAIL for cancer therapy
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TRAIL is probably one of the more promising anti-tumor agents. This promising status is 
based on the pronounced selective activity of TRAIL towards a variety of malignant cells 
and its lack of activity towards normal cells. Treatment with TRAIL induced apoptosis in 
over 40% of all tumor cell lines tested, including tumors of hematopoietic origin as well 




MBOS4-TRAIL[10] Fibroblast activation protein (FAP) Tumor stroma No -






















No Valproic acid[50], Cisplatin[50]




scFvCD19:sTRAIL[57] CD19 B-cell leukemia Yes[57] Valproic acid[57]




sc40-FasL[33] Fibroblast activation protein (FAP) Tumor stroma Yes[33] -




scFvRit:sFasL[36] CD20 B-cell leukemia Yes[36] -
SC36-CD95L-PD[75] 
(and related pro-drug 
constructs)
Fibroblast activation 
protein (FAP) Tumor stroma Yes[75] -
Table 1. scFv:sTRAIL and scFv:sFasL fusion proteins reported
as solid tumors [40]. In addition, TRAIL showed marked anti-tumor activity in xenografted 
tumor models in mice [40]. By now sTRAIL has advanced to phase 1 clinical testing. Pre-
liminary reports from these trials indicate promising results in terms of tolerability of sTRAIL 
in humans, with no major adverse events documented [41-46]. Particularly promising is the 







and rituximab 2 complete responses and 1 partial response were reported in a group of 4 
patients [40;44]. In addition, a recent and larger phase I clinical trial of recombinant human 
rhTRAIL/APO2L in 71 patients with advanced cancer reported no major adverse effects 
and stable disease or better in 46% of patients after 6 months [46].  
The aforementioned complexity of TRAIL-receptor signaling may further offer ways of de-
signing tumor-tailored strategies. For instance, evidence indicates that apoptotic signaling 
in certain tumors, such as chronic myeloid leukemia and pancreatic cancer is mainly medi-
ated via TRAIL-R1, while other tumor types appear to be primarily susceptible to TRAIL-R2 
apoptotic signaling [11;47-49]. This differential use of agonistic TRAIL receptors may be 
exploited by the use of TRAIL-receptor selective sTRAIL mutants with enhanced specific-
ity for the most prevalently expressed TRAIL-receptor in a given tumor type. In addition, 
decreasing the affinity of sTRAIL for decoy receptors may offer significant advantages in 
terms of reducing retention in normal tissue and optimizing occupancy of agonistic TRAIL-
receptors. To date, several sTRAIL mutants with increased selectivity for one of the ago-
nistic receptors have been reported in preclinical studies [11;48-50]. It will be interesting to 
see whether one of these mutants may prove more effective towards pre-selected tumor 
types. Obviously, assessment of potential toxicity due to the introduced amino acid modifi-
cations will need to be carefully assessed. In addition, these modifications may also yield 
new immunogenic epitopes, whereby clinical applicability could be hampered due to the 
development of anti-TRAIL antibody responses.
Despite the obvious and considerable promise of TRAIL-based therapy its clinical efficacy 
may be hampered by the intrinsic resistance to TRAIL observed in various tumor types. 
This is exemplified by primary patient-derived glioma and hepatoma cells of which both dis-
play an almost complete resistance to TRAIL-induced apoptosis [51]. Importantly, TRAIL-
signaling synergizes with most commonly used cytostatic agents and also with novel thera-
peutics. The combinatorial synergistic activity of TRAIL with conventional anticancer drugs 
is reflected by a host of publications on preclinical studies both in vitro and in vivo [52-55]. 
Indeed, co-treatment regimes appear the most promising way forward to overcome TRAIL 
resistance in human malignancies, with various points of crosstalk between the extrinsic 
and the intrinsic apoptotic pathway as possible therapeutic targets. 
Targeted delivery of sTRAIL for cancer therapy
In addition to possible resistance issues, other characteristics of the TRAIL/TRAIL receptor 
system may hamper the clinical efficacy of sTRAIL. Firstly, sTRAIL has a serum half-life of 
only ~30 minutes in humans, which is likely to severely limit tumor accretion [11;41]. Sec-
ondly, TRAIL-receptors are ubiquitously expressed throughout the body, possibly acting as 
a sink for sTRAIL that may preclude efficient tumor accretion. Lastly, TRAIL-R2 signaling 
is relatively poorly activated by sTRAIL, whereas many tumor types frequently express 
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TRAIL-R2 over TRAIL-R1 [9].
Most of these potential limitations of sTRAIL may be overcome by fusion of a tumor-specific 
scFv to sTRAIL. The resultant scFv:sTRAIL fusion protein is homotrimeric with a molecular 
weight of approximately 150 kDa. As a consequence, glomerular excretion of scFv:sTRAIL 
should be decreased, thereby increasing the retention time in the circulation. Furthermore, 
accretion of scFv:sTRAIL at the tumor cell surface should be significantly increased by 
virtue of its high binding affinity for the cell surface target antigen of choice [50;56-58]. Of 
note, since scFv:sTRAIL fusion proteins are trimers, three scFv reading heads are avail-
able yielding a strongly enhanced binding avidity. Importantly, we and others have shown 
that scFv:sTRAIL is capable of efficiently activating not only TRAIL-R1 but also TRAIL-R2 
[10;59]. Upon targeted delivery of sTRAIL to the pan-carcinoma marker EpCAM, mem-
brane-bound scFv:sTRAIL induces apoptosis in a mono- and/or bi/multi-cellular manner 
(Fig. 2) [60]. This bi/multi-cellular mode of action enables the elimination of tumor cells de-
void of target antigen by neighboring target antigen-positive and scFv:sTRAIL loaded cells, 
a feature termed the bystander effect [56;60]. This may be particularly relevant for tumors 
known to be heterogeneous for tumor-associated antigens, such as glioblastoma multifor-
ma. Proof of concept for several scFv:sTRAIL fusion proteins has been obtained including 
those with specificity for the tumor stroma antigen FAP, solid tumor antigens EpCAM and 
EGFR  as well as various leukemia target antigens (CD7, CD19, CD33) [2;10;50;56;57;61] 
(see Table 1 for overview).
For our studies we have had a particular interest in scFv fragments with intrinsic anti-tumor 
activity. The anti-tumor activity of an scFv may come from direct pro-apoptotic activity, or 
by its ability to competitively inhibit survival signaling, thereby sensitizing targeted cells to 
TRAIL-mediated apoptosis. The dual activity of such a bifunctional scFv:sTRAIL fusion pro-
tein is exemplified by fusion protein scFv425:sTRAIL, which contains the EGFR blocking 
scFv425 [61]. Binding of scFv425:sTRAIL to EGFR-positive carcinoma cells inhibited mito-
genic signaling and its subsequent downstream pro-survival signaling events. EGFR sig-
naling inhibition by scFv425:sTRAIL resulted in, among others, down-regulation of cFLIP. 
Concordantly, the TRAIL domain activated TRAIL-R apoptotic signaling. Both in vitro ex-
periments using various EGFR-positive cell lines and in vivo experiments in EGFR+ tumor 
bearing mice demonstrated highly potent anti-tumor activity for scFv425:sTRAIL [58;61]. 
This strategy is probably applicable to a host of other growth factor receptors, such as in-
sulin growth factor receptor (IGFR) and human epidermal growth factor receptor 2 (HER2). 
The promise of combinatorial Growth Factor Receptor targeting and TRAIL-R activation 
is further highlighted by a report in which mAbs directed at HER2 and TRAIL-R2 yielded 
synergistic elimination of tumor cells both in vitro and in vivo [62].
It is worth noting here that pro-survival signaling has also recently been reported for the 







lular region of EpCAM, dubbed EpCAM IntraCellular Domain (EPICD), was found to be 
cleaved from the membrane upon which it translocated to a transcription factor complex in 
the nucleus. In the nucleus, EPICD activated among others the proto-oncogene c-Myc lead-
ing to pro-mitogenic signaling. In light of these new data, it is tempting to speculate that the 
potent apoptotic activity we found for the EpCAM-specific fusion protein scFvC54:sTRAIL 
may be partly related to inhibition of EpCAM processing and concomitant inhibition of  mi-
togenic cell signaling pathways.
The activity of antibody-targeted TRAIL might be further optimized by incorporating the 
aforementioned TRAIL-receptor selective mutants into the fusion protein concept. Indeed, 
a variant of fusion protein scFv425:sTRAIL, containing a TRAIL mutant with increased ac-












Figure 2. Target-cell-restricted induction of apoptosis by scFv:sTRAIL and scFv:sFasL fusion 
proteins. Specific binding of scFv:sTRAIL and scFv:sFasL to the target antigen results in accretion at 
the tumor cell surface. Subsequently apoptosis can be induced in an autocrine manner by binding to 
the cognate death receptors on the same target tumor cell. Similarly, specific binding of scFv:sTRAIL 
and scFv:sFasL fusion proteins to antigen on one target tumor cell can induce activation of cognate 
death receptors on a neighboring antigen-expressing target tumor cell resulting in a paracrine target 
cell apoptosis. In addition, target antigen-positive and scFv:sFasL or scFv:sTRAIL loaded cells can 
present sFasL or sTRAIL to neighboring cells devoid of antigen and thereby enable elimination of 
these bystander tumor cells in a feature termed the bystander effect.
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of all cell lines tested (ref [50]; see also chapter 4).
 
Conclusions and perspectives
As discussed in this review, TRAIL as well as FasL are immune effector molecules that 
may be of considerable interest for antibody-targeted cancer therapy. Genetic fusion of a 
tumor-selective antibody fragment to sTRAIL and sFasL yields highly selective anti-cancer 
therapeutics with favorable anti-cancer features. Antibody-based targeting helps to exploit 
several of the intrinsic characteristics of the interaction of these ligands with their cognate 
receptors to ensure minimal off-target activity and enhanced tumoricidal activity. Important 
features of this approach include the selective accretion to the tumor cell surface and 
subsequent activation of sTRAIL and sFasL to full membrane-like anti-tumor activity. The 
use of antibody fragments in such fusion proteins that have intrinsic tumoricidal activity 
further provides possibilities to optimize tumoricidal activity by simultaneously exploiting 
key signaling events in cancer cells. Such a rationally designed approach may significantly 
synergize the therapeutic potential of antibody-based death ligand fusion proteins.
The most likely application of sTRAIL and sFasL based antibody fusion proteins is in the 
management of residual disease and prevention of cancer relapse. Of specific interest in 
this respect is the fact that cancer relapse in many types of tumors is currently being at-
tributed to so-called cancer stem cells (CSCs). These CSCs represent a small subpopula-
tion of cancer cells that display a stem cell-like phenotype and are particularly resistant to 
conventional cancer therapy. Therefore, CSCs are held responsible for disease relapse 
and their targeted elimination might prove crucial for potentially curative treatment. Inter-
estingly, TRAIL significantly inhibited the clonogenic capacity of acute myeloid leukemia 
(CD34+) CSCs, without affecting normal CD34+ cells [64]. Similarly, colon cancer cells with 
CSC-properties were found to be more sensitive to TRAIL-induced apoptosis [65], although 
others have found that primary colorectal CSCs were relatively resistant to TRAIL [66]. 
However, this TRAIL-resistant phenotype can be fully reverted by blocking of autocrine 
pro-survival IL4 signaling [66]. These findings provide a clear incentive for further investiga-
tion of the therapeutic activity of sTRAIL and antibody-targeted TRAIL for the elimination of 
cancer stem cell populations. An attractive option in the latter case may be the incorpora-
tion of a blocking IL4R antibody. In addition, since carcinoma CSCs are usually identified 
by the expression of high levels of EpCAM [67], we are currently re-evaluating the activity 
of our previously reported EpCAM-targeted scFvC54:sTRAIL fusion protein towards the 
CSCs subpopulation. 
A potential limitation to the scFv:sFasL/scFv:sTRAIL fusion protein approach discussed in 
this review is the potential limitation in tumor-penetration in the case of solid tumors. Anti-
body fragment targeted death ligands are ~twice the size of non-targeted soluble ligands 







likely application of scFv:sFasL/scFv:sTRAIL in solid tumors is in conjunction with surgery 
and/or chemotherapeutics, i.e. to eliminate minimal residual disease. In addition, tumor-
endothelial targeted approaches analogous to those reported for TNF are of interest. In 
such cases, the tumor endothelium will be damaged and the surrounding tumor cells will 
be devoid of crucial supply of oxygen. An added benefit of this approach, as also evident 
from the clinical experience with TNF, would be the enhanced diffusion of any co-adminis-
tered chemotherapeutics or for that matter cancer cell surface-targeted scFv:sTRAIL and 
scFv:sFasL or combinations thereof.
Finally, as more of the specific molecular aberrations responsible for malignant behavior 
of cancer cells are identified, the design of rational combinatorial strategies will take an in-
creasingly prominent place in targeted cancer therapy. Preclinical data provide clear indica-
tions of the promise of combinatorial strategies directed at modulating apoptotic Death Re-
ceptor signaling by conventional or experimental therapeutics [68]. Of note, although Death 
Receptors predominantly signal apoptosis, oncogenic proteins like K-Ras and NF-κB can 
potentially turn death receptors into metastasis-promoting receptors [69-72]. Converting 
metastatic death-receptor signaling to apoptotic signaling via K-Ras or NF-κB inhibition 
might therefore provide further therapeutic benefit. An important factor to be kept in mind 
during design of any combinatorial strategy is the potential for unwanted side-effects. In 
particular, hepatocytes appear to be one of the most vulnerable populations that need to 
be carefully monitored [73]. For instance, co-treatment of TRAIL with proteasome inhibition 
also resulted in liver toxicity, albeit within a therapeutic window [74].
In conclusion, scFv-targeted FasL and TRAIL fusion proteins have yielded promising pre-
clinical data that warrants further clinical evaluation. It will be exciting to see whether these 
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Previously, we demonstrated potent tumor cell-selective pro-apoptotic activity of 
scFv425:sTRAIL, a recombinant fusion protein comprised of EGFR-directed antibody 
fragment (scFv425) genetically fused to human soluble TRAIL (sTRAIL). Here we re-
port on the promising therapeutic systemic tumoricidal activity of scFv425:sTRAIL 
when produced by the replication-deficient adenovirus Ad-scFv425:sTRAIL. In vitro 
treatment of EGFR-positive tumor cells with Ad-scFv425:sTRAIL resulted in the po-
tent induction of apoptosis of not only infected tumor cells, but importantly also of 
up to 60% of non-infected EGFR-positive tumor cells. A single intraocular injection 
of Ad-scFv425:sTRAIL in tumor-free nu/nu mice resulted in predominant liver in-
fection and concomitant high blood plasma levels of scFv425:sTRAIL. These mice 
showed no sign of Ad-scFv425:sTRAIL-related liver toxicity. Identical treatment of 
mice with established intraperitoneal renal cell carcinoma xenografts resulted in 
rapid and massive tumor load reduction and subsequent long-term survival. Taken 
together, adenoviral-mediated in vivo production of scFv425:sTRAIL may be exploit-
able for systemic treatment of EGFR-positive cancer.  
 
Introduction
Adenovirus vectors are attractive gene delivery vehicles for cancer therapy due to their 
ease of production, high stability in vivo, high transgene expression levels, and low patho-
genicity in humans. Adenovirus infection is initiated by interaction between carboxy-termi-
nal knob domains of the viral fibers and the extracellular region of the coxsackie/adenovi-
rus receptor (CAR) expressed on the surface of target cells. Unfortunately, CAR is highly 
expressed on hepatocytes, whereas most cancerous cells only express low levels of CAR. 
Consequently, intravenously administrated therapeutic adenoviruses predominantly target, 
infect, and express the transgene payload in the liver [1, 2]. This lack of tumor-selective 
tropism and strong preference for liver infection has largely excluded the use of therapeutic 
adenoviruses for systemic treatment of metastatic disease.
To date, strategies to enhance the therapeutic potential of adenovirus have been mainly 
dedicated to enhancing specificity and efficiency of gene transfer to target cells and the 
simultaneous untargeting of liver cells [3, 4]. An alternative or complementary approach to 
enhance the applicability of adenoviruses is the rational design of the payload to be deliv-
ered. The aim of this approach is to turn the above-described drawbacks of adenoviruses 
into an advantage for systemic therapy of metastatic disease. Of potential interest in this 
respect is the TNF-related Apoptosis Inducing Ligand (TRAIL). The native form of TRAIL 
is a type II transmembrane protein, but it can also be proteolytically cleaved into soluble 
homotrimeric TRAIL (sTRAIL) [5, 6]. Recombinant forms of sTRAIL have shown potent 







ity towards normal human cells [7-9]. Currently, the tumoricidal activity of sTRAIL is being 
evaluated in clinical trials [10].
The efficacy of sTRAIL is hampered by the ubiquitous expression of the agonistic recep-
tors TRAIL-R1 and TRAIL-R2 and the antagonistic receptors TRAIL-R3 and TRAIL-R4 on 
normal tissues. Upon systemic treatment most of the administered sTRAIL will bind to the 
relative excess of TRAIL-receptors on normal tissues. Consequently, accretion of sTRAIL 
to tumor cells will be limited. In addition, the therapeutic efficacy of sTRAIL is potentially 
hampered by its relative inability to activate the high affinity agonistic receptor TRAIL-R2 
[11, 12].
Recently, we and others have reported that genetic fusion of sTRAIL to a tumor-selective 
single chain Fv (scFv) antibody fragment can optimize the efficacy of TRAIL-based therapy 
[13-19]. Specifically, binding of an scFv:sTRAIL fusion protein to the pre-defined target 
antigen leads to selective tumor cell accretion. In addition, the soluble and conditional-
ly inactive scFv:sTRAIL is hereby converted into a membrane-bound and active form of 
TRAIL that can activate both TRAIL-R1 and TRAIL-R2. Importantly, target antigen-bound 
scFv:sTRAIL can induce bi-/multicellular activation of TRAIL-receptors resulting in apop-
totic activity towards proximal tumor cells. 
Particularly promising for cancer treatment is fusion protein scFv425:sTRAIL, which selec-
tively targets sTRAIL to human Epidermal Growth Factor Receptor (EGFR)-positive cancer 
cells [16]. Previously we have shown that scFv425:sTRAIL selectively binds to EGFR-pos-
itive cancer cells, whereupon EGFR-mitogenic signaling is rapidly inactivated and cancer 
cells are sensitized to apoptosis (16). Simultaneously, the sTRAIL domain of EGFR-bound 
scFv425:sTRAIL potently activates TRAIL-receptor apoptotic signaling (for schematic see 
Fig. 1).
Here, we investigated the therapeutic potential of scFv425:sTRAIL as payload for adeno-
viral gene delivery for systemic therapy of metastatic disease. To this end, we generated 
replication-deficient adenovirus Ad-scFv425:sTRAIL, encoding the cDNA for secreted 
scFv425:sTRAIL. Treatment of EGFR-positive tumor cells with Ad-scFv425:sTRAIL in vitro 
resulted in potent induction of apoptosis in not only infected but also in >60% of non-infect-
ed EGFR-positive tumor cells. Single intravenous injection of Ad-scFv425:sTRAIL in tumor-
free nu/nu mice resulted in liver infection and high blood plasma levels of scFv425:sTRAIL 
in the absence of Ad-scFv425:sTRAIL-related liver toxicity. Identical treatment of mice with 
established intraperitoneal renal cell carcinoma xenografts resulted in rapid and massive 
tumor load reduction and subsequent long-term survival. Taken together, adenoviral-me-
diated in vivo production of scFv425:sTRAIL may be exploitable for improved systemic 
treatment of EGFR-positive carcinoma. 
 
Material and methods
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The EGFR-positive renal carcinoma cell line RC21.luc, lentivirally transduced with firefly 
luciferase, was a generous gift from Prof. Dr. C. Löwik (Leiden University Medical Center, 
Leiden, The Netherlands). RC21.luc cells were cultured in RPMI 1640 (Cambrex Bio Sci-
ence, Verviers, France), supplemented with 10% fetal calf serum (FCS). Cells were cul-
tured at 37°C in a humidified 5% CO2 atmosphere.














Figure 1. Schematic representation of the mechanism of action of scFv425:sTRAIL. Binding of 
scFv425:sTRAIL to the Epidermal Growth Factor Receptor (EGFR), via antibody fragment scFv425, 
inhibits mitogenic signaling of the active EGFR dimer. Consequently, the cell is sensitized to induction 
of apoptosis by TRAIL. In addition, scFv425-mediated binding immobilizes soluble scFv425:sTRAIL 
on the cell surface of EGFR-positive tumor cells and converts soluble scFv425:sTRAIL into a 
membrane bound form. This membrane-bound from of TRAIL can efficiently cross-link and activate 








Cryopreserved human Hepatocytes (tebu-bio bv, Heerhugowaard, The Netherlands) were 
isolated using hepatocyte isolation kit (tebu-bio bv, Heerhugowaard, The Netherlands) 
according to standard protocol. Briefly, vials containing cryopreserved hepatocytes were 
placed in a shaking water bath (37±1°C) for 1.5 minutes. After thawing, hepatocytes were 
centrifuged on a Percoll solution (90g, 5 min), the pellet was washed using nutrient rich 
culture medium and hepatocytes were seeded in a 48 well plate at a density of 0.5x106 
cells/ml for experiments.
Mice
Nu/Nu mice were obtained from Harlan (Harlan Netherlands B.V., Horst, The Netherlands). 
Animals were maintained in a 12h light/dark cycle and fed normal diet and water ad libitum. 
All animal experiments were approved by the local committee for care and use of labora-
tory animals and were performed according to governmental and international guidelines 
on animal experimentation.
Monoclonal antibodies and inhibitors
mAb 425 was kindly provided by Merck (Darmstadt, Germany). mAb425 is a murine IgG2a 
with a high binding affinity for the extra cellular domain of the EGFR. mAb 425 competes 
with scFv425 for binding to the EGFR. TRAIL-neutralizing antibody mAb 2E5 was pur-
chased from Alexis (10P, Breda, The Netherlands). Total caspase inhibitor Z-VAD-FMK was 
purchased from Calbiochem (EMD Biosciences, San Diego, United States). 
Construction and production of Ad-scFv425:sTRAIL 
Ad-scFv425:sTRAIL was generated by introducing the gene encoding scFv425:sTRAIL [16] 
into E1- and E3-deleted replication-incompetent recombinant Ad-5 adenovirus using the 
Ad-Easy system (32). Briefly, cDNA encoding both the κ light chain leader secretion signal 
and the scFv425:sTRAIL gene were cloned from the previously described vector pEE14-
scFv425:sTRAIL [16] into pAdTRACK-CMV using unique HindIII sites. The resulting vector 
pAdTRACK-CMV-scFv425:sTRAIL was co-transformed with the adenoviral genome vector 
pAdEasy1 in E. coli BJ5183. After homologous recombination pAd-scFv425:sTRAIL was 
obtained. Subsequently, pAd-scFv425:sTRAIL was transfected into HEK-293 cells. Adeno-
viral stock was generated by Cesium Chloride purification, dialyzed in a HEPES-sucrose 
buffer and kept at -80°C until use. Viral titer was determined by OD260 measurement of 
viral DNA. Control virus containing luciferase (Ad-Luciferase) was generated essentially as 
described before (33).
Infection of EGFR-positive tumor cells with Ad-scFv425:sTRAIL
Cells were seeded in 24-well or 96-well plate at 50% confluency and were allowed to ad-
Chapter 3: Potent sytemic anti-cancer activity of Ad-scFv425:sTRAIL
Molecular Therapy 2008 Dec; 16(12):1919-26.
C
hapter 3
here for 16h. Infection with Ad-scFv425:sTRAIL and the control virus Ad-Luciferase were 
performed by incubating cells for 24h with the respective adenovirus at the indicated MOI, 
after which medium was aspirated and fresh medium was added. Analyses were performed 
6 days after incubation.
Assessment of tumor cell viability after Ad-scFv425:sTRAIL infection
After infection with Ad-scFv425:sTRAIL, cells were cultured in the presence or absence 
of mAb 425 (0,5µg/ml), mAb 2E5 (2µg/ml) or total caspase inhibitor Z-VAD-FMK (20µM). 
Loss of cell viability was assessed by one of the following assays; MTS assay: Loss of vi-
ability using the MTS assay was performed according to manufacturer’s recommendation 
(Promega Benelux b.v. Leiden, The Netherlands). Cell viability of medium control was set 
100%. Each experimental condition consisted of at least three independent wells. Crystal 
violet assay: After treatment, crystal violet assay was performed as previously described. 
This assay gives quantitative information about the relative density of cells adhering to the 
multi-well dish. The crystal violet stain was solubilised using 1% Sodium Dodecyl Sulfate 
(SDS) after which staining intensity was quantified by OD550 in a micro-plate reader. Me-
dium control was set at 100% cell survival.
Assessment of apoptosis and loss of cell viability after Ad-scFv425:sTRAIL infection
Apoptosis was assessed by one of the following assays; Loss of mitochondrial membrane 
potential (Δψ): Δψ was measured by DiOC6-staining (Eugene, The Netherlands) as previ-
ously described (19). Briefly, after treatment cells were collected and incubated for 20 min 
with DiOC6 (0,1 µM) at 37°C, harvested (1000g for 5 min), re-suspended in PBS, and 
assessed for DiOC6 staining using flow cytometry using an EPICS ELITE flow cytometer 
(Beckman Coulter, Mijdrecht, The Netherlands). Analysis of apoptotic DNA fragmentation: 
Apoptotic cleavage of DNA was shown by harvesting total DNA out of cells (2×106 cells/
well in 6-well plate) 6 days after infection with 100 i.u. AdscFv425:sTRAIL, AdTL or medium 
control. Subsequent isolation of total DNA was performed by use of the DNA isolation kit 
DNeasy Tissue Kit (QIA-GEN, the Netherlands). Equal amounts of DNA were separated 
by electrophoresis on a 1,6% agarose gel and visualized under UV-light after ethidium 
bromide staining.
Induction of apoptosis by secreted scFv425:sTRAIL in non-infected EGFR-positive tumor 
cells
To accurately assess the anti-tumor effect of secreted scFv425:sTRAIL, a trans-well sys-
tem was used in which RC21.luc cells were cultured in the lower well and infected with 
Ad-scFv425:sTRAIL or Ad-TL. Infected cells were separated from cell culture inserts, con-







μm (NUNC, Roskilde, Denmark), which allows free diffusion of the scFv425:sTRAIL fusion 
protein, but not of Ad-scFv425:sTRAIL virus particles.
Production and secretion of scFv425:sTRAIL in nu/nu mice
Nude mice were intra-occularly injected with saline control, Ad-luciferase (1010), Ad-
scFv425:sTRAIL (109), Ad-scFv425:sTRAIL (1010). After 3 days, mice were sacrificed, plas-
ma was collected and liver samples were analyzed for presence of activated caspase-3/-7. 
Briefly, equal mass of liver samples were analyzed for caspase-3/-7 activity using the Cas-
pase-Glo 3/7 Assay according to manufacturer’s recommendations (Promega). As positive 
control for liver toxicity mice were treated with Flag-FasL + anti-Flag mAb. 
Isolated plasma was analyzed for scFv425:sTRAIL presence using TRAIL-ELISA accord-
ing to manufacturer’s instructions (Diaclone SAS, Besançon, France). Plasma samples 
were also tested for tumoricidal activity in vitro by treatment of RC21.luc cells for 16 h in 
vitro, after which apoptosis was assessed by Δψ.
Tissue preparation and histology
Livers were explanted from sacrificed mice at day 35 (saline and Ad-scFv425:sTRAIL 109 
vp treated mice) and at day 64 (Ad-scFv425:sTRAIL 1010 vp treated mice) and immediately 
snap-frozen in liquid nitrogen. Five μm sections were cut from cryofixed tissues, thawed 
and fixed in acetone. H&E staining was performed to assess the histology of livers accord-
ing to standard protocol.
RC21.luc i.p. xenograft model in nu/nu mice
RC21.luc cells ectopically expressing luciferase were intraperitoneally injected (2x106/
mice) in nude/nude mice. Tumor growth was monitored using bioluminescent imaging as 
described in more detail below. After hatching of the xenograft, mice were treated with 1. 
saline, 2. Ad-scFv425:sTRAIL (109), 3. Ad-scFv425:sTRAIL (1010), respectively. The group 
size of saline and Ad-scFv425:sTRAIL (109) was 3. The group size of Ad-scFv425:sTRAIL 
(1010) was 4. 
Response to treatment was measured using bioluminescent imaging. At various time-
points, blood samples were taken from the mice to allow for detection of scFv425:sTRAIL 
production. Control treated mice and Ad-scFv425:sTRAIL (109) were sacrificed at day 32 
after start of treatment. Mice treated with Ad-scFv425:sTRAIL (1010) remained healthy up to 
day 64, after which mice were terminated. At termination, blood was collected for endpoint 
reading of scFv425:sTRAIL concentration.
In vivo bioluminescence imaging of luciferase expression of RC21.luc xenografts
Bioluminescence imaging was performed using an ultra-sensitive charge-coupled device 
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(CCD) camera cooled to -105°C, within the In Vivo Imaging System IVIS®100 (Xenogen, 
Alameda, CA, USA). An aqueous solution of beetle D-luciferin (150 mg/kg; Xenogen) was 
injected intraperitoneally 10 minutes before imaging. Mice were placed into the light-tight 
chamber of the CCD camera imaging system in anesthetized condition (2.5% isoflurane 
in oxygen 1.5 L/min). The mice were imaged from the ventral abdominal side and a digital 
grayscale reference image was taken. Subsequently, the presence and amount of RC21.
luc cells was assessed by detecting photons emitted by RC21.luc cells that were transmit-
ted through the body tissue. The Living Image®2.50 software program (Xenogen, Alame-
da, CA) was used for data acquisition and analysis. This program was used to create a 
pseudocolor image. The luminescence image was merged with the reference image to 
create an overlay image that enables anatomical localization. Images were displayed and 
quantified in log radiance (photons/sec/cm2/sr) enabling absolute comparison between 
bioluminescent images between different treatment groups. Region-of-interest (ROI) mea-
surements, used to quantify the amount of light emission in specific areas of the image, 
were defined to determine the maximum emission from the transfected cells. ROI size and 
shape was kept identical along longitudinal measurements for each subject.
Results
Ad-scFv425:sTRAIL-infection leads to EGFR-restricted induction of apoptosis in infected 
and non-infected EGFR-positive tumor cells
Previously we demonstrated EGFR-restricted and TRAIL-mediated apoptotic activity 
of scFv425:sTRAIL [16]. To assess whether virally produced scFv425:sTRAIL similarly 
induced apoptosis in EGFR-positive tumor cells, RC21.luc cells were infected with Ad-
scFv425:sTRAIL. The viability of RC21.luc cells was strongly reduced with increasing Mul-
tiplicity of Infection (MOI) (Fig. 2a). This loss of viability increased in time after infection, 
from 45% at day 1 to 60% at day 6 post-infection (Fig. 2b). Loss of viability was accom-
panied by typical apoptotic DNA-fragmentation (Fig. 2c). In contrast, infection with con-
trol adenovirus encoding for luciferase (Ad-Luciferase) did not reduce viability nor induce 
DNA-fragmentation (Fig. 2a-c). Importantly, induction of apoptosis by scFv425:sTRAIL was 
abrogated by co-incubation with molar excess of EGFR-blocking mAb 425, as well as by 
a TRAIL-neutralizing antibody or by total caspase inhibitor zVAD-FMK (Fig. 2d). Together, 
this indicates that virally produced scFv425:sTRAIL potently activates TRAIL-mediated 
apoptosis only upon specific binding to cell surface expressed EGFR.
EGFR-specific binding of secreted scFv425:sTRAIL and subsequent bi-/multicellular acti-
vation of TRAIL-receptors provides scFv425:sTRAIL with apoptotic activity towards non-
infected EGFR-positive tumor cells. To evaluate the effect towards non-infected cells, Ad-
scFv425:sTRAIL infected cells and non-infected RC21.luc cells were co-cultured, while 







scFv425:sTRAIL. In these experiments, >60% of non-infected RC21.luc cells were elimi-
nated by apoptosis (Fig. 2e). In similar experiments with Ad-luciferase (MOI 100), no apop-
tosis was induced (Fig. 2e). Taken together, these data demonstrate that virally produced 







































































































































Fig. 2. EGFR-restricted induction of apoptosis by adenovirally produced scFv425:sTRAIL. 
A. RC21.luc cells were infected Ad-scFv425:sTRAIL or Ad-Luciferase at varying MOIs. At 6 days 
post-infection, loss of viability was quantified by MTS assay. B. RC21 cells were infected with Ad-
scFv425:sTRAIL or Ad-Luciferase (MOI 100), after which cell viability was determined at various time-
points. C. RC21.luc cells were infected with Ad-scFv425:sTRAIL  or Ad-Luciferase (MOI 100), after 
which DNA was isolated at day 6 of infection and evaluated for apoptotic DNA-fragmentation. D. 
Supernatant produced by Ad-scFv425:sTRAIL infected RC21.luc cells was used to treat non-infected 
RC21.luc cells in the presence or absence of TRAIL-neutralizing mAb 2E5 or EGFR-blocking mAb 
425. E. RC21.luc cells were seeded in a trans-well system, after which cells in the lower compartment 
were treated with Ad-scFv425:sTRAIL at varying MOI or Ad-Luciferase at MOI 100. After 6 days, 
induction of apoptosis in both infected and non-infected RC21.luc target cells was analyzed by MTS 
assay. Values are representatives of 3 independent experiments.
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non-infected EGFR-positive tumor cells.
Infection of nude/nude mice with Ad-scFv425:sTRAIL yields high plasma levels of 
scFv425:sTRAIL in the absence of liver toxicity 
To determine whether infection with Ad-scFv425:sTRAIL resulted in production and secre-
tion of scFv425:sTRAIL in vivo by hepatocytes, nude mice were infected by intra-ocular 
injection with Ad-scFv425:sTRAIL (109 or 1010 viral particles). Infection with a control aden-
ovirus encoding for luciferase (Ad-Luciferase) confirmed that predominantly liver cells were 
infected, as evidenced by the strong exclusive luminescent signal in the liver (Fig. 3a). At 
3 days post-infection, infection with 1010 vp Ad-scFv425:sTRAIL resulted in high plasma 
levels of  >10 µg/ml scFv425:sTRAIL (Fig. 3b; 11.2+/-8 µg/ml). In contrast, infection with 
109 viral particles (vp) Ad-scFv425:sTRAIL yielded only minimal plasma concentrations of 
scFv425:sTRAIL (Fig. 3b; 60+/-20 ng/ml).
Subsequent in vitro treatment of RC21.luc cells with plasma isolated from the vari-
ous treatment groups revealed that only plasma obtained from mice infected with 1010 
vp of Ad-scFv425:sTRAIL potently induced apoptosis (Fig. 3c). Induction of apoptosis by 
scFv425:sTRAIL was still dependent on scFv425-mediated binding to EGFR, since co-
incubation with parental mAb 425 (20µg/ml) strongly inhibited the induction of apoptosis. 
Moreover, apoptosis was fully TRAIL-mediated, since co-incubation with TRAIL-neutraliz-
ing antibody abrogated apoptosis (Fig. 3d).
No toxicity was detected upon visual inspection of the isolated livers (illustrated in Fig. 4a) 
and no effector caspase activity (caspase-3/-7) was detected in livers of mice infected with 
1010 vp of Ad-scFv425:sTRAIL (Fig. 4b). In contrast, treatment with cross-linked sFasL 
induced strong toxicity with high levels of active caspase-3/-7 (Fig. 4b). Importantly, histo-
logical analysis confirmed the absence of toxicity after adenoviral infection (no centrilobular 
necrosis, cholestasis, hepatocyte injury, fatty changes, hepatitis), with liver morphology 
identical to saline treated mice (Fig. 5a-c). Together, these data indicate that infection with 
1010 vp Ad-scFv425:sTRAIL yields high plasma levels of active scFv425:sTRAIL in the 
absence of liver toxicity.
To further determine the effect of Ad-scFv425:sTRAIL infection on human hepatocytes, 
we performed an initial characterization by infecting primary human hepatocytes (PHH). 
Importantly, infection with Ad-scFv425:sTRAIL only minimally reduced cell viability 3 days 
post-infection (Fig. 5d). Since PHH in culture are known to dedifferentiate, we additionally 
assessed the immediate effect of fusion protein scFv425:sTRAIL, by treating PHH with 
plasma of mice infected with 1010 vp Ad-scFv425:sTRAIL for 16h. Importantly, no signifi-
cant induction of apoptosis was detected (Fig. 5e). In contrast, treatment with killer-FasL, 
a known inducer of apoptosis in hepatocytes, strongly reduced viability after 3 days and 

















































































































































Figure 3. Efficient production and secretion of scFv425:sTRAIL upon Ad-scFv425:sTRAIL 
infection of nude mice. A. Mice (n=3) were infected with control adenovirus Ad-Luciferase and were 
imaged for bioluminescence 3 days post-infection. A representative picture of bioluminescence (ph/sec/
cm2/sr) after Ad-Luciferase infection is given. B. Mice were infected with saline or low and high dose 
of Ad-scFv425:sTRAIL (109 and 1010vp, respectively). After 3 days, concentration of scFv425:sTRAIL 
in plasma was determined by TRAIL ELISA. C. RC21.luc cells were treated with plasma obtained from 
mice treated with saline, Ad-Luciferase, Ad-scFv425:sTRAIL (109vp) or Ad-scFv425:sTRAIL (1010vp). 
After 16h, induction of apoptosis was assessed by Δψ. D. RC21.luc cell were treated with plasma 
obtained from mice infected with high dose Ad-scFv425:sTRAIL in the presence or absence of TRAIL-
neutralizing mAb 2E5 or EGFR-blocking mAb 425. Apoptosis was assessed by Δψ. 
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that Ad-scFv425:sTRAIL infection is not associated with human hepatocyte apoptosis.
scFv425:sTRAIL eradicates established RC21.luc xenografts in nude/nude mice
To asses the tumoricidal activity of Ad-scFv425:sTRAIL, nu/nu mice with established in-
tra-peritoneal RC21.luc xenografts were infected with Ad-scFv425:sTRAIL (109 vp) or Ad-
scFv425:sTRAIL (1010 vp) by intraocular injection. The xenografted RC21.luc cells express 
firefly luciferase, allowing for real-time in vivo imaging of tumor size and response to ther-
apy. In saline treated mice, RC21.luc xenografts continued to grow rapidly until mice had 
to be sacrificed at day 32 (Fig. 6a). Compared to saline-treated mice, already a significant 
inhibition in tumor growth was detected in mice treated with 109 vp of Ad-scFv425:sTRAIL 
(Fig. 6b). However, injection with 1010 vp of Ad-scFv425:sTRAIL resulted in a rapid and 
dramatic reduction in tumor size (Fig. 6c). All 1010 vp Ad-scFv425:sTRAIL-treated mice 
remained healthy until the end of the experiment.
Conversion of the quantitative bioluminescent imaging data into a relative percentage 
of tumor size compared to start of treatment revealed that in saline treated mice tumors 
grew exponentially to ~3500% of initial size (Fig. 7a). Upon treatment with low dose of Ad-
scFv425:sTRAIL (109 vp), mice showed retarded tumor growth. In these mice, tumor growth 






















































Figure 4. No detectable liver damage after infection with Ad-scFv425:sTRAIL. A. A representative 
picture of an isolated liver after Ad-scFv425:sTRAIL (1010 vp) infection. B. Isolated livers of saline, low 
and high dose Ad-scFv425:sTRAIL treated mice were analyzed for caspase-3/-7 activity. As positive 
control for liver caspase-3-7 activation, mice were treated with Flag-FasL secondarily cross-linked with 







vp); 900% of initial size, saline; 3500% of initial size). Importantly, in mice treated with 1010 
vp of Ad-scFv425:sTRAIL a dramatic reduction of 97% of initial tumor size occurred within 
days of treatment (Fig. 7a). Two of the four mice retained a minimal residual tumor that cor-
responded to ~2% of initial tumor size until the end of the experiment at day 64. 
Of note, the conversion of the raw bioluminescent data of Fig 6 to a relative percentage of 
tumor size in Fig 7a reveals a very important aspect of the data, namely, that the increase 
or decrease in tumor size after treatment is remarkably constant for each treatment group. 
Therefore, the effect of the respective treatments appears robust and reproducible along 
the range of variable tumor sizes detected in the mice.
In close agreement with the above experiment in tumor free mice, plasma scFv425:sTRAIL 
levels in Ad-scFv425:sTRAIL (109 vp) treated mice reach a peak plasma level of only 12 ng/

























































































Figure 5. No detectable liver damage after infection with Ad-scFv425:sTRAIL. Normal liver 
histology, as determined by H&E staining upon saline treatment (A), Ad-scFv425:sTRAIL (109 vp) 
treated (B) and in Ad-scFv425:sTRAIL (1010 vp) treated mice (C). Original magnification 200x. D. PHH 
were infected with Ad-scFv425:sTRAIL (MOI 100), Ad-Luciferase (MOI 100) or treated with killer-FasL 
(5µg/ml). Viability 3 days after infection was measured using MTS assay. E. PHH were treated for 16h 
with plasma obtained from mice infected with Ad-scFv425:sTRAIL (1010 vp), yielding a concentration 
of 5µg/ml, saline control or killer-FasL (5µg/ml). Apoptosis was assessed by Δψ.
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Figure 6. Ad-scFv425:sTRAIL infection eradicates established RC21.luc xenografts in nude 
mice. Nude mice with established i.p. RC21.luc xenografts were treated with (A) saline, (B) Ad-
scFv425:sTRAIL (109vp), (C) Ad-scFv425:sTRAIL (1010vp). Tumor size was monitored real-time using 
BLI. The luminescence image was merged with the reference image to create an overlay image that 
enables anatomical localization. Images were displayed and quantified in log radiance (photons/sec/
cm2/sr), enabling absolute comparison between bioluminescent images between different treatment 
groups. Mice treated with saline and low dose Ad-scFv425:sTRAIL were sacrificed after 32 days. Mice 
treated with high dose of Ad-scFv425:sTRAIL were sacrificed at day 64. The two panels in a, b and c 
show the variability in tumor size within each treatment group at the start of treatment.
significantly delayed the outgrowth of RC21.luc xenografts from 3500% to 900% at the time 
of sacrifice. In mice infected with 1010 vp Ad-scFv425:sTRAIL, plasma scFv425:sTRAIL 
concentrations proved to be very high, with a peak level of ~380 µg/ml 7 days post-infection 
(Fig. 7c).
In the minimal residual tumors of mice treated with 1010 vp Ad-scFv425:sTRAIL, there 














































































































































Figure 7. Ad-scFv425:sTRAIL infection eradicates established RC21.luc xenografts in nude 
mice. A. Graph of tumor size in mice treated with saline, Ad-scFv425:sTRAIL (109vp) and Ad-
scFv425:sTRAIL (1010vp). Tumor size was monitored using BLI and is represented as relative size 
compared to tumor size at start of treatment. B. Concentration of plasma scFv425:sTRAIL in mice 
treated with Ad-scFv425:sTRAIL (109vp). C. Concentration of plasma scFv425:sTRAIL in mice treated 
with Ad-scFv425:sTRAIL.(1010vp) D. Concentration of scFv425:sTRAIL in plasma and i.p. fluid in mice 
treated with Ad-scFv425:sTRAIL (109vp) at day 64 post-infection. In B-D, TRAIL concentrations were 
determined using TRAIL ELISA.
by scFv425:sTRAIL, since the luminescent signal remained constant until the end of the 
experiment. Based on the small size of the tumors, we wondered whether the activity 
of scFv425:sTRAIL might be hampered by poor tumor vascularization. In the absence of 
vasculature, scFv425:sTRAIL would first need to diffuse over the peritoneal membrane 
and then into the tumor. Although suggestive, in one of the mice that retained an RC21.
luc xenograft the diffusion of scFv425:sTRAIL into the intra-peritoneal fluid proved to yield 
an >30 fold lower concentration scFv425:sTRAIL compared to plasma concentrations (Fig. 
7d), indicating that intra-peritoneal and subsequent intra-tumoral diffusion might be a rate-
limiting step for scFv425:sTRAIL activity.
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Previously we reported on the pro-apoptotic activity of the EGFR-targeted fusion protein 
scFv425:sTRAIL. Here, we show that combining this therapeutic approach with the typical 
characteristics of adenoviral gene therapy yields promising pro-apoptotic activity in vitro 
and exerts potent tumoricidal activity in vivo. Our in vitro experiments demonstrate that 
virally induced production of scFv425:sTRAIL leads to apoptotic activity according to the 
intended mechanism of action. Specifically, antibody-fragment mediated binding to EGFR 
results in cell surface accretion of scFv425:sTRAIL and concomitant potent induction of 
apoptosis by the now fully active sTRAIL domain. Importantly, scFv425:sTRAIL exerts its 
pro-apoptotic activity by binding to cell surface expressed EGFR and TRAIL-receptors (for 
schematic see Fig. 1). As a result, scFv425:sTRAIL induces apoptosis in infected cells and 
in non-infected cells with equal efficiency.
The mechanism of action of scFv425:sTRAIL endows this fusion protein with supe-
rior qualities for systemic gene therapeutic approaches. In particular, virally expressed 
scFv425:sTRAIL is efficiently secreted and inactive towards normal human cells. More-
over, scFv425:sTRAIL induces apoptosis upon selective binding to EGFR on the cell sur-
face of targeted tumor cells only. Therefore, there is no need for a direct infection of tumor 
cells or, for that matter, for a complete infection of all tumor cells. This is in contrast to most 
gene therapeutic strategies aimed at the delivery of toxic moieties. The safety and effi-
cacy of these approaches critically depends on the restricted infection of tumor cells only, 
in order to prevent toxicity towards normal human cells [2, 20]. Moreover, gene therapy 
with e.g. pro-drug converting enzymes (GDEPT) relies on the intracellular production of 
toxic metabolites in the cytoplasm of the infected cell that then need to diffuse to non-
infected bystander cells [21]. Usually, these toxic metabolites cannot freely transit the cell 
membrane but require e.g. gap-junctional inter-cellular communication (GJIC) [22]. Unfor-
tunately, most cancer cells lack functional GJIC, thereby largely restricting the tumoricidal 
activity to infected cells.
For systemic therapy, Ad-scFv425:sTRAIL infection should be followed by the correct and 
high level production, subsequently yielding high blood plasma levels of scFv425:sTRAIL. 
An initial in vivo assessment of scFv425:sTRAIL production after intra-ocular injection with 
1010 viral particles Ad-scFv425:sTRAIL revealed high plasma concentrations of up to 10 
µg/ml. Interestingly, infection with only 10-fold lower concentration of Ad-scFv425:sTRAIL 
yielded only plasma levels of ~60 ng/ml fusion protein. Such marked differences in plasma 
concentrations relative to viral titer have been described previously and were attributed 
mainly to adenoviral particle clearance by liver Kupffer cells [23], most likely by scavenger 
receptors [24]. Our control in vivo bioluminescent imaging experiments with Ad-luciferase 
confirmed that predominantly liver cells were infected upon intra-ocular injection. Together, 







eliminated, whereas at higher MOI the Kupffer cells are saturated and hepatocytes are 
infected.
Importantly, the µg/ml range of scFv425:sTRAIL produced in the liver after infection with 
1010 viral particles Ad-scFv425:sTRAIL is not associated with obvious liver damage, as 
evidenced by a normal healthy appearance of isolated livers, absence of signs of hepato-
toxicity, the absence of liver caspase-3/-7 activity, as well as the minimal activity on primary 
cultured human hepatocytes. Taken together, the efficient production and lack of toxicity 
confirm the potential of Ad-scFv425:sTRAIL for systemic adenoviral therapy.
Subsequent xenograft studies with Ad-scFv425:sTRAIL revealed promising tumoricidal 
activity of systemically produced fusion protein. Infection with 109 viral particles of Ad-
scFv425:sTRAIL, yielding only low ng/ml scFv425:sTRAIL blood plasma levels, retarded 
tumor outgrowth from 3500% to 900% at 32 days after infection. Apparently, this low sys-
temic concentration is already sufficient to significantly inhibit tumor growth. Intriguingly, 
tumor growth started to diverge only at later time-points, from approximately 25 days after 
start of treatment. Upon increasing tumor size, the rate of growth of tumor will increasingly 
rely on neovascularization. At the same time, increased vascularization will optimize infu-
sion of scFv425:sTRAIL to the tumor cells. Together, this suggests that the divergence in 
tumor growth at later time-points may be due to an increase in neovascularization and 
consequently increased access of scFv425:sTRAIL to tumor cells. 
After infection with 1010 viral particles two of the four mice achieved a complete remis-
sion. In the two other mice, there was a rapid and dramatic reduction in tumor size, which 
in time was followed by the continued presence of a minimal residual tumor. Importantly, 
these minimal residual tumors retained an identical bioluminescent signal from day 20 up 
to day 64 post-infection, indicating that tumor growth was completely halted. Apparently, 
there was a balance between proliferation of tumor cells and the induction of apoptosis by 
scFv425:sTRAIL. 
Small tumor nodules of 1-2 mm in diameter are in the so-called avascular phase and do 
not require neovascularization for survival [25]. Based on the apparent equilibrium between 
proliferation and apoptosis in the minimal residual tumors, we wondered whether the tu-
moricidal activity of scFv425:sTRAIL might be hampered by a lack of vascularization or 
poor vascularization. In the absence of vasculature, scFv425:sTRAIL can only diffuse into 
the tumor from the intraperitoneal fluid. Circumstantial evidence for this hypothesis can be 
found from the fact that the intra-peritoneal concentration of scFv425:sTRAIL proved to be 
30-fold lower than the plasma concentration of scFv425:sTRAIL. This finding suggests that 
diffusion of scFv425:sTRAIL from plasma to the intraperitoneal fluid and from the intraperi-
toneal fluid into the tumor might indeed be a limiting step for the tumoricidal activity. 
From our data it is clear that without direct infection of tumor cells, Ad-scFv425:sTRAIL 
yields potent tumoricidal activity towards established renal cell carcinoma xenografts, this 
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in contrast to e.g. immunotoxin-based gene therapeutic strategies, where it is imperative 
to solely infect targeted tumor cells. Obviously, systemic infection with Ad-scFv425:sTRAIL 
can be further combined with tumor localized production of scFv425:sTRAIL by intra-tu-
moral injection of Ad-scFv425:sTRAIL or by incorporating the adenovirus retargeting strat-
egies that are being developed by other researchers. For instance, Ad-scFv425:sTRAIL 
can be retargeted to specifically infect EGFR-positive tumor cells using bispecific antibody 
425:S11 [24] or alternatively to any other carcinoma-associated antigen [26]. 
An advantageous feature of using TRAIL as payload is the fact that the pro-apoptotic activi-
ty of TRAIL is synergized by a wide variety of other therapeutic approaches, including novel 
drugs such as EGFR-tyrosine kinase inhibitor Iressa and proteasome inhibitor velcade [16, 
27]. Of particular interest in the context of adenoviral delivery of TRAIL-based therapeutics 
is the histone deacetylase inhibitor (HDACi) Valproic Acid (VPA). Recently, VPA was shown 
to enhance the efficacy of adenoviral infection due to upregulation of the CAR receptor 
[28], which may help to increase infection of hepatocytes at lower doses of adenovirus. In 
this respect, further combination with inhibition of uptake and concomitant degradation of 
adenovirus by Kupffer cells using polyinosinic acid, as recently described by us [24], may 
be a strategy worthwhile pursuing. Taken together with the established synergistic activity 
of combined treatment of tumor cells with HDACi and TRAIL [19, 29], VPA may be an ideal 
candidate to both optimize the efficiency of Ad-scFv425:sTRAIL infection as well as the 
tumoricidal activity of scFv425:sTRAIL.
In conclusion, our data clearly show that systemic infection with Ad-scFv425:sTRAIL re-
sults in potent tumoricidal activity towards EGFR-positive human carcinoma xenografts. 
Adenoviral-mediated in vivo production of scFv425:sTRAIL and possibly other scFv:sTRAIL 
fusion proteins may be exploitable for improved systemic treatment of cancer.
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Chapter 4: Superior apoptotic activity of an EGFR-targeted sTRAIL mutant




Previously, we have shown that EGFR-selective delivery of sTRAIL, by genetic fu-
sion to antibody fragment scFv425, enhances the tumor-selective pro-apoptotic 
activity of sTRAIL. Insight into the respective contribution of the agonistic recep-
tors TRAIL-R1 and TRAIL-R2 to TRAIL-induced apoptosis may provide a rational 
approach to further optimize TRAIL-based therapy. Recently, this issue has been 
investigated using sTRAIL mutants designed to selectively bind to either receptor. 
However, the relative contribution of the respective TRAIL receptors, in particular 
TRAIL-R1, in TRAIL-signaling is still unresolved. Here, we fused scFv425 to de-
signed sTRAIL mutant sTRAILmR1-5, reported to selectively activate TRAIL-R1, and 
investigated the therapeutic apoptotic activity of this novel fusion protein. EGFR-
specific binding of scFv425:sTRAILmR1-5 potently induced apoptosis, which was 
superior to the apoptotic activity of scFv425:sTRAIL-wt and a non-targeted MOCK-
scFv:sTRAILmR1-5. During co-treatment with cisplatin or the histone deacetylase in-
hibitor VPA, scFv425:sTRAILmR1-5 retained its superior pro-apoptotic activity com-
pared to scFv425:sTRAIL-wt. However, in catching-type ELISAs with TRAIL-R1:Fc 
and TRAIL-R2:Fc, scFv425:sTRAILmR1-5 was found to not only bind to TRAIL-R1 
but also to TRAIL-R2. Binding to TRAIL-R2 also had functional consequences, since 
the apoptotic activity of scFv425:sTRAILmR1-5 was strongly inhibited by a TRAIL-
R2 blocking monoclonal antibody. Moreover, scFv425:sTRAILmR1-5 retained apop-
totic activity upon selective knockdown of TRAIL-R1 using small inhibitory RNA. 
Collectively, these data indicate that both agonistic TRAIL-receptors are functionally 
involved in TRAIL-signaling by scFv425:sTRAILmR1-5 in solid tumor cells. More-
over, the superior target cell-restricted apoptotic activity of scFv425:sTRAILmR1-5 
indicates its therapeutic potential for EGFR-positive solid tumors.
Introduction
The Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) is normally present 
as a type II transmembrane protein on immune effector cells, such as NK-cells. As such, 
TRAIL is involved in the elimination of e.g. metastasizing cancer cells (1,2). TRAIL can 
also be proteolytically cleaved into a homotrimeric soluble form (sTRAIL) that partly retains 
tumoricidal activity (3,4). Several recombinant derivatives of sTRAIL have been generated 
that all display promising anti-tumor activity in vitro and in human xenografted tumor mouse 
models (5,6,7). 
Recently, we and others have demonstrated that the tumor-cell specific activity of sTRAIL 
can be augmented by genetic fusion to a tumor-selective antibody fragment (8,9,10,11,12). 
Antibody fragment-mediated binding of such scFv:sTRAIL fusion proteins to a cell surface-







membrane-bound TRAIL. Subsequently, agonistic TRAIL receptors are efficiently activated 
in a monocellular and/or bicellular manner.
TRAIL signals apoptosis by binding to the agonistic receptors TRAIL-R1 and TRAIL–R2 
(13,14,15). Concomitantly, an intracellular cascade of caspase activation ensues that ulti-
mately results in the apoptotic demise of the cell. These agonistic receptors are character-
ized by a cytoplasmic region known as the Death Domain, which is critical for signal trans-
duction upon TRAIL-binding. TRAIL can also interact with three antagonistic receptors, 
TRAIL-R3, TRAIL-R4 and osteoprotegerin (OPG). TRAIL-R3 is a phospholipid-anchored 
receptor that lacks a cytoplasmic domain (16,14,17). TRAIL-R4 has a truncated intracel-
lular domain incapable of transmitting the apoptotic signal (18,19,20). Osteoprotegerin is a 
soluble receptor for TRAIL (21) that is best known for its involvement in bone homeostasis 
as a soluble receptor for the TNF homolog RANKL.
This intricate receptor system, with five distinct receptors that differentially bind and interact 
with TRAIL, suggests that the outcome of TRAIL-signaling is subject to a high degree of 
regulation (22). Therefore, insight into the respective contribution of the agonistic receptors 
TRAIL-R1 and TRAIL-R2 to apoptotic signaling by TRAIL may provide a rational approach 
to optimize TRAIL therapy for a specific tumor type.
Several laboratories have studied this issue using sTRAIL mutants designed to selec-
tively bind to one of the agonistic TRAIL-receptors and not to the antagonistic receptors 
(23,24,25). Using TRAIL-R1 and TRAIL-R2 selective sTRAIL mutants Kelley et al. ascribed 
a greater contribution of TRAIL-R2 to TRAIL-apoptotic signaling in solid tumor cells (23). 
Similarly, van der Molen et al. reported that selective TRAIL-R2 activation results in en-
hanced pro-apoptotic activity (24). On the other hand, MacFarlane et al. concluded that 
apoptosis signaling was exclusively mediated by TRAIL-R1 in Chronic Lymphocytic Leu-
kemia (25). Importantly, experimental data in the latter paper indicates that the TRAIL-R1 
selective sTRAIL mutant used by Kelley et al. is actually largely inactive. Thus, the exact 
contribution of TRAIL-R1 and TRAIL-R2 to TRAIL-induced apoptosis remains to be eluci-
dated.
Previously, we have demonstrated that EGFR-targeted delivery of wild-type sTRAIL, us-
ing scFv425:sTRAIL, enhanced the tumor-selective binding and activity (10). Here, we 
genetically fused antibody fragment scFv425 to sTRAILmR1-5, reported by MacFarlane 
et al. to selectively activate TRAIL-R1, and investigated the therapeutic apoptotic activity 
of this novel fusion protein. Fusion protein scFv425:sTRAILmR1-5 showed superior apop-
totic activity compared to the corresponding wild-type sTRAIL fusion protein on half of the 
EGFR-positive solid tumor cell lines tested and showed a non-significant trend to higher 
apoptotic activity on the other cell lines. Furthermore, scFv425:sTRAILmR1-5 showed su-
perior apoptotic activity in comparison to a MOCK-scFv:sTRAILmR1-5 fusion protein, with 
irrelevant target specificity. However, in contrast to the findings of MacFarlane et al. we 
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found that the sTRAILmR1-5 domain in our scFv425:sTRAILmR1-5 fusion protein also 
bound to and partly signaled apoptosis via TRAIL-R2. Taken together, EGFR-selective 
delivery and induction of apoptosis by scFv425:sTRAILmR1-5 is a potentially promising 




The following cell lines were purchased from the American Type Culture Collection (ATCC, 
Manassas, USA); Jurkat (ALL T-cell line), Ramos (Burkitt Lymphoma), A431 (epidermoid 
carcinoma), OVCAR-3 (ovarian carcinoma), WiDr, HT-29 (both colon carcinoma), A549 
(lung carcinoma), Sk-rc-52 (renal cell carcinoma), PC-3M (prostate carcinoma), A172 
(glioblastoma multiforme), HS-683 (medullablastoma). Jurkat.EGFRvIII was generated as 
previously described (10). RC21 cells (renal cell carcinoma) were generously provided by 
Prof. Dr. Clemens Löwik (University Medical Center Leiden, Leiden, The Netherlands). All 
cell lines were cultured at 37°C, in a humidified 5% CO2 atmosphere. All cell lines were 
cultured in RPMI 1640 (Cambrex Bio Science, Verviers, France) supplemented with 10% 
fetal calf serum.
Expression of EGFR and TRAIL receptors
Membrane expression levels of EGFR were analyzed using mAb425. Membrane expres-
sion levels of TRAIL-receptors 1, 2, 3, and 4, were analyzed by flow cytometry using a 
TRAIL-receptor antibody kit purchased from Alexis (10P’s, Breda, The Netherlands). Brief-
ly, cells were harvested, washed using serum free RPMI, and resuspended in 100 µl fresh 
medium containing the appropriate primary mAb. Specific binding of the primary antibody 
was detected using a PE-conjugated secondary antibody (DAKO, Glostrup, Denmark). All 
antibody incubations were performed at 0°C for 45 min and were followed by two washes 
with serum free medium.
Recombinant sTRAIL, monoclonal antibodies and inhibitors
Flag-tagged sTRAIL and secondarily cross-linked kTRAIL were both purchased from Alex-
is. MAb 425 (kindly provided by Merck, Darmstadt, Germany) is a murine IgG2a with high 
binding affinity for the extra-cellular domain of EGFR and EGFRvIII. TRAIL neutralizing 
mAb 2E5 was purchased from Alexis (10P’s, Breda, The Netherlands). MAb 425 competes 
with scFv425 for binding to the same epitope. The histone deacetylase inhibitor valproic 
acid (VPA) was from Sigma-Aldrich (Zwijndrecht, The Netherlands) and was dissolved at 
100 mM in dH2O. The cytostatic drug cisplatin was dissolved at 1 mg/ml in 0.9% NaCl. 
IKK inhibitor wedelolactone was purchased from Sigma-Aldrich and dissolved at 5 mM 







from Calbiochem (VWR International B.V., Amsterdam, The Netherlands) and dissolved at 
10 mM in DMSO. Final working concentrations of cisplatin, VPA, caspase inhibitors and 
wedelolactone were diluted in standard medium.
Production of scFv:sTRAIL fusion proteins
scFv425:sTRAIL-wt, scFv425:sTRAILmR1-5 and MOCK-scFv:sTRAILmR1-5, targeted at 
the B-cell marker CD20, were constructed and produced essentially as described previous-
ly using expression vector pEE14 (10). This plasmid encodes an N-terminal hemagglutinin 
(HA) tag upstream of two multiple cloning sites. In the first MCS, the high-affinity antibody 
fragment scFv425 (Vh-(G4S)3-Vl format) (26) was directionally inserted using the unique 
SfiI and NotI restriction enzyme sites. Alternatively, the upstream MCS of pEE14 was used 
to insert DNA fragment scFvCD20.  The synthetic DNA sequence encoding scFvCD20 
was generated by splice overhang extension PCR-technology using published sequence 
data of the VH - and VL domains of the murine anti-CD20 mAb 2B8. The VH and VL se-
quences were genetically linked via a flexible peptide linker ((GGGGS)3). Moreover, re-
striction enzyme sites SfiI (GGCCCAGCCGG) and NotI (GCGGCCGC) were added to the 
5’-end and 3’-end of the sequence, yielding a 756 bp DNA fragment. In the second MCS, a 
PCR-truncated 593 bp DNA fragment encoding the extracellular domain of human TRAIL 
(sTRAIL) was cloned in frame using restriction enzymes XhoI and HindIII, yielding plasmid 
pEE14-scFv425:sTRAIL-wt. Alternatively, the cDNA encoding sTRAILmR1-5 was inserted 
in the second MCS. This sTRAIL mutant encodes 5 amino acid substitutions compared to 
sTRAIL-wt (25) (see table 1). The resultant expression vectors were transfected into CHO-
K1 cells using Fugene 6 reagent (Roche Diagnostics, Almere, The Netherlands) according 
to manufacturer’s instructions. Transfectants were selected by the glutamine synthetase 
system as described (27). Single cell sorting using the MoFlo high speed cell sorter (Cyto-
mation, Fort Collins, USA) established clones of scFv425:sTRAIL-wt, stably secreting 2.1 
μg/ml, scFv425:sTRAILmR1-5, stably secreting 2.7 μg/ml and MOCK-scFv:sTRAILmR1-5, 
stably secreting 2.3 μg/ml.
amino acid pos. 189 191 193 199 201 213 215 264 266 267
scFv425:sTRAIL-wt Tyr Arg Gln Asn Lys Tyr Ser His Ile Asp
scFv425:sTRAIL-mR1 Tyr Arg Ser Val Arg Trp Asp His Ile Asp
Table 1. Changes in amino acid sequence of the sTRAIL domains of scFv425:sTRAILmR1-5 
compared to scFv425:sTRAIL-wt.
TRAIL-receptor selective ELISA
TRAIL-receptor binding selectivity of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 was 
investigated with a catching-type ELISA with either TRAIL-R1-Fc or TRAIL-R2-Fc (both 
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from Alexis, 10P’s BVBA) coated to the plates. Briefly, maxisorb ELISA plates were coated 
overnight with 1µg/ml TRAIL-R1:Fc or TRAIL-R2:Fc, blocked with PBS/0.1% TWEEN/3% 
Bovine Serum Albumine (Sigma), washed twice with PBS/0.1% TWEEN, and incubated 
for 3 hours with scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, respectively. Specific 
binding was assessed by staining for the N-terminal hemagglutinin tag using Horseradish 
Peroxidase-conjugated anti-HA antibody (Roche). Specific binding was visualized using 
3,3′,5,5′-Tetramethylbenzidine (TMB)(Sigma) and measured using an ELISA plate reader at 
OD450. Where indicated, incubation with scFv425:sTRAIL-wt/scFv425:sTRAILmR1-5 was 
performed in the presence of soluble TRAIL-R1:Fc, TRAIL-R2:Fc or Flag-tagged sTRAIL.
EGFR-specific binding of scFv425:sTRAIL fusion proteins 
EGFR-specific binding of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 was assessed 
by flow cytometry using the EGFR-positive tumor cell line Jurkat.EGFRvIII. In short, 1x106 
cells were incubated with fusion protein (300 ng/ml). Specific binding was detected using 
PE-conjugated anti-TRAIL mAb B-S23 (Diaclone SAS, Besançon, France) and subsequent 
FACS analysis using a Calibur flow cytometre (Beckman Coulter, Mijdrecht, The Nether-
lands). Incubations were carried out for 45 min at 0°C and were followed by two washes 
with serum free medium.
EGFR-restricted induction of apoptosis by scFv425:sTRAIL fusion proteins
EGFR-restricted induction of apoptosis by the scFv425:sTRAIL fusion proteins was as-
sessed by loss of mitochondrial membrane potential (∆ψ) or by crystal violet cytotoxicity 
assay as described in more detail below. Where indicated, treatment with scFv425:sTRAIL 
fusion proteins or the MOCK-scFv:sTRAILmR1-5 was performed in the presence or ab-
sence of mAb 425 (3 µg/ml) or mAb 2E5 (1 µg/ml). Loss of mitochondrial membrane po-
tential (∆ψ); ∆ψ was analyzed using the stain DiOC6 (Eugene, The Netherlands) as previ-
ously described (10). Briefly, cells were pre-cultured in a 48-well plate at a concentration of 
0.3x105 cells/well. Subsequently, cells were treated for 16 h with the various experimental 
conditions, after which cells were harvested and incubated for 20 min with DiOC6 (0,1 
µM) at 37°C, harvested (1000g, 5 min.), resuspended in PBS, and assessed for staining 
by flow cytometry. Cell viability assessed by crystal violet cytotoxicity assay; cells were 
pre-cultured in a 96-well plate at a concentration of 0.3x105 cells/well. Subsequently, cells 
were treated for 16 h with the various experimental conditions in a final volume of 200 µl. 
Cell viability was determined by crystal violet staining (Sigma, Germany) as described 
previously (8). Experimental apoptosis induction was quantified as the percentage of apop-
tosis induction compared to medium control. Each experimental condition consisted of six 
independent wells. Luminescent assay for caspase-8, caspase-9 and caspase-3/-7 activ-







and Caspase-Glo® 3/7 Assay according to manufacturer’s instructions (Promega Benelux 
BV, Leiden, The Netherlands). The assays are based on the cleavage of non-luminescent 
substrates by activated caspases into a luminescent product. Luminescence is quantified 
using an ELISA plate reader.
Immunoblot analysis of caspase-8, cFLIPL and NFκB
Cells were seeded in 6 well plates at a final concentration of 2.0x106 cells/ml and treated as 
indicated. Cell lysates were prepared and immunoblot analysis was performed essentially 
as described before (26). Antibodies used were anti-caspase-8 (Cell signaling technology, 
Beverly, MA, USA), anti-cFLIPL clone NF6 (Alexis), NFkB p100/p52, NFkB p105/p50, NFkB 
p65 (all from Santa-Cruz; Tebu-Bio, Heerhugowaard, The Netherlands). Appropriate sec-
ondary PO-conjugated antibodies were from DAKO Cytomation (Glostrup, Denmark). 
Selective knock-down of TRAIL-R1 or TRAIL-R2 using small inhibitory (si)RNA 
OVCAR-3 cells were pre-cultured in 6-well plates to 60% confluency, after which cells 
were treated with 10pM TRAIL-R1 siRNA (sense: 5’-CACCAAUGCUUCCAACAAU-3’; 
antisense: 5’-AUUGUUGGAAGCAUUGGU-3’) or TRAIL-R2 siRNA (sense:5’-GACCCUU-
GUGCUCGUUGUC-3’; antisense: 5’-GACAACGAGCACAAGGGUC-3’) (Eurogentec S.A., 
Liege, Belgium). Treated cells were cultured for 3 days, after which selective TRAIL-recep-
tor down-regulation was verified by flow cytometry. Subsequently, cells were plated in a 48-
well plate at 3x104 cells/well and treated with scFv425:sTRAIL-wt, scFv425:sTRAILmR1-5, 
agonistic TRAIL-R1 mAb or agonistic TRAIL-R2 mAb. Apoptosis was assessed by ∆ψ. For 
siRNA apoptosis experiments, the experimental apoptosis was calculated using the follow-
ing formula: experimental apoptosis = (specific apoptosis - spontaneous apoptosis)/(100 
- spontaneous apoptosis) x 100%.
Synergistic induction of apoptosis by scFv425:sTRAIL fusion proteins and conventional 
and experimental therapeutic drugs
Cells were plated at 3.0x104 cells/well in a 48-well plate and allowed to adhere over-
night. Subsequently, cells were concurrently treated for 24h with scFv425:sTRAIL-wt or 
scFv425:sTRAILmR1-5 with or without cisplatin or histone deacetylase inhibitor VPA. Addi-
tive or synergistic apoptotic effects were determined using the cooperativity index (CI). CI 
was determined with the following formula; the sum of apoptosis induced by single-agent 
treatment divided by apoptosis induced by combination-treatment. When CI<0.9, treatment 
was termed synergistic; when 0.9<CI<1.1, treatment was termed additive; when CI>1.1, 
treatment was termed antagonistic.
IL-8 ELISA
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To determine IL-8 production in response to scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, 
RC21, PC3-M, HT-29, A549 and WiDr cells were treated with 850 ng/ml fusion protein in 
the presence or absence of total caspase inhibitor zVAD-FMK. After 16 h, supernatants 
were analyzed for IL-8 levels using IL-8 ELISA according to manufacturer’s protocol (San-
quin reagents, Amsterdam, The Netherlands).
Statistical analysis
Data reported are mean values + standard error of the mean of at least three independent 
experiments. Where appropriate, statistical analysis was performed using two-sided, un-




EGFR-selective binding and induction of apoptosis by scFv425:sTRAIL-wt and 
scFv425:sTRAILmR1-5
To determine whether the sTRAILmR1-5 domain of scFv425:sTRAILmR1-5 had any influ-
ence on EGFR-specific binding compared to scFv425:sTRAIL-wt, Jurkat.EGFRvIII cells 
were incubated with scFv425:sTRAIL-wt and scFv425:sTRAIL-mR1 and assessed for 
EGFR-specific binding (Fig.1A). As expected, both fusion proteins possessed identical 
binding characteristics to Jurkat.EGFRvIII (Fig. 1A). Binding was EGFR-specific since pre-
incubation with parental EGFR-blocking mAb 425 specifically inhibited the binding of both 
scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 (data not shown).
To determine whether scFv425:sTRAILmR1-5, similar to scFv425:sTRAIL-wt, showed 
EGFR-restricted apoptotic activity, EGFR-positive RC21 cells were treated with 350ng/
ml scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5. Both fusion proteins potently induced 
apoptosis in RC21 cells (Fig. 1B). Importantly, induction of apoptosis by scFv425:sTRAIL-wt 
and scFv425:sTRAILmR1-5 in RC21 cells was specifically inhibited by co-incubation with 
molar excess of parental EGFR-blocking mAb 425 (Fig. 1B). Thus, scFv425:sTRAILmR1-5 
selectively binds to EGFR, after which apoptosis is induced by TRAIL-receptor cross-link-
ing.
Subsequently, we determined whether the EGFR-selective accretion of sTRAILmR1-5 to the 
cell surface of tumor cells resulted in enhanced apoptotic activity compared to non-targeted 
sTRAILmR1-5. To this end, EGFR-positive cells were treated with scFv425:sTRAILmR1-5 
and a MOCK-scFv:sTRAILmR1-5 fusion protein containing an scFv antibody frag-
ment of irrelevant specificity, targeted at the B-cell marker CD20. Dose escalation ex-
periments, exemplified here for PC-3M (Fig. 1C), identified that scFv425:sTRAILmR1-5 
showed superior apoptotic activity compared to MOCK-scFv:sTRAILmR1-5 in PC-3M, 







Figure 1. EGFR-selective binding and induction of apoptosis by scFv425:sTRAIL-wt and 
scFv425:sTRAILmR1-5. A. Jurkat.EGFRvIII cells were incubated with PE-conjugated anti-TRAIL 
mAb B-S23 (solid fill), scFv425:sTRAIL-wt + mAb B-S23 (solid line), or scFv425:sTRAILmR1-5 + mAb 
B-S23 (dotted line), after which specific binding was assessed by flow cytometry. B. EGFR-positive 
RC21 cells were treated with 350ng/ml scFv425:sTRAIL-wt or scFv425:sTRAILmR1-5 in the absence 
or presence of parental EGFR-blocking mAb 425. C. PC-3M cells were treated for 16h with increasing 
concentrations of scFv425:sTRAILmR1-5 or the non-targeted MOCK-scFv:sTRAILmR1-5. D. EGFR-
positive cell lines PC-3M, A431 and RC21 were treated with 850 ng/ml scFv425:sTRAILmR1-5 or 
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totic activity of scFv425:sTRAILmR1-5 compared to the non-targeted soluble MOCK-
scFv:sTRAILmR1-5.
scFv425:sTRAILmR1-5 has superior apoptotic activity on a subset of EGFR-positive solid 
tumor cell lines
To evaluate the apoptotic activity of scFv425:sTRAILmR1-5, we tested a panel of ten 
EGFR-positive tumor cell lines with scFv425:sTRAILmR1-5 and scFv425:sTRAIL-wt. 
Dose-escalation experiments, exemplified here with PC-3M cells (Fig. 2A), identified that 
scFv425:sTRAILmR1-5 had superior apoptotic activity compared to scFv425:sTRAIL-wt in 
OVCAR3, A549, HT-29, HS-683, A431 and PC-3M cells (Fig. 2A and B). Dose escalation 
experiments, exemplified here for RC21 (Fig. 2C), on RC21, WiDr, Sk-rc-52, and A172 
identified no significant difference in apoptotic activity (Fig. 2D). Of note, in the latter cell 
lines scFv425:sTRAILmR1-5 consistently showed a non-significant trend towards higher 
apoptotic activity compared to scFv425:sTRAIL-wt.
To determine whether scFv425:sTRAILmR1-5 retained its superior apoptotic activity com-
pared to scFv425:sTRAIL-wt upon co-treatment with other conventional/experimental anti-
cancer therapeutics, OVCAR-3 cells were treated with the respective fusion proteins alone 
or in combination with VPA or cisplatin (Fig. 3A and B). Importantly, co-treatment with cispl-
atin and VPA synergistically enhanced the apoptotic activity of both scFv425:sTRAIL-wt (CI 
of 0.73 and 0.42, respectively) and scFv425:sTRAILmR1-5 (CI of 0.57 and 0.42, respec-
tively). However, the scFv425:sTRAILmR1-5 fusion protein retained a significantly higher 
pro-apoptotic activity compared to scFv425:sTRAIL-wt (p<0.001 and p<0.05, respectively). 
The synergistic effect of co-treatment with VPA and cisplatin was still fully dependent on 
EGFR-selective binding of the respective fusion protein, since co-treatment with EGFR-
blocking mAb 425 abrogated the induction of apoptosis (data not shown).
The apoptotic activity of scF425:sTRAIL-wt and scFv425:sTRAILmR1-5 does not correlate 
with EGFR- or TRAIL-receptor expression
Since the sTRAILmR1-5 domain was described to be selective for TRAIL-R1, we subse-
quently analyzed whether the differences in apoptotic activity of scFv425:sTRAIL-wt and 
scFv425:sTRAILmR1-5 in the subset of cell lines was due to differential TRAIL-receptor 
expression. To this end, we determined the relative TRAIL-receptor expression levels of 
the cell lines as well as the expression level of EGFR (Table 2). In agreement with our 
previous findings for scFv425:sTRAIL-wt, the activity of scFv425:sTRAILmR1-5 did not 
correlate with the level of EGFR expression. Importantly, there was also no correlation with 
the expression levels of TRAIL-R1, TRAIL-R2 or TRAIL-R4 and the apoptotic activity of the 
fusion proteins. In addition, there was not a clear correlation between the various ratios of 







Figure 2. Fusion protein scFv425:sTRAILmR1-5 has superior apoptotic activity on a subset 
of EGFR-positive solid tumor cell lines. A. Dose-response curve of induction of apoptosis in PC-
3M cells by increasing concentrations of scFv425:sTRAIL-wt or scFv425:sTRAILmR1-5. B. OVCAR3, 
A549, HT-29, HS-683, A431 and PC-3M cells were treated with scFv425:sTRAIL-wt (850 ng/ml) or 
scFv425:sTRAILmR1-5 (850 ng/ml). Cell viability in HS-683 was assessed by crystal violet toxicity 
assay. C. Dose-response curve of apoptosis induction in RC21 cells treated with increasing concentra-
tions of scFv425:sTRAIL-wt or scFv425:sTRAILmR1-5. D. RC21, WiDr, Sk-rc-52 and A172 cells were 
treated with scFv425:sTRAIL-wt (850 ng/ml) or scFv425:sTRAILmR1-5 (850 ng/ml). Unless indicated 
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(66%) cell lines that were significantly more sensitive to scFv425:sTRAILmR1-5 appeared 
to have a more balanced TRAIL-R2/TRAIL-R1 ratio, in comparison to 2 out of 4 (50%) of 
the other cell lines. A particularly intriguing finding is the fact that some of the cell lines, 
most sensitive to scFv425:sTRAILmR1-5, have a very low expression of TRAIL-R1 (Table 
2, HT29; MFI of 8.1, HS683; MFI of 0.5, PC-3M; MFI of 1.9).
scFv425:sTRAIL-wt but also scFv425:sTRAILmR1-5 binds to both TRAIL-R1 and TRAIL-
R2
The sTRAILmR1-5 mutant we genetically fused to scFv425 was reported by MacFarlane 
et al. to selectively activate TRAIL-R1. However, we found no clear correlation between the 
TRAIL-R1 status and activity of scFv425:TRAILmR1-5, with in certain cell lines very low 
TRAIL-R1 expression that coincided with high apoptotic activity of scFv425:sTRAILmR1-5. 
Therefore, we performed a catching-type ELISA in which plates were coated either with 
TRAIL-R1-Fc or TRAIL-R2-Fc to assess whether the sTRAILmR1-5 domain was indeed 
selective for TRAIL-R1. As expected, binding of scFv425:sTRAIL-wt was observed in both 
TRAIL-R1:Fc and TRAIL-R2:Fc coated plates (Fig. 4A and B, open squares). Surprisingly 
Figure 3. Fusion protein scFv425:sTRAILmR1-5 has superior activity in combination with con-
ventional/experimental therapeutics. A. OVCAR3 cells were treated alone or with a combination of 
the HDACi VPA (2 mM) and scFv425:sTRAIL-wt (350 ng/ml) or scFv425:sTRAILmR1-5 (350ng/ml). B. 
OVCAR3 cells were treated alone or with a combination of cisplatin (3 µg/ml) and scFv425:sTRAIL-wt 
(350 ng/ml) or scFv425:sTRAILmR1-5 (350 ng/ml). Unless indicated otherwise, apoptosis was as-






































































































however, scFv425:sTRAILmR1-5 also proved to bind to both TRAIL-R1:Fc and TRAIL-
R2:Fc (Fig. 4A and B, open triangles).
To establish whether this interaction was indeed specific, we competitively inhibited the bind-
ing of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, as observed in the TRAIL-R1:Fc 
ELISA, using soluble TRAIL-R1:Fc and TRAIL-R2:Fc (Fig 4C and D). Importantly, binding 
of both fusion proteins was competitively inhibited by TRAIL-R1:Fc and TRAIL-R2:Fc (Fig. 
4C and D). Of note, whereas scFv425:sTRAIL-wt binding was more efficiently inhibited by 
addition of TRAIL-R2:Fc, binding of scFv425:sTRAIL-mR1-5 was more efficiently inhibited 
by TRAIL-R1:Fc. Thus, scFv425:sTRAILmR1-5 appears to preferentially bind to TRAIL-R1, 
whereas scFv425:sTRAIL-wt appears to preferentially bind to TRAIL-R2. In addition, bind-
ing of scFv425:sTRAIL-wt and scFv425:sTRAIL-mR1-5 to TRAIL-R1:Fc was competitively 
inhibited by Flag-tagged wildtype sTRAIL (Fig. 4E). Together, these results clearly show 
that scFv425:sTRAILmR1-5 specifically binds to not only TRAIL-R1 but also TRAIL-R2.
 
scFv425:sTRAIL-wt but also scFv425:sTRAILmR1-5 activate apoptosis via both TRAIL-R1 
and TRAIL-R2
To determine whether binding of scFv425:sTRAILmR1-5 to TRAIL-R2 also had func-
tional consequences, RC21 renal cancer cells (TRAIL-R1+/R2+) were treated with 
scFv425:sTRAILmR1-5 in the presence of TRAIL-R1 blocking mAb, TRAIL-R2 blocking mAb, 
or a combination of both mAbs. Importantly, induction of apoptosis by scFv425:sTRAILmR1-5 
in RC21 cells was significantly inhibited not only by TRAIL-R1 mAb, but also by the TRAIL-
R2 mAb (Fig. 5A). Of note, the TRAIL-R2 mAb was even more effective than the TRAIL-R1 
mAb in blocking scFv425:sTRAILmR1-5 activity. Co-treatment with both blocking mAbs 
abrogated the apoptotic activity of scFv425:sTRAILmR1-5. Similar results were obtained 
for scFv425:sTRAIL-wt (Fig.5B) as well as killer TRAIL (kTRAIL) (Fig.5C), an artificially 
Table 2.  EGFR/TRAIL-receptor expression and the correlation with the apoptotic activ-
ity of scFv425:sTRAIL-wt/scFv425:sTRAILmR1-5. The percentage of induction of apoptosis by 
scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 are the percentages obtained by treatment with 850 
ng/ml. P-values were obtained using unpaired Student’s T-test. The MFI values of EGFR and TRAIL-
receptor expression are representatives of three independent experiments. n.s.; no significant differ-
ence, n.d.; not determined
Cell line scFv425:sTRAIL-wt scFv425:sTRAILmR1-5 P-value EGFR TRAIL-R1 TRAIL-R2 TR2/TR1 TRAIL-R4 TR1/TR4 TR2/TR4 p53 status
OVCAR-3  57,1±8,6 78,8±5,0 0,0048 629 167,1 207,8 1,2 n.a. - - mut
A549  23,8±5,7 46,8±14,4 0,0106 1.755 69,7 151,5 2,2 8,3 8,4 18,2 wt
HT-29  51,5±1,7 65,2±4,5 0,0468 317 8,1 35,1 4,3 5,2 1,6 6,8 mut
HS683 69±0,9 76,87±2,1 0,0313 436 0,5 44,8 98,4 8,6 0,1 5,2 mut
A431 21,3±8,1 45,6±10,1 0,0313 2727 4,7 7,8 1,7 n.a. - - mut
PC3-M 56,8±3,2 84,4±2,2 0,0003 34 1,9 45,3 23,4 6,86 0,3 6,6 null
RC21  57,6±18,0 66,8±13,6 n.s. 3.648 214,9 398,6 1,9 29,6 7,3 13,5 n.a.
Sk-rc-52  64,9±4,6 78,49±6,9 n.s. 1.263 12,1 133,0 11,0 13,5 0,9 9,9 n.a.
A172  70,5±2,3 75,5±4,8 n.s. 182 0,6 112,2 178,2 3,6 0,2 31,2 wt
WiDR 86,6±13,3 93±2,2 n.s. 256 17,8 56,3 3,2 1,9 9,5 29,9 mut
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Figure 4. scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 bind to TRAIL-R1 and TRAIL-R2. A. In-
creasing concentrations of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 were incubated with TRAIL-
R1:Fc coated plates. B. Increasing concentrations of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 
were incubated with TRAIL-R2:Fc coated plates. C. Binding of scFv425:sTRAIL-wt (850 ng/ml) was 
competitively inhibited by co-incubation with increasing concentrations of TRAIL-R1:Fc and TRAIL-
R2:Fc. D. Binding of scFv425:sTRAILmR1-5 (850 ng/ml) was competitively inhibited by co-incubation 
with increasing concentrations of TRAIL-R1:Fc and TRAIL-R2:Fc. E. Binding of scFv425:sTRAIL-wt 
and scFv425:sTRAILmR1-5 (600 ng/ml) was competitively inhibited by co-incubation with increasing 
concentrations of recombinant Flag-tagged sTRAIL-wt. In all experiments, TRAIL-receptor specific 







cross-linked sTRAIL preparation. However, compared to the scFv425:sTRAILmR1-5 fusion 
protein, both scFv425:sTRAIL-wt as well as kTRAIL were far less efficiently blocked by 
TRAIL-R1 mAb, TRAIL-R2 mAb or the combination of both mAbs. 
In addition, treatment of RC21 cells with scFv425:sTRAILmR1-5 in the presence of TRAIL-
R1:Fc or TRAIL-R2:Fc potently inhibited the induction of apoptosis (Fig. 5D). Of note, 
TRAIL-R2:Fc was more efficient than TRAIL-R1:Fc in blocking apoptosis. Similarly, TRAIL-
R1:Fc and TRAIL-R2:Fc also inhibited the apoptotic activity of scFv425:sTRAIL-wt and 
kTRAIL (Fig. 5D), although again to a lesser extent than scFv425:sTRAILmR1-5. 
To further verify that both TRAIL-R1 and TRAIL-R2 signaling are involved in activation 
of apoptosis in solid tumor cells by scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, 
siRNA-mediated knock-down of TRAIL-R1 or TRAIL-R2 was performed in OVCAR3 
cells. Normally, OVCAR3 cells express TRAIL-R1 and TRAIL-R2 at approximately equal 
levels on the cell surface (Fig. 6A). In addition, treatment with scFv425:sTRAIL-wt and 
scFv425:sTRAILmR1-5 potently activates apoptosis (Fig. 6B). Treatment of OVCAR3 cells 
with TRAIL-R1 specific siRNA resulted in ~92% down-regulation of TRAIL-R1 (Fig. 6C). 
Similarly, treatment with TRAIL-R2 specific siRNA resulted in ~91% down-regulation of 
TRAIL-R2 (Fig. 6D). 
The absence of TRAIL-R1 or TRAIL-R2 signaling, respectively, upon siRNA treatment was 
confirmed using TRAIL-receptor selective agonistic antibodies. A TRAIL-R1 agonistic mAb 
was largely inactive on OVCAR3 cells treated with TRAIL-R1 siRNA (Fig. 7A), while a 
TRAIL-R2 agonistic mAb was largely inactive on OVCAR3 cells treated with TRAIL-R2 
siRNA (Fig. 7B). Thus, treatment with the respective TRAIL-R1 or TRAIL-R2 siRNA indeed 
functionally down-regulates the receptor. However, scFv425:sTRAILmR1-5 potently in-
duced apoptosis in these cells irrespective of TRAIL-R1 or TRAIL-R2 down regulation (Fig. 
7A and B), indicating that both receptors can be activated by scFv425:sTRAILmR1-5. In 
addition, the pro-apoptotic activity of scFv425:sTRAIL-wt was markedly reduced compared 
to scFv425:sTRAILmR1-5 when TRAIL-R2 was knocked-down, thus confirming previous 
reports that wild-type sTRAIL preferentially signals via TRAIL-R2.
scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 activate similar caspase-signaling
The differential reliance on TRAIL-R1/R2 for induction of apoptosis by scFv425:sTRAIL-
wt and scFv425:sTRAILmR1-5 after siRNA-mediated receptor down regulation, prompt-
ed us to assess whether the type of apoptosis induced by the two fusion proteins was 
similar or divergent. Therefore, we treated RC21 and PC-3M cells with scFv425:sTRAIL-
wt and scFv425:sTRAILmR1-5 and determined caspase-activity at various time-points. 
In both RC21 and PC-3M cells, induction of apoptosis by scFv425:sTRAIL-wt and 
scFv425:sTRAILmR1-5 was associated with a similar activation profile for caspase-8 (Fig. 
8A), caspase-9 (Fig. 8B) and caspase-3/-7 (Fig. 8C). As expected, caspase levels for 
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Figure 5. Induction of apoptosis by scFv425:sTRAILmR1-5 and MOCK-scFv:sTRAILmR1-5 is 
inhibited by TRAIL-R2 blocking mAb. RC21 cells were treated with A. scFv425:sTRAILmR1-5 (500 
ng/ml), B. scFv425:sTRAIL-wt (500 ng/ml) and C. kTRAIL (50 ng/ml) in the presence or absence of 
TRAIL-R1 blocking mAb (1 µg/ml), TRAIL-R2 blocking mAb (1 µg/ml), or a combination of TRAIL-R1 
and TRAIL-R2 blocking mAbs. D. RC21 cells were treated with scFv425:sTRAILmR1-5 (500 ng/ml), 
scFv425:sTRAIL-wt (500 ng/ml), or kTRAIL (50 ng/ml) in the presence or absence of TRAIL-R1:Fc or 































































































































































Figure 6. siRNA-mediated down-regulation of TRAIL-R1 or TRAIL-R2. A. OVCAR3 cells were 
incubated with PE-conjugated Goat-anti-Mouse polyclonal Ab (GaM-PE) (solid fill), TRAIL-R1 mAb + 
GaM-PE (solid line), or TRAIL-R2 mAb + GaM-PE (dotted line), after which TRAIL-receptor expres-
sion was assessed by flow cytometry as described in materials and methods. B. OVCAR3 cells were 
treated with scFv425:sTRAIL-wt (850 ng/ml) or scFv425:sTRAILmR1-5 (850 ng/ml). C. OVCAR3 cells 
were treated for 72h with TRAIL-R1 siRNA and D. TRAIL-R2 siRNA, after which expression of TRAIL-
receptors was assessed by incubating cells with TRAIL-R1 mAb and TRAIL-R2 mAb. The depicted 
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scFv425:sTRAILmR1-5 were consistently higher in PC-3M cells (Fig. 8A, B and C). Subse-
quent inhibition of caspase-8, caspase-9 or total caspases confirmed that scFv425:sTRAIL-
wt and scFv425:sTRAILmR1-5 have a similar dependency on caspases for execution of 
apoptosis (Fig. 8D). Interestingly, immunoblot analysis of the caspase-8 inhibitor cFLIPL 
revealed a striking difference between scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5. 
Cells treated with scFv425:sTRAILmR1-5 displayed a total absence of cFLIPL, whereas in 
scFv425:sTRAIL-wt treated cells cFLIPL was markedly upregulated compared to medium 
control (Fig. 8E and F). However, this difference was found for both RC21 and PC-3M cells 
suggesting that it is not the underlying reason for the differential activity of scFv425:sTRAIL-
wt and scFv425:sTRAILmR1-5.  
The differential activity of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 is not due to 
NFκB signaling
Analysis of the pro-apoptotic signaling pathways by scFv425:sTRAIL-wt and 
scFv425:sTRAILmR1-5 revealed an intriguing difference in cFLIPL. Since this apop-
totic modulator has been linked to the NFκB pathway, we further analyzed the NFκB 
Figure 7. scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 activate apoptosis after siRNA-medi-
ated down-regulation of TRAIL-R1 or TRAIL-R2. A. After incubation with TRAIL-R1 siRNA for 72h, 
OVCAR3 cells were treated with scFv425:sTRAIL-wt, scFv425:sTRAILmR1-5, agonistic TRAIL-R1 
mAb, or agonistic TRAIL-R2 mAb. B. After incubation with TRAIL-R2 siRNA for 72h, OVCAR3 cells 
were treated with scFv425:sTRAIL-wt, scFv425:sTRAILmR1-5, agonistic TRAIL-R1 mAb, or agonistic 




































































































Figure 8. scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 activate similar caspase-signal-
ing. Activity of A. Caspase-8, B. Caspase-9 and C. Caspase-3/-7 was assessed in PC-3M and 
RC21 cells after incubation for 1, 2, 3, 4, 5, 6 or 16h with either scFv425:sTRAIL-wt (850 ng/ml) or 
scFv425:sTRAILmR1-5 (850 ng/ml) D. PC-3M cells were treated for 16h with scFv425:sTRAIL-wt 
(850 ng/ml) or scFv425:sTRAILmR1-5 (850 ng/ml) in the presence or absence of zIETD-FMK (20 μM), 
zLEHD-FMK (20 μM) or zVAD-FMK (20 μM). Apoptosis was assessed by ∆ψ. E. RC21 and F. PC-3M 
cells were incubated for 6h with scFv425:sTRAIL-wt (850 ng/ml) or scFv425:sTRAILmR1-5 (850 ng/
ml) in the presence or absence of zVAD-FMK (20 μM). Whole cell lysates were analyzed for the pres-
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survival signaling as measured by IL-8 production in response to scFv425:sTRAIL-wt 
and scFv425:sTRAILmR1-5 treatment in RC21 and PC-3M cells (Fig. 9A). Contrary to 
expectations, scFv425:sTRAILmR1-5 consistently induced more NFκB signaling than 
scFv425:sTRAIL-wt, also in A549, HT-29 and WiDr cells (Fig. 9B). Interestingly, upon im-
munoblot analysis of p100/p52 and p105/p50 a clear processing of p100 into p52 was de-
tected in scFv425:sTRAIL-wt, but not in scFv425:sTRAILmR1-5 treated cells in both RC21 
and PC-3M (Fig. 9C and D), indicating that the fusion proteins activate different subunits of 
NFκB. To determine the relevance of this observation for the differential apoptotic activity of 
scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, NFκB-signaling was inhibited using IKK 
inhibitor Wedelolactone. Unfortunately, co-treatment yielded a similar and marginal increase 
in apoptosis for both fusion proteins (Fig. 9E and F). Thus, although an intriguing difference 
in NFκB signaling exists between scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, this 
can not account for the differential activity of these fusion proteins on PC-3M.
 
Discussion
Insight into the contribution of the respective agonistic TRAIL-receptors to induc-
tion of apoptosis by sTRAIL in selected tumor types may help optimize TRAIL-based 
therapeutic strategies. The role of TRAIL-R1 in TRAIL-signaling in particular is sub-
ject to debate. Therefore, we here evaluated the pro-apoptotic activity of fusion protein 
scFv425:sTRAILmR1-5, comprising EGFR-blocking antibody fragment scFv425 and the 
previously described TRAIL-R1 selective sTRAIL mutant sTRAILmR1-5 (25). Fusion pro-
tein scFv425:sTRAILmR1-5 showed significantly superior apoptotic activity compared to 
the corresponding scFv425:sTRAIL-wt fusion protein on ~60% of the EGFR-positive solid 
tumor cell lines tested and showed a non-significant trend to higher apoptotic activity on the 
other cell lines. Both scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 showed synergistic 
pro-apoptotic activity upon co-treatment with cisplatin or the histone deacetylase inhibitor 
VPA, but scFv425:sTRAILmR1-5 remained significantly more potent when compared to the 
wild type sTRAIL fusion protein. Induction of apoptosis by scFv425:sTRAILmR1-5 as well 
as the synergistic induction of apoptosis with VPA and cisplatin is dependent on binding to 
EGFR, since co-incubation with parental EGFR-blocking mAb 425 strongly inhibits apop-
tosis. Importantly, compared to a non-targeted MOCK-scFv:sTRAILmR1-5 fusion protein, 
directed at the B-cell marker CD20, scFv425:sTRAILmR1-5 showed superior apoptotic 
activity.
Mutant sTRAILmR1-5 was reported by MacFarlane et al. to be selective for TRAIL-R1. 
This conclusion was mainly based on the differential apoptotic activity of this mutant to-
wards Jurkat (TRAIL-R1-/TRAIL-R2+) and Ramos cells (TRAIL-R1+/TRAIL-R2+) (24). How-
ever, our experiments collectively demonstrate that sTRAILmR1-5 is actually not selective 







Figure 9. The differential activity of scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5 is not due 
to NFκB signalling. A. RC21, PC-3M and B. A549, HT29 and WiDr cells were incubated for 16h with 
scFv425:sTRAIL-wt (850 ng/ml) or scFv425:sTRAILmR1-5 (850 ng/ml) in the presence or absence of 
zVAD-FMK (20 μM), after which supernatant was analyzed for IL-8 levels. C. RC21 and D. PC-3M cells 
were incubated in the presence or absence of zVAD-FMK (20 μM). Whole cell lysates were analyzed 
for the presence of NFκB subunits p100/p52, p105/p50 and p65. E. RC21 and F. PC-3M cells were 
treated for 6h with scFv425:sTRAIL-wt (850 ng/ml) or scFv425:sTRAILmR1-5 (850 ng/ml) in the pres-
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catching-type ELISA. Furthermore, binding of scFv425:sTRAILmR1-5 to TRAIL-R1:Fc was 
competitively inhibited by addition of soluble TRAIL-R2:Fc. Interestingly, TRAIL-R1:Fc was 
superior to TRAIL-R2:Fc in inhibiting scFv425:sTRAILmR1-5, whereas the reverse was 
true for scFv425:sTRAIL-wt, indicating a reversal in affinity between sTRAIL-wt and the 
sTRAILmR1-5 domain for TRAIL-R1 and TRAIL-R2. Of note, the only interaction that is 
being investigated in these ELISAs is that of the sTRAIL domain with TRAIL-receptors. 
Thus, these experiments demonstrate that the sTRAILmR1-5 domain in itself is capable of 
binding to TRAIL-R2. 
The binding of the sTRAILmR1-5 domain to TRAIL-R2 also has functional implications, 
since induction of apoptosis by scFv425:sTRAILmR1-5 was markedly inhibited by a TRAIL-
R2 blocking antibody. In actual fact, the TRAIL-R2 blocking mAb was more effective than 
the TRAIL-R1 blocking mAb. Moreover, ~92% down-regulation of TRAIL-R1 by small in-
hibitory RNA did not abrogate the apoptotic activity of scFv425:sTRAILmR1-5. Indeed, 
some of the more sensitive cell lines actually have very low TRAIL-R1 expression (Table 
2). Collectively, these data indicate that target antigen-bound scFv425:sTRAILmR1-5 is 
capable of binding to and activation of TRAIL-R2. Therefore, our data also warrant a re-
evaluation of the conclusion of MacFarlane et al. that non-targeted sTRAILmR1-5 is selec-
tive for TRAIL-R1.
Interestingly, induction of apoptosis by scFv425:sTRAILmR1-5 fusion protein was 
more effectively inhibited by TRAIL-R blocking mAbs than the induction of apoptosis by 
scFv425:sTRAIL-wt or kTRAIL. These experiments suggest that the wild-type sTRAIL do-
main has a relatively higher affinity for its receptors and can thus more efficiently compete 
with the TRAIL-R blocking mAbs for binding to the receptors. Together, this also implies 
that, while en route to the tumor, scFv425:sTRAILmR1-5 will display a more transient bind-
ing to the ubiquitously expressed TRAIL-receptors. As a result, tumor cell accretion is ex-
pected to be more efficient for scFv425:sTRAILmR1-5 compared to scFv425:sTRAIL-wt.
Our experimental data regarding the activity of scFv425:sTRAILmR1-5 also highlight an 
intriguing question, namely: what is the molecular mechanism for the enhanced activity 
of this sTRAIL mutant on EGFR-positive tumor cell lines as reported here and on pri-
mary patient-derived B-CLL cells as reported previously. First and foremost, based on our 
experimental evidence it is obvious that both TRAIL-R1 and TRAIL-R2 signaling are an 
integral part of the apoptotic activity of this mutant. However, there is no obvious correla-
tion between the apoptotic activity of scFv425:sTRAILmR1-5 and the expression levels of 
the respective TRAIL-receptors, nor the ratios of the various TRAIL-receptors (TRAIL-R2/
TRAIL-R1, TRAIL-R1/TRAIL-R4, TRAIL-R2/TRAIL-R4).
One possible explanation for our and MacFarlane’s observations may be found in the in-
completely characterized complexity of TRAIL-receptor biology. Several groups have found 







can also form heterotrimeric complexes comprising TRAIL-R1 and TRAIL-R2 monomers 
(28,29). As such, TRAIL-R1/TRAIL-R2 heterotrimers may represent nature’s strategy to 
fine tune the apoptotic response to TRAIL.
It is tempting to speculate that sTRAILmR1-5, besides activating homotrimeric TRAIL-R1, 
may be better able to activate TRAIL-R1/R2 heterotrimers than wild type sTRAIL. Such a 
differential capacity to activate heterotrimers might explain the superior induction of apop-
tosis by scFv425:sTRAILmR1-5 in a subset of cell lines. This hypothesis is in line with 
most of our observations, including the finding that scFv425:sTRAILmR1-5 is inactive on 
A2780 cells that only express TRAIL-R2 (data not shown), while induction of apoptosis by 
scFv425:sTRAILmR1-5 is potently inhibited by a TRAIL-R2 agonistic antibody on TRAIL-
R1+/TRAIL-R2+ cells. Moreover, siRNA knock-down of either TRAIL-R1 or TRAIL-R2 by 
>90% does not block induction of apoptosis by scFv425:sTRAILmR1-5.
Further circumstantial evidence for heterotrimeric TRAIL-R1/TRAIL-R2 can be found in a 
recent report in which it was shown that selective activation of either TRAIL-R1 or TRAIL-
R2 with receptor specific agonistic mAbs in B-CLL cells is not as effective as sTRAIL-
mediated apoptosis of the same cells (30). These results point to a benefit of simultaneous 
triggering of both TRAIL-receptors. Interestingly, sTRAIL versions such as Apo2L/sTRAIL 
(Genentech) that activate apoptosis predominantly through TRAIL-R2 were less effica-
cious than those versions that also signal apoptosis via TRAIL-R1, which is in agreement 
with our finding that scFv425:sTRAILmR1-5 is more active than scFv425:sTRAIL-wt.
An alternative or complementary hypothesis for the enhanced activity of 
scFv425:sTRAILmR1-5 may be found in the recently described potential for S-nitrosylation 
of TRAIL-R1 and not TRAIL-R2 (31). Tang et al. found that treatment of OVCAR3 cells with 
a nitric oxide donor resulted in the S-nitrosylation of TRAIL-R1 at cysteine residue 336, 
with a concomitant superior induction of apoptosis by TRAIL. Therefore, the presence of S-
nitrosylated TRAIL-R1 in certain cell lines, intrinsically subject to higher nitric oxide stress, 
may account for the superior apoptotic activity of scFv425:sTRAILmR1-5.
Importantly, the superior apoptotic activity of scFv425:sTRAILmR1-5 on certain cell lines is 
not related to PI3K signaling, JNK-signaling (data not shown), nor on differential caspase-
signaling or NFκB-signaling. However, independent of the differential apoptotic activity of 
scFv425:sTRAIL-wt and scFv425:sTRAILmR1-5, we observed an intriguing difference in 
the level of cFLIPL in treated cells. Treatment with scFv425:sTRAIL-wt was associated with 
an increased level of cFLIPL, whereas scFv425:sTRAILmR1-5 treated cells lacked cFLIPL 
expression altogether. At the same time, scFv425:sTRAILmR1-5 treated cells showed 
increased levels of NFκB activation, as judged by IL-8 production. Therefore, although 
cFLIPL has been predominantly described as a constitutive activator of NFκB signaling 
our data actually highlight a potential opposite correlation, with loss of cFLIPL occurring 
concurrently with higher NFκB activity. This finding is in agreement with a previous report 
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by Wajant et al., who also demonstrated an inhibitory role of cFLIPL. A further intriguing 
finding regarding the NFκB pathway, is the differential processing of the pro-units p100 
into p52 by scFv425:sTRAIL-wt but not by scFv425:sTRAILmR1-5. Although puzzling, our 
data highlight the very complex relationship between TRAIL-receptor signaling and NFκB 
activation. 
Of note, mutant sTRAILmR1-5 is a derivative of another designed TRAIL-R1 selective 
sTRAIL mutant, sTRAILmR1-6, that was generated by Kelley et al. (23). Based partly on 
mutant sTRAILmR1-6, Kelley et al. ascribed a greater role for TRAIL-R2 in TRAIL-apoptot-
ic signaling in solid tumors. Since this mutant was later found to be inactive and we here 
clearly demonstrate TRAIL-R1 signaling in solid tumor cells, the conclusions of Kelley et al. 
that TRAIL-R1 is not important in solid tumors may need to be revised.
Although homotrimeric wildtype sTRAIL is widely regarded as non-toxic towards normal 
human cells, an important issue to consider in the use of mutated versions of sTRAIL, 
such as sTRAILmR1-5, is the potential presence of toxicity resulting from the incorporated 
amino acid mutations. A future in depth toxicological evaluation in primary human cells and 
in appropriate animal models will be required to accurately assess the toxicity profile, and 
thus the therapeutic potential, of scFv425:sTRAILmR1-5.
In conclusion, the EGFR-specific delivery of mutant sTRAILmR1-5 results in superior 
apoptotic activity towards EGFR-positive tumor cells. Further preclinical development of 
scFv425:sTRAILmR1-5 appears warranted to determine the therapeutic potential of this 
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Chapter 5: MCSP-targeted delivery of sTRAIL inhibits melanoma outgrowth




Advanced melanoma is characterized by a pronounced resistance to therapy lead-
ing to a limited patient survival of ~6-9 months. Here, we report on a novel bifunc-
tional therapeutic fusion protein, designated anti-MCSP:TRAIL, that is comprised of 
a melanoma-associated chondroitin sulfate proteoglycan (MCSP)-specific antibody 
fragment (scFv) fused to soluble human TRAIL. MCSP is a well-established target 
for melanoma immunotherapy and has recently been shown to provide important 
tumorigenic signals to melanoma cells. TRAIL is a highly promising tumoricidal cy-
tokine with no or minimal toxicity towards normal cells. Anti-MCSP:TRAIL was de-
signed to 1. selectively accrete at the cell surface of MCSP-positive melanoma cells 
and inhibit MCSP tumorigenic signaling and 2. activate apoptotic TRAIL-signaling. 
Treatment of a panel of MCSP-positive melanoma cell lines with anti-MCSP:TRAIL 
induced TRAIL-mediated apoptotic cell death within 16h. Of note, treatment with 
anti-MCSP:TRAIL was also characterized by a rapid dephosphorylation of key pro-
teins, such as FAK, implicated in MCSP-mediated malignant behavior. Importantly, 
anti-MCSP:TRAIL treatment already inhibited anchorage-independent growth by 
50% at low picomolar concentrations, whereas >100 fold higher concentrations of 
non-targeted TRAIL failed to reduce colony formation. Daily i.v. treatment with a low 
dose of anti-MCSP:TRAIL (0.14mg/kg) resulted in a significant growth retardation 
of established A375M xenografts. Anti-MCSP:TRAIL activity was further synergized 
by co-treatment with rimcazole, a σ-ligand currently in clinical trials for the treat-
ment of various cancers. In conclusion, anti-MCSP:TRAIL has promising pre-clinical 
anti-melanoma activity that appears to result from combined inhibition of tumori-
genic MCSP-signaling and concordant activation of TRAIL-apoptotic signaling. Anti-
MCSP:TRAIL alone, or in combination with rimcazole, may be of potential value for 
the treatment of malignant melanoma.
 
Background
Patients diagnosed with localized melanoma have a 10-year survival rate of up to 95%. In 
contrast, the life expectancy of patients with metastasized melanoma is limited to only 6-9 
months [1]. The poor survival of patients with advanced melanoma is largely attributable 
to resistance towards current treatment modalities such as chemo- and radiotherapy [2]. 
Therefore, the development of novel therapeutic approaches that can trigger melanoma-
selective cell death appears warranted.
One target molecule of potential relevance for the tumorigenicity of melanoma is the mel-
anoma chondroitin sulfate proteoglycan (MCSP), also known as high molecular weight 
melanoma associated antigen (HMW-MAA). MCSP is highly expressed on the cell surface 







ly, over-expression of MCSP correlates with an unfavorable prognosis [4]. Expression of 
MCSP on normal tissue is mainly restricted to cells of the melanocyte lineage, but has also 
been detected in basal cells of the epidermis and within the hair follicle, in pericytes, chon-
drocytes and smooth muscle cells [3]. Recent studies have revealed that MCSP expression 
may provide important tumorigenic signals to melanoma cells. MCSP signaling stimulates 
growth, motility, and tissue invasion by melanoma cells, e.g. by enhancing integrin function 
[5], activation of Focal Adhesion Kinase (FAK) [6], mitogenic ERK signaling [7] and matrix 
metalloproteinase 2 [8]. Furthermore, non-metastatic radial growth tumor cells acquired 
anchorage-independent growth characteristics upon ectopic expression of MCSP [6]. Of 
note, anti-MCSP antibody treatment can partly inhibit MCSP-tumorigenic signaling in vitro, 
as evidenced by a pronounced inhibition of FAK [6]. 
Thus, MCSP appears to be important for melanoma tumorigenicity and appears to be a 
promising target for both naked monoclonal antibody (mAb) as well as immunotoxin-based 
strategies [9,10]. Notably, anti-MCSP mAbs proved to have beneficial effects on the clinical 
course of the disease of melanoma patients [3,11].
In recent years, we have demonstrated that scFv antibody fragment-targeted delivery of 
the immuno cytokine TRAIL holds particular promise for tumor-selective induction of apop-
tosis in various cancer types. TRAIL (Tumor Necrosis Factor Related Apoptosis Induc-
ing Ligand) is a highly promising anti-cancer agent with pronounced pro-apoptotic activity 
towards various malignant cell types, including melanoma. Importantly, TRAIL essential-
ly lacks activity towards normal cells [12]. Based on these characteristics, recombinant 
soluble TRAIL (sTRAIL) preparations have recently entered clinical trials, with promising 
preliminary reports on anti-tumor activity and safety [13]. 
Antibody fragment-mediated targeting of TRAIL can further selectively enhance the anti-
tumor activity of TRAIL towards various types of cancer, including carcinomas and Acute 
Myeloid Leukemia [12] [14-20] (see also chapter 2). Briefly, genetic fusion of TRAIL to an 
scFv antibody fragment allows for the selective delivery of TRAIL to a pre-selected tumor-
associated antigen at the tumor cell surface. The resulting high levels of tumor cell surface 
bound TRAIL then efficiently activate apoptotic signaling via the agonistic TRAIL-receptors 
TRAIL-R1 and TRAIL-R2 in a mono- and/or bi/multicellular manner [14-18,20]. Of note, 
non-targeted sTRAIL has no intrinsic tumor-selective binding activity and is less efficient in 
cross-linking and activating TRAIL-R2 [21].
Here we preclinically evaluated the anti-melanoma activity of MCSP-targeted delivery of 
TRAIL, using fusion protein anti-MCSP:TRAIL. Anti-MCSP:TRAIL was designed to se-
lectively bind to MCSP at the cell surface of melanoma cells and simultaneously inhibit 
tumorigenic signaling by MCSP. Once bound to MCSP-expressing melanoma cells, the 
anti-MCSP:TRAIL fusion protein can activate apoptotic TRAIL-signaling. Since TRAIL re-
sistance has been reported for melanoma [22] we further evaluated a combinatorial strat-
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egy in which anti-MCSP:TRAIL treatment was combined with rimcazole. Rimcazole is a 
sigma ligand currently in clinical trials for various cancers that has shown potent single-
agent anti-tumor activity towards glioma and breast cancer [23,24]. Sigma ligand-based 
therapy may also be of value for the treatment of melanoma since σ-receptors 1 and 2 are 
strongly overexpressed in this tumor [25,26].
MCSP targeting with anti-MCSP:TRAIL indeed appeared to inhibit MCSP-signaling and 
activated TRAIL-apoptotic signaling in melanoma cells in vitro and in vivo. Furthermore, 
TRAIL-apoptotic signalling in melanoma cells can be further increased by combinatorial 
treatment with rimcazole. The dual anti-melanoma activity of anti-MCSP:TRAIL alone, or in 
combination with rimcazole, may be of interest for treatment of melanoma.
Materials and Methods
Reagents
MAb 9.2.27 is a murine IgG2a with high binding affinity for human MCSP [10]. TRAIL-neu-
tralizing mAb 2E5 was purchased from Alexis (10P’s, Breda, The Netherlands). Caspase 
inhibitors zVAD-fmk and zLEHD-fmk were from Calbiochem (VWR International B.V., Am-
sterdam, The Netherlands) and dissolved at 10 mM in DMSO. Rimcazole (BW 239U) and 
(+)pentazocine were from Sigma Aldrich (Sigma-Aldrich Chemie B.V. Zwijndrecht, Nether-
lands). Stock solutions of rimcazole (3.9 mM in ethanol) and pentazocine (10 mM in 0.1N 
hydrochloric acid) were freshly prepared for each experiment.
Cell lines 
MCSP-positive/EpCAM-negative melanoma cell lines A375M, A2058 and SK-MEL-28 
were obtained from and characterized (STR profiling, karyotyping, isoenzyme analysis) by 
the American Tissue Culture Collection (ATCC). The MCSP-negative melanoma cell line 
M14 and transfectant cell line M14.MCSP were provided by Prof. Dr. G.H. Fey. Expression 
of MCSP was determined by flow cytometry using anti-MCSP mAb 9.2.27 and a FITC-
conjugated goat-anti-mouse mAb. A375M.FADD-DED cells were generated by transfec-
tion of parental A375M cells using Fugene (Roche BV, Woerden, The Netherlands). All 
cell lines were cultured at 37°C, in a humidified 5% CO2 atmosphere. A375M, A2058, 
SK-MEL-28 and M14 cells were cultured in RPMI 1640 medium (Cambrex Bio Science, 
Verviers, France) supplemented with 10% fetal calf serum. M14.MCSP cells were cultured 
in RPMI 1640 medium supplemented with 10% fetal calf serum and 400 μg/ml Geneticin. 
A375M.FADD-DED cells were cultured in RPMI 1640 medium supplemented with 10% 
fetal calf serum and 500 μg/ml Geneticin. 
Primary human hepatocytes (PHH) and melanocytes







Netherlands) were isolated according to standard protocol using hepatocyte isolation kit 
and melanocyte isolation kit, respectively (tebu-bio bv, Heerhugowaard, The Netherlands). 
For experiments, hepatocytes and melanocytes were seeded in a 48 well plate at a density 
of 0.5x106 cells/ml.
Construction of fusion protein anti-MCSP:TRAIL
A scFv antibody fragment in the VH-VL format was derived from mAb 9.2.27 using standard 
antibody-phage display technology [10]. Fusion protein anti-MCSP:TRAIL was constructed 
by cloning the cDNA of antibody fragment MCSP in frame with soluble TRAIL into in-house 
constructed vector pEE14 using unique SfiI and NotI restriction enzyme sites, yielding 
plasmid pEE14-anti-MCSP:TRAIL. Fusion protein anti-MCSP:TRAIL was produced in 
CHO-K1 cells using previously described methods [14,16]. Culture medium containing 
anti-MCSP:TRAIL was cleared by centrifugation (10.000 g, 10 min), filter sterilized, and 
stored at -80°C until further use. Fusion protein anti-MCSP:TRAIL was purified via the 
N-terminal Hemagglutinin (HA)-tag using anti-HA affinity chromatography. Fusion protein 
scFvC54:sTRAIL [14], for reasons of clarity hereafter renamed into anti-EpCAM:TRAIL, is 
a fusion protein that is essentially identical to anti-MSCP:TRAIL except that it contains an 
anti-EpCAM scFv instead of an anti-MSCP scFv.  
Assessment of apoptosis
MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL was assessed on a panel  of 
melanoma cell lines. Briefly, melanoma cells were pre-cultured in a 48-well plate at a con-
centration of 3.0x104 cells/well. Subsequently, cells were treated as indicated and apopto-
sis was assessed by: Loss of mitochondrial membrane potential (∆ψ); ∆ψ was analyzed 
by DiOC6 staining (Eugene, The Netherlands) as previously described [16]. After 16 h 
treatment, cells were harvested and incubated for 20 min with DiOC6 (0,1 μM) at 37°C, har-
vested (1000 g, 5 min.), resuspended in PBS, and assessed for staining by flow cytometry. 
Caspase-8, caspase-9 and caspase-3/-7 activity; caspase activity was assessed using the 
Caspase-Glo 8, 9 and 3/7 Assay according to manufacturer’s instructions (Promega Ben-
elux BV, Leiden, The Netherlands). The assay is based on the cleavage of non-luminescent 
substrates by activated caspases into a luminescent product. Luminescence was quanti-
fied using a Victor3 multi-label plate reader (Perkin Elmer, Groningen, The Netherlands). 
Soft agar colony forming assay
Soft agar colony forming assays were performed in 24-well plates pre-coated with 0.5 ml 
solidified 0.4% agarose in RPMI 1640 medium. Cells were resuspended at a density of 
10x103 cells/well in 0,6% agarose in RPMI 1640 medium supplemented with 20% fetal calf 
serum and layered on the solidified 0.4% agarose in a 24-well plate. Tumor cell contain-
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ing agarose was allowed to solidify for 10 minutes at 4°C before addition of 1 ml of RPMI 
1640 medium supplemented with 20% fetal calf serum. Cells were treated as indicated 
and subsequently cultured at 37°C, in a humidified 5% CO2 atmosphere. Colony formation 
was assessed 21 days after start of treatment. Assays were performed in quadruplicate. 
Number of colonies was quantified and percentage of colony growth was calculated with 
the formula: Percentage of colony growth = (number of colonies in experimental condition) 
/ (number of colonies in medium control) x 100%. For A375M cells, the number of colonies 
in untreated samples ranged from 30±5 to 262±35 between individual experiments.
Proteome Profiler array
The effect of MCSP targeting on protein tyrosine kinase activity was assessed by the Hu-
man Phospho-Kinase Array Kit (R&D Systems) according to the manufacturer’s recom-
mendations. Briefly, per condition 1 x 107 cells were treated for 0, 30, 60, or 240 min. at 
37°C as indicated. Lysate (500 μg/condition) was added to the NC-membranes contain-
ing spotted Phospho-Kinase (PK) antibodies. Subsequently, secondary Biotin-conjugated 
anti-Kinase antibodies and Horseradish Peroxidase-conjugated Streptavidin were added 
to detect the presence of phosphorylated kinases. Between incubation steps, membranes 
were rigorously washed. Blots were developed by standard chemoluminescence (Roche). 
Luminescent signals were quantified using the IVIS Spectrum bioluminescent imager (Cali-
per Biosciences) as photons/sec/sr/cm2. After background luminescence subtraction, the 
relative kinase activity in treated conditions was calculated by the formula: (PK activity 
experimental condition / PK activity medium control)*100%.
A375M xenograft mouse model
Experiments involving animals were performed in accordance with the experimental proto-
col approved by the Committee for Research and Animal Ethics of the UMCG. Six week old 
healthy male athymic mice (n=8) were purchased from Harlan (Harlan Netherlands B.V., 
Horst, The Netherlands). Mice were housed in IVC cages and fed ad libitum. Subsequently, 
mice were subcutaneously inoculated with 2 x 106 A375M cells suspended in 100 μl matri-
gel. Tumor growth was monitored daily by electronic caliper measurements. After reaching 
tumor size of ~50 ± 6 mm3, mice were randomly assigned into two groups with a sample 
size of 4. Mice received daily i.v. saline injections or anti-MCSP:TRAIL injections (0.14 mg/
kg). After two weeks of treatment, mice were sacrificed by cervical dislocation. Tumor size 
was calculated by the formula: V = 0,5234 x H x L x W [mm3]. Tumor size was expressed 
as the percentage of maximum tumor size in Sham-treated mice.
Liver histopathology







stained with hematoxylin-eosin and microscopically inspected for hepatic tissue damage 
and inflammation. 
Combination treatment with anti-MCSP:TRAIL and σ-ligands
Cells were plated at 3.0 x 104 cells / well in a 48-well plate and allowed to adhere overnight. 
Cells were concurrently treated for 24h with anti-MCSP:TRAIL with or without rimcazole 
(15 μM), and (+)pentazocine (200 nM). Synergy was assessed by calculating the coopera-
tivity index (CI) in which the sum of apoptosis induced by single-agent treatment is divided 
by apoptosis induced by combination treatment. When CI was less than 1, treatment was 
considered synergistic; when CI equaled 1, treatment was considered additive; when CI 
was greater than 1, treatment was considered antagonistic.
Statistical analysis
Data reported are mean values ± standard error of the mean of at least three independent 
experiments. Statistical analysis was performed by one-way ANOVA followed by Tukey-
Kramer post test or by two-sided unpaired Student’s t-test. p < 0.05 was defined as a 
statistically significant difference.
Results and Discussion
MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL
We and others have previously demonstrated that selective delivery of the cytokine TRAIL 
by genetic fusion to an appropriate tumor-selective scFv antibody fragment significantly 
enhances the anti-tumor activity of TRAIL towards the corresponding type of cancer [14-
20]. Here, we adapted this targeted approach to malignant melanoma by exploiting an 
ant-MCSP scFv antibody fragment that was derived from the well-established monoclonal 
antibody (mAb) 9.2.27. The resultant fusion protein, anti-MCSP:TRAIL, was equipped to 
selectively accrete at the cell surface of MCSP-positive cells only and subsequently trigger 
TRAIL-mediated apoptosis. 
Indeed, treatment of MCSP-transfected M14 melanoma cells (M14.MCSP) with anti-
MCSP:TRAIL resulted in dose-dependent activation of apoptosis within 16h, whereas 
parental MCSP-negative M14 cells were resistant to treatment with anti-MCSP:TRAIL 
(Fig.1A). Similarly, treatment of a series of MCSP-positive cell lines (A375M, A2058 and 
SK-MEL-28) with anti-MCSP:TRAIL resulted in a marked induction of apoptosis (Fig. 1B). 
In a control experiment we treated the same series of melanoma cells with fusion protein 
anti-EpCAM:TRAIL, a fusion protein that is essentially identical to anti-MCSP:TRAIL except 
that it contains an anti-EpCAM scFv instead of an anti-MCSP scFv antibody fragment [14]. 
EpCAM is a well established carcinoma-associated cell surface target antigen that is not 
expressed on melanoma cells. Indeed, no signs of apoptosis were observed when A375M, 
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A2058 or SK-MEL-28 cells were treated with anti-EpCAM:TRAIL (Fig. 1C and D).
Treatment of MCSP-positive A375M, A2058 or SK-MEL-28 cells with the parental anti-
MCSP antibody mAb 9.2.27 failed to induce any signs of apoptosis (Fig.1D). Importantly, 
also co-treatment with MAb 9.2.27 and anti-EpCAM:TRAIL did not induce any significant 
signs of apoptosis (Fig. 1D). Thus, treatment of MCSP-positive melanoma cells with fusion 
protein anti-MCSP:TRAIL efficiently activates apoptosis that is MCSP-restricted and that is 
superior to combined treatment with TRAIL and the parental anti-MCSP mAb 9.2.27. 
Induction of apoptosis by anti-MCSP:TRAIL was abrogated when treatment was performed 
in the presence of the parental mAb 9.2.27 (Fig. 2A). Thus, anti-MCSP:TRAIL activity is 
strictly dependent on binding to cell surface-expressed MCSP on malignant cells. Further-
more, addition of the TRAIL-neutralizing mAb 2E5 fully abrogated the apoptotic effect of 
anti-MCSP:TRAIL (Fig.2A), indicating that induction of apoptosis is dependent on interac-
tion of TRAIL with its agonistic TRAIL-receptors. In addition, induction of apoptosis was 
inhibited when treatment is performed in the presence of pan-caspase-inhibitor zVAD-fmk 
(Fig. 2A), further suggesting involvement of TRAIL-mediated apoptotic signaling. Indeed, 
treatment of melanoma cells with anti-MCSP:TRAIL was characterized by time-dependent 
activation of initiator caspase-8 (Fig. 2B) as well as effector caspases 3 and 7 (Fig. 2C).
To further confirm that TRAIL-signaling is involved, the mutant cell line A375M.FADD-DED 
that ectopically overexpresses a dominant negative mutant of the adaptor protein FADD, 
was produced. FADD is a pivotal adaptor protein in TRAIL-receptor signaling. The mu-
tant FADD protein that was ectopically expressed in A375M.FADD-DED cells lacks the 
so-called DED domain, which results in a general and strong resistance against TRAIL-me-
diated apoptosis. Indeed, TRAIL-mediated apoptotic signaling was fully halted in A375M.
FADD-DED cells, as is evidenced by the fact that these cells were fully resistant to ubiq-
uitously active recombinant human TRAIL (rhTRAIL) (Fig. 2D). Likewise, A375M.FADD-
DED cells were also fully resistant to treatment with anti-MCSP:TRAIL (Fig. 2D). Taken 
together, these data clearly demonstrate that the pro-apoptotic activity of anti-MCSP:TRAIL 
is TRAIL-mediated.
Previously, we and others have shown that upon binding to the respective target antigen, 
scFv:TRAIL fusion proteins can efficiently activate TRAIL-R2, whereas untargeted sTRAIL 
preparations have a markedly reduced capacity to activate TRAIL-R2 signaling. Indeed 
A375M cells, that solely express TRAIL-R2 at the cell surface (Fig. 3A) are sensitive to 
treatment with anti-MCSP:TRAIL (Fig. 3B), indicating that anti-MCSP:TRAIL can potently 
activate TRAIL-R2 signaling in MCSP-positive melanoma cells. This feature may be of 
special relevance for melanoma since TRAIL-R2 is the most prevalent agonistic TRAIL-
receptor expressed on melanoma cells [27].







Figure 1. MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL A M14 and M14.MCSP 
cells were treated with increasing concentrations of anti-MCSP:TRAIL for 16h and apoptosis was as-
sessed. B MCSP-negative cell line M14 and MCSP-positive cell lines M14.MCSP, SK-MEL-28, A2058 
and A375M were treated with 500 ng/ml anti-MCSP:TRAIL for 16h and apoptosis was assessed. C 
A2058 cells were treated with increasing concentrations of anti-MCSP:TRAIL or anti-EpCAM:TRAIL for 
16h and apoptosis was assessed D A375M, A2058 and SK-MEL-28 cells were treated with equimolar 
concentrations of anti-MCSP:TRAIL, anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL+anti-
MCSP mAb for 16h and apoptosis was assessed. In all experiments, apoptosis was assessed by ∆ψ





























































































































Chapter 5: MCSP-targeted delivery of sTRAIL inhibits melanoma outgrowth
Molecular cancer 2010 Nov; 23(9):301
C
hapter 5
Figure 2. Caspase-dependent induction of apoptosis by anti-MCSP:TRAIL A A2058 cells were 
treated with 500 ng/mL anti-MCSP:TRAIL in the absence or presence of parental MCSP-blocking mAb 
9.2.27, TRAIL-neutralizing mAb 2E5 or pan-caspase inhibitor zVAD-fmk for 16h and apoptosis was 
assessed. B A375M cells were treated with 500 ng/mL anti-MCSP:TRAIL for the time-points indicated 
and caspase-8 activation was assessed. C A2058 cells were treated with 500 ng/mL anti-MCSP:TRAIL 
in the absence or presence of parental MCSP-blocking mAb 9.2.27 or TRAIL-neutralizing mAb 2E5 
and caspase-3/-7 activation was assessed. D A375M and A375M.FADD-DED cells were treated with 











































































































































The MCSP antibody fragment used in this study was derived from mAb 9.2.27. In earlier 
studies, mAb 9.2.27 partly inhibited MCSP-tumorigenic signaling in vitro, as evidenced 
by inhibition of FAK [9]. Since ectopic expression of MCSP was also recently shown to 
induce anchorage-independent growth capacity, anti-MCSP:TRAIL was evaluated for its 
effect on anchorage-independent growth of melanoma cells. In a soft agar assay, treatment 
of the MCSP-positive cell lines A375M and A2058 cells with anti-MCSP:TRAIL abrogated 
colony outgrowth in a dose-dependent manner (Fig.4A). Of note, anti-MCSP:TRAIL re-
duced colony formation by 50% already at very low concentrations (0.1 ng/ml and 1ng/ml 
for A375M and A2058 cells, respectively). Induction of apoptosis by anti-MCSP:TRAIL at 
these concentrations in adherent growth conditions was marginal (see Fig. 3B for dose-
response curves of apoptosis induction). In contrast, treatment with similar concentrations 
of anti-EpCAM:TRAIL or with anti-MCSP mAb 9.2.27 only marginally reduced colony for-
mation (Fig. 4B). Importantly, also combinatorial treatment with equimolar concentrations 
of anti-EpCAM:TRAIL and mAb 9.2.27 failed to significantly inhibit colony outgrowth of 
A375M cells at the highest concentrations tested (Fig.4B). Furthermore, rhTRAIL failed to 
significantly reduce colony outgrowth (Fig. 4C). Thus, anti-MCSP:TRAIL uniquely and ef-
ficiently prevents colony outgrowth. 
Treatment of A375M cells with anti-MCSP:TRAIL in the presence of the TRAIL-neutralizing 
mAb 2E5 largely blocked the effect of anti-MCSP:TRAIL on colony outgrowth (Fig.4D). 
Figure 3. Anti-MCSP:TRAIL induces apoptosis in TRAIL-R1 negative cell lines. A A375M cells 
were incubated with anti-TRAIL-R1 (thin line) or anti-TRAIL-R2 (thick line) mAb and expression of 
TRAIL-R1 and TRAIL-R2 was analyzed by flow cytometry. Shaded area indicates the fluorescence 
signal when cells were incubated with fluorescent-labeled secondary antibody alone. B A2058 and 
A375M cells were treated with increasing concentrations of anti-MCSP:TRAIL for 16h and apoptosis 
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Similarly, treatment of cells with anti-MCSP:TRAIL in the presence of the parental anti-
MCSP mAb 9.2.27 inhibited anti-MCSP:TRAIL activity, although the number of colonies 
still remained significantly lower than medium control (Fig.4D). Of note, co-incubation with 
pan-caspase inhibitor zVAD-fmk abrogated the inhibitory effect of anti-MCSP:TRAIL on 
colony outgrowth (Fig.4D), suggesting that apoptotic signaling is required for the inhibitory 
effect of anti-MCSP:TRAIL. 
To further evaluate whether TRAIL-induced caspase-signaling was required for the inhibi-
tory effect of anti-MCSP:TRAIL on colony outgrowth, TRAIL-resistant A375M.FADD-DED 
cells were treated with anti-MCSP:TRAIL. Importantly, colony formation of A375M.FADD-
DED cells was inhibited by anti-MCSP:TRAIL treatment although ~50-100 fold higher 
concentrations were required to obtain the same magnitude of inhibition as observed for 
parental A375M cells (Fig. 5A). Of note, treatment of A375M.FADD-DED cells with anti-
EpCAM:TRAIL did not inhibit colony formation (Fig. 5B), nor did combination treatment of 
anti-EpCAM:TRAIL and mAb 9.2.27 (Fig. 5B). In contrast, mAb 9.2.27 alone did significantly 
inhibit colony outgrowth in this cell line, although to a lesser extent than anti-MCSP:TRAIL 
(Fig. 5B). Together, these experimental data suggest that the simultaneous interaction of 
anti-MCSP:TRAIL with MCSP and TRAIL-receptors uniquely blocks anchorage-indepen-
dent growth of melanoma cells at low concentrations.
Anti-MCSP:TRAIL dephosphorylates proteins involved in cell proliferation and apoptosis 
resistance
The efficacy of anti-MCSP:TRAIL on inhibition of colony formation by melanoma cells in 
3D-culture suggests that antibody fragment-dependent sensitization of cells to concurrent 
TRAIL-signaling may contribute to its therapeutic effect. Previously, we generated proof 
of concept data for such dual therapeutic signaling with scFv:TRAIL fusion proteins, using 
an scFv:TRAIL fusion protein that targeted the Epidermal Growth Factor Receptor [16,19] 
(see also chapter 3 and 4). Here, the EGFR-inhibitory antibody fragment blocked mitogen-
ic EGFR-signaling and synergized TRAIL apoptotic signaling [16,19]. To assess whether 
the MCSP-specific antibody fragment might contribute to the anti-tumor activity of anti-
MCSP:TRAIL, a focused set of 48 cellular phosphoproteins was examined for the level of 
phosphorylation after treatment with anti-MCSP:TRAIL (Fig.6A, B), anti-MCSP mAb 9.2.27 
(Fig. 6C) and rhTRAIL (Fig. 6D). Interestingly, although A375M cells were treated with 
anti-MCSP:TRAIL in adherent growth conditions in view of experimental limitations with 
3D-cultures, significant dephosphorylation of various proteins involved in cell survival and 
proliferation was detected after 1h of treatment (Fig.6A, B). This dephosphorylation in-
duced by anti-MCSP:TRAIL was detectable within 30 minutes and increased for up to 4h 
after start of treatment (Fig. 6E). Treatment with mAb 9.2.27 and rhTRAIL also triggered 







Figure 4. Inhibition of anchorage-independent growth by anti-MCSP:TRAIL. A A375M and A2058 
cells were treated with increasing concentrations of anti-MCSP:TRAIL for 21 days and colony forma-
tion was assessed. B A375M cells were treated with increasing concentrations of anti-MCSP:TRAIL, 
anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL+anti-MCSP mAb for 21 days and colo-
ny formation was assessed. C A375M cells were treated with rhTRAIL, anti-EpCAM:TRAIL or anti-
MCSP:TRAIL for 21 days and colony formation was assessed. D A375M cells were treated with 100 
ng/ml anti-MCSP:TRAIL in the absence or presence of TRAIL-neutralizing mAb 2E5, parental anti-MC-










































































































































panel (Fig. 6C and D, respectively).
First and foremost, the previously reported down-stream target of MCSP, FAK, was de-
phosphorylated by a factor 2 compared to medium control. The parental anti-MCSP mAb 
9.2.27 has been shown to prevent association of MCSP with integrins, thereby preventing 
activation of FAK [6]. Thus, although not determined here for anti-MCSP:TRAIL, a similar 
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Figure 5. Inhibition of anchorage-independent growth by anti-MCSP:TRAIL partly relies on 
TRAIL-independent signaling. A A375M and A375M.FADD-DED cells were treated with increasing 
concentrations of anti-MCSP:TRAIL for 21 days and colony formation was assessed. B A375M.FADD-
DED cells were treated with increasing concentrations of anti-MCSP:TRAIL, anti-EpCAM:TRAIL, anti-
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inhibition of MCSP / integrin interaction by the mAb 9.2.27-derived antibody fragment may 
be responsible for the inhibitory effect of anti-MCSP:TRAIL on FAK. Intriguingly, cross-
linking of MCSP by bead-coated mAb 9.2.27 has also been used to achieve activation of 
MCSP-signaling [6]. The different outcome of treatment with soluble vs. coated mAb sug-
gests that the extent of cross-linking of MCSP by the antibody determines the activation or 
inhibition, respectively, of downstream signaling. It will be interesting to evaluate in future 
studies whether the three MCSP reading heads in trimeric anti-MCSP:TRAIL are perhaps 
better suited for inhibition of MCSP-signaling.
The activity of ERK1/2, another established downstream effector of MCSP signaling [6], 
was not affected after 1h of treatment with anti-MCSP:TRAIL. One possible reason for this 
finding is a perhaps delayed effect of anti-MCSP:TRAIL on ERK1/2 signaling at later and 
not  examined time-points. In addition, it has been shown that MCSP enhances FAK and 
Erk1/2 signaling by distinct mechanisms [6]. It is therefore also conceivable that FAK is 
dephosphorylated while Erk1/2 is not a target of inhibition by anti-MCSP:TRAIL. 
In addition to the established MCSP-target FAK, a panel of other proteins was dephos-
phorylated upon anti-MCSP:TRAIL treatment, including the kinase Fyn,  and the Src ki-
nases Src, Hck, Lyn and Yes. The relative impact of these respective proteins on MCSP 
tumorigenic signaling is currently being evaluated in extended ongoing studies using e.g. 
constitutively active and/or dominant negative mutants as well as small inhibitory RNA-







Figure 6. Anti-MCSP:TRAIL triggers dephosphorylation of cellular proteins. A375M cells were 
treated with anti-MCSP:TRAIL, anti-MCSP mAb 9.2.27, rhTRAIL or left untreated for 1h. Whole cell 
lysates were analyzed for phosphorylation of 48 cellular kinases. A  Phosphorylation of 28 kinases in 
untreated cells (left panel) or anti-MCSP:TRAIL-treated cells (right panel) are depicted. Images are 
representative of three independent experiments. B, C, D Changes in the phosphorylation of 21 ki-
nases after treatment with B anti-MCSP:TRAIL, C anti-MCSP mAb 9.2.27 or D rhTRAIL are expressed 
as a percentage of the phosphorylation measured in untreated cells. E A375M cells were treated with 
anti-MCSP:TRAIL for 0, 30, 60 or 240 min. Whole cell lysates were analyzed for phosphorylation of 48 
cellular kinases. Changes in phosphorylation of the different kinase groups as indicated in panel B are 
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ments need to be performed not only in 2D, but more importantly also in 3D-cultures, in 
order to reliable determine the relative importance of the here identified proteins for MCSP-
dependent anchorage-independent growth of melanoma cells.
Perhaps counter intuitively, the proto-oncogene Beta-Catenin (ß-Catenin) was also de-
phosphorylated by treatment with anti-MCSP:TRAIL, as well as by treatment with mAb 
9.2.27 and rhTRAIL (Fig. 6B, C and D, respectively). Dephosphorylation of ß-Catenin does 
not inactivate ß-Catenin but actually prevents proteasomal degradation and increases cel-
lular levels of ß-Catenin. In turn, this leads to activation of pro-oncogenic gene transcription 
[28]. However, the exact role of ß-Catenin-induced gene transcription in melanoma is still 
a matter of debate. Based on mouse models with activating mutations in ß-Catenin, an on-
cogenic role of ß-Catenin in melanoma was proposed [29]. On the other hand, others have 
shown that ß-Catenin induces a transcriptional profile in melanoma cells that is reminiscent 
of normal melanocyte differentiation [30]. This transcriptional profile is moreover associ-
ated with increased patient survival and is lost upon malignant progression [30].
Taken together, anti-MCSP:TRAIL dephosphorylates a panel of established MCSP targets 
as well as newly identified proteins. Thus, the kinase array data support a dual anti-mela-
noma activity by anti-MCSP:TRAIL that partly relies on inhibition of tumorigenic signaling 
by the anti-MCSP antibody fragment.
Anti-tumor activity of low dose anti-MCSP:TRAIL towards A375M xenografts
To further characterize the anti-melanoma activity of anti-MCSP:TRAIL, A375M cells were 
xenografted subcutaneously in nude mice and allowed to form small tumors (~50 mm3). 
Subsequently, mice were treated daily by intra-peritoneal injection with a low dose of anti-
MCSP:TRAIL (~0.14 mg/kg) or with saline. Of note, anti-MCSP mAb 9.2.27 and therefore 
anti-MCSP:TRAIL do not cross-react with mouse MCSP [3]. Compared to sham-treated 
mice, tumor size of the anti-MCSP:TRAIL-treated mice was strongly retarded in time 
(Fig.7A), with a 50% reduction in tumor size at the end of the experiment (Fig.7B). Of note, 
earlier animal studies with A375M cells and non-targeted rhTRAIL were performed at >300 
times higher concentrations (50 mg/kg) compared to the here employed treatment regimen 
with anti-MCSP:TRAIL [31]. Thus, in analogy to the low dose required for therapeutic activ-
ity in colony formation assays, anti-MCSP:TRAIL already has potent in vivo anti-melanoma 
activity at a very low dose. 
Anti-MCSP:TRAIL lacks apoptotic activity towards normal cells
Earlier studies have shown that tumor targeted delivery of TRAIL augments the tumor-
specific activity of TRAIL, while not affecting the absence of toxicity on normal human 
cell types. Indeed, although anti-MCSP:TRAIL strongly bound to MCSP on normal human 






 5Figure 7. Anti-tumor activity of anti-MCSP:TRAIL towards A375M xenografts. A Mice were inocu-lated with A375M tumor cells at day 0 and developed xenografts of ~50mm3 after 12 days. Starting at 
day 12, mice were injected daily with saline (n = 4) or anti-MCSP:TRAIL (0,14 mg/kg, n = 4) and tumor 




























































was performed with 4μg/ml anti-MCSP:TRAIL (Fig. 8B). Also extended treatment (up to 8 
days) of melanocytes with 4μg/ml anti-MCSP:TRAIL did not yield significant increases in 
apoptosis compared to medium control (Fig. 8C). Similarly, normal human MCSP-negative 
hepatocytes were fully resistant to treatment with anti-MCSP:TRAIL (Fig. 8B). Hepatocytes 
have previously been shown to be one of the most vulnerable normal cell types to possible 
TRAIL-related toxicity [32]. Importantly, also in nude mice carrying A375M xenografts treat-
ment with anti-MCSP:TRAIL had no deleterious effect on liver morphology, with morphology 
of liver sections comparable to the morphology of liver sections of Sham-treated mice (Fig. 
8D and E). The here obtained data regarding the absence of activity of anti-MCSP:TRAIL 
towards normal cell types are in line with the large body of evidence in literature on the 
preclinical safety profile of sTRAIL. Indeed, ongoing clinical trials with rhTRAIL confirm the 
relative safety of TRAIL treatment with no serious adverse effects and no dose-limiting 
toxicity reported to date.
Synergistic induction of apoptosis by anti-MCSP:TRAIL and σ-ligands 
Since resistance of melanoma cells towards sTRAIL has previously been reported [22] a 
combinatorial strategy was evaluated of anti-MCSP:TRAIL with rimcazole, a σ-ligand in 
clinical trials for various cancers. Sigma receptors are expressed in the central nervous, 
immune, endocrine, and reproductive systems, but also in peripheral organs like kidney; 
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Figure 8. Anti-MCSP:TRAIL lacks apoptotic activity towards normal cells A MCSP-restricted 
binding of anti-MCSP:TRAIL to melanocytes was assessed by flow cytometry using a PE-conjugated 
anti-TRAIL mAb.  Specific binding was demonstrated by pre-incubating melanocytes with mAb 9.2.27 
followed by incubation with anti-MCSP:TRAIL. B MCSP-positive melanocytes and MCSP-negative 
leukocytes and hepatocytes were treated with 500 ng/ml anti-MCSP:TRAIL for 16h and apoptosis was 
assessed by ∆ψ. C Melanocytes were treated with 4 μg/mL anti-MCSP:TRAIL for up to 14 days and 
apoptosis was assessed by ∆ψ at time points indicated. D Liver pathology of mice carrying A375M 









































































liver; and gastrointestinal tract. Although the precise function of these receptors remains 
unknown, both σ-R1 and σ-R2 are strongly overexpressed in rapidly proliferating cells such 
as melanoma and may be exploited as possible targets for melanoma therapy [26]. Treat-
ment of A375M cells with the sigma ligand rimcazole (σ-R1/σ-R2 antagonist) synergistically 
enhanced induction of apoptosis by anti-MCSP:TRAIL (Fig. 9A and B). Of note, treatment in 
the presence of the σ-R1 agonist (+)pentazocine did not abrogate synergy, suggesting that 
rimcazole synergizes with anti-MCSP:TRAIL activity via σ-R2 (Fig. 9C). Rimcazole did not 
upregulate TRAIL-R1 or TRAIL-R2 expression (data not shown), but augmented the activa-
tion of initiator caspase-8 and initiator caspase-9 upon anti-MCSP:TRAIL treatment (Fig. 
10A, B, respectively). Moreover, inhibition of either initiator caspase abrogated cytotoxic 







Figure 9. Synergistic induction of apoptosis by anti-MCSP:TRAIL and rimcazole A. A375M cells 
were treated with increasing concentrations of anti-MCSP:TRAIL in the presence or absence of rimca-
zole for 16h and apoptosis was assessed by ∆ψ. B A375M cells were treated with rimcazole (15 μM), 
anti-MCSP:TRAIL (100 ng/ml) or both for 16h, apoptosis was assessed by ∆ψ and the cooperativity 
index (CI) was calculated as indicated in the materials and methods section. C A375M cells were 
treated with rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/mL) or both in the presence or absence of 
pentacozine (200 nM) for 16h and apoptosis was assessed by ∆ψ. D Hepatocytes were treated with, 
rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/ml) or both for 16h and apoptosis was assessed by ∆ψ. 
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Figure 10. Synergy between rimcazole and anti-MCSP:TRAIL is caspase dependent. Activity of 
A Caspase-8, B Caspase-9 was assessed in A375M cells after incubation with anti-MCSP:TRAIL in 
the presence or absence of rimcazole (15 μM) for 1, 2, 3, 4, 5, 6 or 16h C A375M cells were treated 
for 16h with 100 ng/mL of anti-MCSP:TRAIL and/or rimcazole (15 μM)  in the presence or absence of 































































































by promoting caspase-8 activation. Of note, anti-MCSP:TRAIL in combination with rimca-
zole lacked apoptotic activity towards hepatocytes (Fig. 9D), suggesting that this combina-
tion retains the favorable toxicity profile associated with TRAIL and rimcazole alone.
Conclusions







ma-expressed MCSP, inhibits MCSP tumorigenic signaling and simultaneously induces 
TRAIL apoptotic signaling. Consequently, fusion protein anti-MCSP:TRAIL potently inhib-
its outgrowth of melanoma cells both in vitro and in vivo and this effect can be further 
enhanced with the cytotoxic agent rimcazole. Based on the above, we postulate the fol-
lowing working model for anti-MCSP:TRAIL (see also Fig. 11B); anti-MCSP:TRAIL binds 
to MCSP and inhibits MCSP-signaling, which includes inhibition of src-kinases and FAK, 
the STAT transcription factors, and various anti-apoptotic modulators such as p53, TOR, 
JNK. Concurrently, interaction of the sTRAIL domain with its agonistic receptors TRAIL-R1 
and TRAIL-R2 triggers potent induction of apoptosis. Notably, TRAIL/TRAIL-R interaction 
also triggers dephosphorylation of the STAT family, which may contribute to sensitization 
of cells to apoptosis [33,34]. Thus, melanoma cells are eliminated on the one hand by 
MCSP-mediated sensitization of melanoma cells to apoptosis and on the other hand by the 
concurrent activation of TRAIL-apoptotic signaling. Taken together, anti-MCSP:TRAIL is a 
novel immunotherapeutic agent that, either alone or in combination with rimcazole, may be 


















































Figure 11. Schematic representation of the anti-melanoma activity of anti-MCSP:TRAIL. A Direct 
or indirect MCSP-mediated signaling involves (integrin-dependent) FAK and Src phosphorylation and 
maintains phosphorylation of downstream transcription factors and apoptotic modulators. MCSP thus 
contributes to pro-survival and metastatic signals. B Binding of anti-MCSP:TRAIL inhibits MCSP-me-
diated signaling and concomitant activation of pro-metastatic/-survival signals and thereby sensitizes 
cells to apoptosis induction via binding of the TRAIL moiety to TRAILR.
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Adoptive T-cell therapy generally fails to induce meaningful anti-cancer responses 
in patients with solid tumors. Here, we present a novel strategy designed to selec-
tively enhance the tumoricidal activity of T-cells by targeted delivery of TRAIL to 
the T-cell surface. We constructed, produced and purified two fusion proteins: anti-
CD3:TRAIL and K12:TRAIL that selectively target TRAIL to the T-cell surface antigens 
CD3 and CD7, respectively. Tumoricidal activity of T-cells in the presence of these 
fusion proteins was assessed in solid tumor cell lines, primary patient-derived ma-
lignant cells and in a murine xenograft model.  Both anti-CD3:TRAIL and K12:TRAIL 
increased the tumoricidal activity of T-cells towards cancer cell lines and primary 
patient-derived malignant cells >500-fold. Furthermore, T-cell surface delivery of 
TRAIL strongly inhibited tumor growth and increased survival time of xenografted 
mice >6-fold. In conclusion, targeted delivery of TRAIL to cell surface antigens of 
T-cells potently enhances the tumoricidal activity of T-cells. This approach may be 
generally applicable to enhance the efficacy of adoptive T-cell therapy.
 
Introduction
While efficacious in certain virus-mediated cancers, adoptive T-cell therapy generally fails 
to induce meaningful anti-cancer responses in patients with solid tumors. The cause for 
this lack of clinical efficacy is multi-factorial by nature and includes the intrinsic or acquired 
resistance of malignant cells to cytotoxic T-cell effector mechanisms such as granzyme/
perforin-mediated lysis (1-5) and Fas-mediated killing (6;7). To overcome or circumvent 
this potential pitfall of adoptive T-cell therapy, we propose to selectively expand the T-cell 
armamentarium with additional tumoricidal effector molecules, in particular with the Tumor 
Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL).
TRAIL is a type II transmembrane protein normally expressed on NK cells, where it is es-
sential for NK-cell-mediated tumor immune surveillance (8;9). In contrast, the expression 
of TRAIL on resting T-cells is typically very low (10;11). Nevertheless, a slight induction of 
TRAIL expression on T-cells, by ectopic expression of TRAIL or by ex vivo co-stimulation 
with anti-CD3 and IFN-α, already potently increases their tumoricidal activity (11;12). Fur-
thermore, T-cell expressed TRAIL is essential for graft versus tumor (GVT) activity during 
allogeneic hematopoietic cell transplantation (AHCT) (10). Importantly, T-cell expressed 
TRAIL does not contribute to deleterious graft versus host disease (GVHD) activity (10). 
Taken together, these findings suggest that T-cells should gain additional tumoricidal po-
tential when equipped with TRAIL at the cell surface. 
Previously, we and others have reported an approach that may be particularly useful in 
this respect. In brief, recombinant soluble TRAIL (sTRAIL) was genetically linked to a tu-







produced, purified and subsequently used to selectively deliver TRAIL to the cell surface 
of tumor cells. Treatment of tumor cells expressing the relevant target antigen resulted in 
cell surface accretion of the scFv:sTRAIL fusion protein. Subsequently, tumor cell-bound 
TRAIL efficiently eliminated cancer cells (reviewed in chapter 2; ref (13)). Here, we utilized 
and adapted this approach to the selective delivery of high levels of TRAIL to the cell 
surface of T-cells, with the aim of expanding the cytotoxic armament of these T-cells with 
TRAIL (for schematic see Fig.1).
This approach was pre-clinically evaluated using two novel recombinant fusion proteins, 
designated anti-CD3:TRAIL and K12:TRAIL, that selectively bind to the T-cell surface anti-
gen CD3 and CD7, respectively. Fusion protein anti-CD3:TRAIL contains a CD3-stimulato-
ry antibody fragment, whereas K12:TRAIL contains a soluble form of the CD7-ligand K12. 
Anti-CD3:TRAIL and K12:TRAIL strongly potentiated the tumoricidal activity of T-cells on a 
panel of cancer cell lines, primary patient-derived malignant cells and in a murine xenograft 
model. This strategy may represent an easy to incorporate approach to enhance the ef-













Figure 1. Cell surface 
delivery of TRAIL 
to augment the tu-
moricidal activity of 
T-cells. Fusion pro-
teins K12:TRAIL and 
anti-CD3:TRAIL were 
designed to selectively 
bind to T-cell markers 
CD7 and CD3, respec-
tively, and enhance 
levels of TRAIL on 
the surface of T-cells. 
Tumoricidal activity of 
T-cells should be aug-
mented by virtue of 
TRAIL-TRAILR recep-
tor mediated signaling 
in tumor cells.
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Anti-CD7 mAb TH-69 competes with K12:TRAIL for binding to CD7 and was a gift from 
Prof. Dr. Martin Gramatzki (University of Kiel, Germany). TRAIL-neutralizing mAb 2E5 was 
purchased from Kordia Life Sciences, FasL-neutralizing mAb Alf2.1 was purchased from 
Sigma-aldrich and TNF-α neutralizing fusion protein Enbrel was purchased from Wyeth. 
PE-labeled anti-TRAIL mAb B-S23 was purchased from Diaclone SAS and PE-labeled an-
ti-CD69 mAb was purchased from IQ-products. Anti-TRAILR antibodies HS-201, HS-202, 
HS-203 and HS-204 and soluble TRAIL receptors TRAILR1-Fc, TRAILR2-Fc, TRAILR3-
Fc and TRAILR4-Fc were purchased from Alexis. TRAIL ELISA was purchased from Di-
aclone and Cytokine ELISA was from SA Biosciences. DiI, DiO and FLUO-3-AM were 
purchased from Invitrogen. DioC6 was purchased from molecular probes. Actinomycin 
D, Valproic acid and Cyclohexamide were purchased from Sigma-Aldrich. Pan-caspase 
inhibitor zVAD-FMK, caspase-8 inhibitor zLEHD-fmk and caspase-9 inhibitor zIETD-fmk 
were purchased from Calbiochem. Anti-CD3 mAb and recombinant IL-2 were purchased 
from ImmunoTools. TNF-α was purchased from Abcam. FasL-Fc was a kind gift from Prof. 
Dr. Harald Wajant (University of Würzburg, Germany). RhTRAIL was purchased from R&D 
technologies.
Production of K12:TRAIL and anti-CD3:TRAIL
Fusion protein K12:TRAIL and anti-CD3:TRAIL were constructed by cloning the cDNA 
of soluble human K12 (aa 29-143) or the anti-CD3 antibody fragment scFvUCHT-1v9 in 
frame with human soluble TRAIL into previously described vector pEE14, yielding plasmids 
pEE14-K12:TRAIL and pEE14-anti-CD3:TRAIL, respectively. Fusion proteins K12:TRAIL 
and anti-CD3:TRAIL were produced in CHO-K1 cells essentially using previously described 
methods (14). Culture medium containing K12:TRAIL or anti-CD3:TRAIL was cleared by 
centrifugation (10.000 x g, 10 min), filter sterilized, and stored at -80°C until further use. 
Fusion proteins were purified via the N-terminal Hemagglutinin (HA)-tag using anti-HA af-
finity chromatography. Fusion protein anti-MCSP:TRAIL is a fusion protein that is essen-
tially identical to anti-CD3:TRAIL except that it contains an anti-MCSP scFv instead of an 
anti-CD3 scFv. MCSP is expressed on cells of the melanocyte lineage, but not on T-cells 
or carcinoma cells.
Cell lines 
SK-OV-3, OvCAR-3, A2780, HCT-8, HT29, A375M, A2058, SK-MEL-28, HEP3B, PLC-
PRF-5, FADU, PC-3M, HK-2 and Ramos were obtained from the American Tissue Cul-







analysis. A375M.FADD-DED cells were generated by transfection of parental A375M cells 
with a dominant negative FADD-DED construct using Fugene (Roche BV, Woerden, The 
Netherlands). A375M.FADD-DED cells were cultured in RPMI 1640 medium supplemented 
with 10% fetal calf serum and 500 μg/ml Geneticin. HCT116-Luc was from Caliper Biosci-
ences (Xenogen, Alameda, CA). NHDF-juv cells were from Promocell. Human umbilical 
vein endothelial cells (HUVEC) were isolated as described previously. Unless otherwise 
indicated, cells were cultured in standard RPMI (Cambrex Bio Science, Verviers, France) 
supplemented with 10% fetal calf serum. 
Isolation of primary patient-derived tumor cells, T-cells and activation of T-cells
Experiments were approved by the local Medical Ethical Committee and patients/healthy 
volunteers signed for informed consent. Tumor tissues and ascitic fluids were obtained dur-
ing surgery procedures and if necessary minced, after which adherent cells were cultured. 
Experiments were performed before passage number 5. Samples with a background apop-
tosis >30% were excluded from analysis. Normal fibroblast cultures originating from tumor 
tissue/ascitis were essentially established as described above for primary cancer cell cul-
tures. Tumor infiltrating T-cells were isolated from the primary tumor cultures using Ammo-
nium Chloride lysis. Peripheral blood lymphocytes (PBL) from blood of healthy donors were 
isolated using standard density gradient centrifugation (Lymphoprep, Axis-Shield PoC As., 
Oslo, Norway). Activated T cells were generated by culturing PBLs with anti-CD3 mAb (0.5 
µg/mL; 72 h) and IL-2 (100 ng/mL; 48 h). 
Analysis of fusion protein binding and TRAILR expression
The presence of cell surface-bound TRAIL was assessed by incubating cells with PE-
conjugated anti-TRAIL mAb B-S23 (Diaclone SAS) for 60 min at 4°C followed by 3 washes. 
Cells were subsequently measured on an Accuri C6 flow cytometer. Cell surface display 
of TRAIL in time was determined by incubating cells with 50 pg/T-cell K12:TRAIL or anti-
CD3:TRAIL for 60 minutes at 4°C followed by 3 washes in PBS. Cells were then incubated 
at 37°C for the time-points indicated and TRAIL expression was determined using mAb 
B-S23. The amount of K12:TRAIL or anti-CD3:TRAIL bound to an individual T-cell was 
determined using TRAIL ELISA. Briefly, 1x105 T-cells were incubated with increasing con-
centrations of K12:TRAIL or anti-CD3:TRAIL for 1h. Subsequently, cells were centrifuged 
and supernatants used for TRAIL ELISA. Loss of K12:TRAIL and anti-CD3:TRAIL from the 
supernatant was calculated using the same concentration range of K12:TRAIL and anti-
CD3:TRAIL in the absence of T-cells as a reference. Expression of TRAIL receptors was 
determined by incubating cells with mAb HS-201, HS-202, HS-203 or HS-204 for 60 min 
at 4°C, followed by 3 washes with PBS and incubation with PE-labeled Goat-anti-Mouse 
Ab. Cells were subsequently washed 3 more times with PBS and TRAILR expression was 
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determined using an Accuri C6 flow cytometer.
Analysis of cell death
For cell death assays, cancer cells were labeled with red fluorescent membrane label DiI 
(Invitrogen) in serum free medium for 15 min. followed by three washes in serum containing 
medium and subsequent culture in a 48-well plate (3.0x104cells/well). After 24 hours, can-
cer cells were treated for 16 hours with T-cells (activated or resting) at the indicated ratios 
in the presence or absence of K12:TRAIL (50 pg/T-cell), anti-CD3:TRAIL (50 pg/T-cell) or 
anti-MCSP:TRAIL (50 pg/T-cell) after which apoptosis was assessed in tumor cells by loss 
of mitochondrial membrane potential (∆Ψ) as previously described (14) using an Accuri C6 
flow cytometer. Where indicated, caspase inhibitors were used at a final concentration of 
10 μM. Actinomycin D was used at a final concentration of 2 μg/mL. Anti-TRAIL (2E5) and 
anti-FasL (Alf2.1) neutralizing mAbs and TNF-α neutralizing fusion protein Enbrel were 
used at a final concentration of 5μg/mL. For experiments involving Valproic acid (VPA), 
tumor cells were pre-treated for 24 h with 1 mM of VPA prior to addition of T-cells at the 
indicated ratios. For experiments involving concanamycin A, T-cells were treated with the 
indicated concentrations of concanamycin A for 2h prior to addition to tumor cells. Tumor 
cells were subsequently treated with these T-cells for 4h in the presence of concanamycin 
A after which induction of apoptosis was assessed. For outgrowth experiments using pa-
tient ascitic fluid, anti-CD3:TRAIL, anti-CD3 mAb or rhTRAIL were added at a final concen-
tration of 100 ng/mL to a mixture of ascitic fluid and normal culture medium (50% v/v).
Time-lapse confocal microscopy
Tumor cells were labeled with membrane label DiO (green) by incubation of 1x106 cells with 
5 μL DiOI in serum free RPMI1640 for 5 min. at 37°C. Cells were then washed three times 
with RPMI1640+10% FCS and DiO-labeled tumor cells were cultured in a glass cover slide 
(3.0x104 cells/well). After 24 hours, T-cells labeled with DiI (red) using the same procedure 
were added to the tumor cells at the indicated Effector-to-Target (E:T) ratios. Time-lapse 
confocal microscopy was performed on a Solamere Nipkow Disk CLSM equipped with 
temperature/CO2 controlled cabinet and multi-cell track table.
Mechanical stimulation of CD3-signaling and Calcium Flux
Glass coverslides in petridishes were coated overnight with 10 μg/mL TRAILR1-Fc, 
TRAILR2-Fc, TRAILR3-Fc or TRAILR4-Fc. Coverslides were subsequently washed with 
PBS and blocked with normal human serum for 1h. T-cells were labeled with FLUO-3-AM 
by incubating the cells with 5 μM FLUO-3-AM ester in 100 μL PBS for 15 minutes at 20°C, 
followed by addition of 400 μL PBS with 10% FCS and 45 minutes of incubation at 37°C. 







glass slides. T-cells were mechanically stimulated by using a micropipette as previously 
described (15). Ca-flux was measured and quantified on a TILL iMIC fluorescence micro-
scope equipped with temperature/CO2 controlled cabinet. Ca-flux is depicted as the mean 
fluorescent intensity (MFI) at any given time point (MFIT) / the MFI at T=0.
Cytokine ELISA
T-cells were incubated with tumor cells for 16h at an effector-to-target ratio of 5:1 in the pres-
ence or absence of 50 pg/T-cell anti-CD3:TRAIL. Where indicated, mAb 2E5 was added 
to block TRAIL-TRAILR interaction. Alternatively, T-cells were treated with anti-CD3 mAb 
for 16h to elicit T-cell activation and cytokine release. Cell supernatants were harvested, 
centrifuged and used for cytokine ELISA according to the manufacturer’s instructions.  
HCT-116-luc xenograft mouse model
Experiments were approved by the Committee for Research and Animal Ethics of the 
UMCG. Male athymic mice (Harlan) were intra-peritonealy inoculated with HCT116-luc (1 
x 106 cells). Animals were subsequently treated with a single i.p. dose of 5x106 T-cells 
and ~150 μg/Kg K12:TRAIL or anti-CD3:TRAIL as indicated. Tumor growth was monitored 
by luminescent imaging of mice from the ventral abdominal side using an IVIS Spectrum 
(Xenogen) optical imager. Animals were sacrificed by cervical dislocation when biolumi-
nescent signal was increased 10-fold compared to day of inoculation. For localization of 
T-cells, T-cells were labeled with CellVue®NIR815 membrane labeling kit according to the 
manufacturer’s instructions. Specific fluorescent signal was determined by subtracting the 
fluorescent signal from saline treated mice.
Statistical analysis
Data reported are mean values±SD of three independent experiments. Data was analyzed 
by one-way ANOVA followed by Tukey-Kramer post test or, where appropriate, by two-
sided unpaired Student’s t-test. Where indicated * = p<0.05; ** = p<0.01; *** = p<0.001. 
 
Results
Tumoricidal activity of T-cells is potently augmented by delivery of TRAIL to the T-cell sur-
face 
In order to selectively deliver TRAIL to the cell surface of T-cells, the CD3-targeted fusion 
protein anti-CD3:TRAIL and the CD7-targeted fusion protein K12:TRAIL were generated. 
In line with literature, ex vivo activated T-cells obtained from healthy volunteers did not 
detectably express TRAIL (Fig.2A). Incubation of these TRAIL-negative T-cells with anti-
CD3:TRAIL or K12:TRAIL lead to the display of high levels of TRAIL on the T-cell surface 
(Fig.2A). A subsequent TRAIL ELISA demonstrated that a single T-cell binds ~50 pg of 
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K12:TRAIL and/or ~10 pg of anti-CD3:TRAIL (data not shown). This T-cell binding by anti-
CD3:TRAIL or K12:TRAIL was selectively blocked by anti-CD3 or anti-CD7 monoclonal 
antibody (mAb), respectively (data not shown) and did not induce reciprocal T-cell death 
(Fig. 2B). 
Importantly, T-cell selective binding by anti-CD3:TRAIL and K12:TRAIL did potentiate the 
tumoricidal activity of activated T-cells towards cancer cells, with >90% apoptosis at an 
Effector-to-Target (E:T) ratio of 2:1 (Fig. 2C). Activated T-cells alone failed to induce apop-
tosis at these E:T ratios, with only ~40% apoptosis at an E:T ratio of 100:1 (Fig. 2C). Ad-
dition of an analogous TRAIL fusion protein that cannot bind T-cells (anti-MCSP:TRAIL; 
chapter 5) did not augment cell death in OvCAR-3 cells (Fig. 2D). 
This enhanced tumoricidal activity towards OvCAR3 was dose-dependent (Fig. 3A and 
3B), apparent within 2h and progressed to a maximum effect within 16h (Fig. 3C and Video 
S1 and S2). In addition, while the display of K12:TRAIL and anti-CD3:TRAIL on the T-cell 
surface was reduced over time (Fig. 3D and 3E, respectively), T-cells pre-incubated with 
excess K12:TRAIL or anti-CD3:TRAIL prior to addition to tumor cells (up to 48 h) fully 
retained their enhanced apoptotic activity (Fig. 3F). This indicates that in the presence of 
normal receptor turnover, sufficient K12:TRAIL or anti-CD3:TRAIL remain displayed on the 
T-cell surface. Importantly, the potentiating effect of anti-CD3:TRAIL and K12:TRAIL on 
the tumoricidal activity of T-cells was detected in a panel of 14 solid tumor cell lines (Fig. 
4A) and in an extensive panel of short term cultures of primary patient-derived cancer cell 
samples (Fig. 4B; anti-CD3:TRAIL, Fig. 4C;  K12:TRAIL). In these patient-derived malig-
nant cell cultures, treatment with anti-CD3:TRAIL or K12:TRAIL and T-cells, completely dis-
rupted the monolayer within 5h as exemplified for K12:TRAIL in Fig. 4D and Video S3 and 
S4. Consistent with other reports on TRAIL sensitivity, we found no correlation between 
TRAILR expression and sensitivity to K12:TRAIL (Fig. 5). However, there was a slight 
negative correlation between sensitivity to anti-CD3:TRAIL and expression of TRAILR4 
(Fig. 5D), but not TRAILR1, R2 and R3 (Fig. 5A-C). 
Taken together, anti-CD3:TRAIL and K12:TRAIL both potently augment the tumoricidal ac-
tivity of activated T-cells toward cancer cell lines and patient-derived malignant cells by 
~500-fold.
Anti-CD3:TRAIL induces tumoricidal activity by activation of resting T-cells
Anti-CD3:TRAIL comprises a T-cell stimulating CD3-antibody fragment. By virtue of this 
antibody fragment, anti-CD3:TRAIL might also be able to activate intrinsic cytotoxic effector 
mechanisms of T-cells. In line with this hypothesis, resting T-cells that lacked activity in co-
culture experiments with OvCAR-3 gained potent cytotoxic activity in the presence of anti-
CD3:TRAIL (Fig.6A, 100% apoptosis at E:T ratio 10:1). In contrast, resting T-cells remained 
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Figure 2. Tumoricidal activity of T-cells is potently augmented by delivery of TRAIL T-cell sur-
face. A TRAIL expression on anti-CD3 + IL-2 activated T-cells was assessed by incubation of T-
cells with PE-conjugated anti-TRAIL mAb (thin line). Cell surface TRAIL expression after binding of 
K12:TRAIL or anti-CD3:TRAIL was determined by pre-incubating T-cells with K12:TRAIL (hashed line) 
or anti-CD3:TRAIL (solid line). Shaded grey area represents fluorescence of PE-labeled isotype con-
trol. B Activated T-cells were incubated with OvCAR-3 cells in the presence or absence of K12:TRAIL 
(50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) for 16h at the indicated E:T ratios and apoptosis 
was assessed in OvCAR-3 cells. C Anti-CD3 + IL-2 activated T-cells were treated with 50 pg/T-cell 
K12:TRAIL, 50 pg/T-cell anti-CD3:TRAIL or 2 μg/ml actinomycin D for 16h, after which cell death was 
quantified by flow cytometry. D Activated T-cells were incubated with OvCAR-3 cells in the presence 
or absence of anti-MCSP:TRAIL (50 pg/T-cell) for 16h at the indicated E:T ratios and apoptosis was 
assessed in OvCAR-3 cells.
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Figure 3. Tumoricidal activity of T-cells is potently augmented by delivery of TRAIL T-cell sur-
face. A Activated T-cells were incubated with OvCAR-3 cells for 16h in the presence or absence of 
increasing concentrations of K12:TRAIL or B anti-CD3:TRAIL at an E:T ratio of 1:1 and apoptosis was 
assessed in OvCAR-3 cells. C Activated T-cells were incubated with OvCAR-3 cells in the presence 
or absence of K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) at an E:T ratio of 10:1 for the 
indicated time points and apoptosis was assessed in OvCAR-3 cells. D T-cells were incubated with 
K12:TRAIL (50 pg/T-cells) or E anti-CD3:TRAIL (50 pg/T-cell) for 1h and washed three times with PBS. 
TRAIL expression was subsequently determined at the indicated time-points using a PE-conjugated 
anti-TRAIL mAb. F T-cells were pre-incubated with K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 
pg/T-cell) for 0, 24 or 48h prior to addition to tumor cells. Tumor cells were subsequently treated for 
16h with these T-cells and apoptosis was assessed.
tested (Fig. 6A). Furthermore, anti-CD3:TRAIL consistently reduced long term outgrowth 
by >50% in ascitic fluid from ovarian cancer patients that contains both primary malignant 
cells and autologous T-cells (Fig. 6B and 6C). Neither an anti-CD3 stimulatory mAb nor an 
untargeted soluble rhTRAIL preparation alone inhibited cancer cell outgrowth (Fig. 6B). 
In line with these activating properties, anti-CD3:TRAIL induced a rapid calcium-flux in T-







in the number of T-cells positive for the activation marker CD69 (Fig. 7B) and the release 
of pro-inflammatory T-cell cytokines (Fig. 7C). Interestingly, preventing cellular contact be-
tween T-cells and tumor cells abolished T-cell activation induced by anti-CD3:TRAIL (Fig. 
7D), as did the addition of TRAIL neutralizing and TRAILR-blocking antibodies (Fig. 7B). In 
contrast, caspase inhibition did not block activation of anti-CD3:TRAIL-armed T-cells (Fig. 
7B), but did block induction of apoptosis by rhTRAIL (data not shown). Further analysis 
using T-cells mechanically manipulated using a micropipet (Fig. 8A for schematic repre-
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Figure 4. Tumoricidal activity of T-cells is potently augmented by delivery of TRAIL T-cell sur-
face. A Cancer cell lines SK-OV-3, OvCAR-3, A2780, HCT-116, HCT-8, HT29, A375M, A2058, SK-
MEL-28, HEP3B, PLC-PRF-5, FADU, PC-3M and RAMOS were treated for 16h with activated T-cells 
at an E:T ratio of 5:1 in the presence or absence of K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 
pg/T-cell) and apoptosis was assessed. B, C Primary ovarian cancer cells were treated as indicated 
at an E:T ratio of 5:1 for 16h and apoptosis was assessed. D Primary tumor cells were fluorescently 
labeled using membrane label DiO (green) and incubated with DiI (red)-labeled activated T-cells in 
the presence or absence of K12:TRAIL (50 pg/T-cell) at an E:T ratio of 10:1. Subsequently, cells were 
used for live fluorescent imaging (5h) to observe morphological changes. For purpose of clarity, only 
green fluorescent cancer cells are depicted. See also video S1, S2, S3 and S4.
Chapter 6: Cell surface delivery of TRAIL strongly augments T-cell tumoricidal activity
Clinical Cancer Research 2011 Sep. 1; 17(17):5626-37
C
hapter 6
sentation) indicated that anti-CD3:TRAIL-mediated T-cell activation was likely due to shear 
stress upon simultaneous binding of anti-CD3:TRAIL to CD3 on T-cells and TRAILR2 on 
tumor cells (Fig. 8A-C).
K12:TRAIL and anti-CD3:TRAIL enhance tumoricidal activity of resting T-cells via distinct 
mechanisms
Based on these activating properties, T-cell cytotoxicity induced by anti-CD3:TRAIL may at 
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Figure 5. Tumoricidal activity of TRAIL-”armed” T-cells does not correlate with TRAILR expres-
sion levels. Expression of A TRAILR1 B TRAILR2 C TRAILR3 D TRAILR4 was determined on SK-
OV-3, OvCAR-3, A2780, HCT-116, HCT-8, HT29, A375M, A2058, SK-MEL-28, HEP3B, PLC-PRF-5, 
FADU, PC-3M and RAMOS and plotted against the fold increase in apoptosis induced by T-cells 
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Figure 6. K12:TRAIL and anti-CD3:TRAIL enhance tumoricidal activity of resting T-cells via 
distinct mechanisms. A OvCAR-3 cells were treated with resting T-cells at the indicated E:T ratios 
for 48h in the presence or absence of K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) 
and apoptosis was assessed. B Ascitic fluid (n=5), was mixed with culture medium at a 1:1 ratio and 
treated with anti-CD3:TRAIL (50 pg/T-cell), anti-CD3 mAb (2 μg/mL) or rhTRAIL (100 ng/mL) for 12 
days after which cell viability was assessed. C Tumor cells and Lymphocytes derived from OC patient 
ascitic fluid were treated for 16h with anti-CD3:TRAIL (50 pg/T-cell) and CD69 expression on lympho-
cytes was determined by flow cytometry using anti-CD3 as a T-cell marker.
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Figure 7. Anti-CD3:TRAIL induces activation of resting T-cells. A T-cells were labeled with 
FLUO-3-AM and added to OvCAR-3 cells grown on glass inserts in a Petri dish. Subsequently, anti-
CD3:TRAIL (50 pg/T-cell) was added and Ca-flux was measured in T-cells (n=19). B Resting T-cells 
were incubated ± tumor cells and anti-CD3:TRAIL (50 pg/T-cell) in the presence or absence of TRAIL-
neutralizing mAb 2E5, TRAILR blocking antibodies or pan-caspase inhibitor zVAD-fmk for 16h and 
CD69 expression on T-cells was assessed by flow cytometry. C Resting T-cells were co-incubated with 
tumor cells for 16h in the presence or absence of anti-CD3:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL 
+ anti-TRAIL mAb. Alternatively, T-cells were treated with anti-CD3 mAb (2 μg/mL). T-cell superna-
tants were harvested and relative cytokine levels in culture supernatant were determined by ELISA. D 
OvCAR-3 cells were coated in the top well of a trans-well system and resting T-cells were added to the 
top and bottom well. Subsequently, cells were treated with anti-CD3:TRAIL (50 pg/T-cell) or anti-CD3 
mAb (2 μg/mL) for 16h and CD69 expression on T-cells was assessed.
least partly be attributable to stimulation of intrinsic T-cell cytotoxicity. Indeed, the potentiat-
ing effect on T-cell activity by anti-CD3:TRAIL, but not by K12:TRAIL, was dose-depend-
ently blocked by the granzyme/perforin release inhibitor Concanamycin A (CMA) (Fig. 9A 







protein FADD (FADD-DED) that inhibits TRAILR mediated caspase activation, remained 
sensitive to treatment with T-cells+anti-CD3:TRAIL, but not to T-cells + K12:TRAIL (Fig. 
9C). Inhibition of other typical cytotoxic T-cell effectors, such as the tumoricidal proteins 
FasL and TNF-α, failed to inhibit apoptotic activity of anti-CD3:TRAIL/K12:TRAIL towards 
OvCAR-3 cells (Fig. 9D). Apoptotic activity of anti-CD3:TRAIL/K12:TRAIL-armed T-cells 
was abrogated by a pan-caspase inhibitor (Fig. 9D) and by inhibition of caspase-8 or cas-
pase-9 (Fig. 9D). Of note, the potentiating effect of anti-CD3:TRAIL on tumoricidal T-cell 
activity closely resembled that of T-cells redirected with the bispecific antibody Bis-1 (anti-
CD3:anti-EpCAM), which was also abrogated by CMA (Fig. 9E). Therefore, the mode of 
action of anti-CD3:TRAIL appears to be largely dependent on granzyme/perforin-mediated 
lysis, whereas K12:TRAIL functions via activation of initiator caspase-8/-9 and effector cas-


















































Figure 8. Anti-CD3:TRAIL can induce activation of resting T-cells via shear stress. A Schematic 
representation of mechanical CD3-mediated Ca-flux. In brief, FLUO-3-AM labeled T-cells are added 
to TRAILR-coated wells, after which a micropipette is used to induce mechanical shear stress and 
fluorescent intensity is monitored by microscopy. B Ca-Flux induced in anti-CD3:TRAIL-loaded T-cells 
on TRAIL-R1, -R2, -R3 or -R4 coated wells. C representative images of Ca-flux upon mechanical 
stimulation of anti-CD3:TRAIL-loaded T-cells on TRAILR2 coated wells. 
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drial amplification of the caspase-8 apoptotic signal is required for effective tumoricidal 
activity.















































































































































































Figure 9. K12:TRAIL and anti-CD3:TRAIL enhance tumoricidal activity of resting T-cells via 
distinct mechanisms. A OvCAR-3 or B A375M cells were incubated for 4h at an E:T of 10:1 with 
activated T-cells ± K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) in the presence of the 
indicated concentrations of concanamycin A and apoptosis was assessed. C A375M or A375M.FADD-
DED cells were treated rhTRAIL (100ng/mL), act-T-cells (5:1) ± K12:TRAIL (50 pg/T-cell) or anti-
CD3:TRAIL (50 pg/T-cell) for 16h and apoptosis was assessed. D OvCAR-3 cells were treated for 
16h with activated T-cells ± K12:TRAIL (50 pg/T-cell) or anti-CD3:TRAIL (50 pg/T-cell) at an E:T ratio 
of 10:1 in the presence or absence of TRAIL-neutralizing mAb 2E5, FasL-neutralizing mAb Alf2.1, 
TNF-α neutralizing fusion protein Enbrel, pan-caspase inhibitor zVAD-fmk, caspase-8 inhibitor zIETD-
fmk or caspase-9 inhibitor zLEHD-fmk and apoptosis was assessed. E OvCAR-3 cells were treated 
with activated T-cells, anti-CD3:TRAIL-armed T-cells or activated T-cells redirected using bispecific 








The potent in vitro effects of K12:TRAIL and anti-CD3:TRAIL prompted us to evaluate 
activity against tumor cells in vivo. To this end, we xenografted colorectal carcinoma cell 
line HCT116-luc intraperitoneally in mice as a model for advanced metastatic colon carci-
noma. HCT116-luc cells rapidly established tumor nodules throughout the abdominal cav-
ity, resulting in a median survival of only 7 days (Fig. 10B and 10C). Importantly, growth of 
HCT116-luc in vivo was significantly suppressed by co-treatment with K12:TRAIL and acti-
vated T-cells, compared to treatment with either K12:TRAIL or T-cells alone. Indeed, medi-
an survival was increased 6-fold and one mouse survived for the duration of the experiment 
(70d) with minimal residual disease (Fig. 10A, 10B; 42d vs. 7d). Of note, co-treatment with 
K12:TRAIL and T-cells did not have obvious off-target toxicity in these mice, with no appar-
ent weight loss (data not shown). In addition, fibroblasts (NHDF-juv), normal kidney cells 
(HK-2) and endothelial cells (HUVEC) were resistant to co-treatment with K12:TRAIL and 
T-cells (data not shown). Similarly, co-treatment of mice with T-cells and anti-CD3:TRAIL 
resulted in a striking increase in median survival with all treated mice remaining tumor free 
for the duration of the experiment (Fig. 10A and 10C). Treatment with anti-CD3:TRAIL 
alone had no effect on animal survival (Fig. 10C). Of note, while no deleterious effects on 
animal well being were observed during the experiment, treatment of NHDF-juv, HK-2 and 
HUVEC with anti-CD3:TRAIL in vitro did enhance T-cell-mediated toxicity towards these 
cells (data not shown). To determine whether T-cells remained localized to the intraperito-
neal cavity, we used fluorescently labeled T-cells (Fig. 11). Treatment with activated T-cells 
alone had no effect on tumor load (3/3 mice), although T-cells did localize to tumor nodes in 
the abdominal cavity (Fig. 11). Treatment with activated T-cells+K12:TRAIL resulted in 1 tu-
mor-free mouse after 2 days and 2 out of 3 tumor-free mice after 5 days. Interestingly, one 
of the mice still bearing tumor cells after 2 days displayed a focal co-localization of T- and 
tumor-cells (Fig.11) resulting in tumor cell eradication two days later (Fig. 11). T-cells+anti-
CD3:TRAIL also co-localized to tumor sites (Fig. 11), but only 1 out of 3 mice were tumor 
free after 5 days. Taken together, K12:TRAIL and anti-CD3:TRAIL potently enhance anti-
tumor activity of T-cells and inhibit growth of colorectal xenografts in vivo. 
K12:TRAIL and anti-CD3:TRAIL are compatible with experimental strategies to ameliorate 
GvHD and optimize GvT
Earlier studies have shown that TRAIL-expression on T-cells is required for optimal graft-
vs-tumor (GVT) activity during allogeneic hematopoietic cell transplantation (AHCT), but 
does not exacerbate graft-vs.-host disease (GVHD). Therefore, it was examined whether 
K12:TRAIL could be used in conjunction with therapies currently being evaluated for op-
timizing AHCT. In particular, the so-called Histone deacytelase inhibitors (HDACi) inhibit 
GVHD in preclinical settings (16;17), but are also well known to synergize with the pro-
apoptotic activity of TRAIL (18;19). Of note, HDACi do not potentiate the GvT effect. In line 
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Figure 10. K12:TRAIL and anti-CD3:TRAIL inhibit growth of colorectal carcinoma in vivo. A 
Male athymic mice were injected i.p. with 1 x 106 HCT-116-luc cells followed by i.p. injection with either 
saline, activated T-cells (5 x 106), K12:TRAIL (0.25 mg/kg), anti-CD3:TRAIL (0.25 mg/kg), activated 
T-cells+K12:TRAIL or activated T-cells + anti-CD3:TRAIL and tumor growth was monitored by biolumi-
nescence. Mice were sacrificed when tumor size reached a ten-fold increase compared to initial tumor 
load. Representative images of mice from all treatment groups on day 3 and day 14 after tumor cell 
injection are depicted. B Mice survival following treatment with act. T-cells, K12:TRAIL or act. T-cells 
+ K12:TRAIL, as determined by a ten-fold increase in tumor size compared to start of treatment, was 
plotted in a Kaplan-Meier curve. C Mice survival following treatment with act. T-cells, anti-CD3:TRAIL 
or act. T-cells + anti-CD3:TRAIL, as determined by a ten-fold increase in tumor size compared to start 
of treatment, was plotted in a Kaplan-Meier curve. See also Video S5 and S6.
with this, pre-treatment with HDACi valproic acid (VPA) did not enhance the tumoricidal 
activity of T-cells alone (Fig.12A). In contrast, pre-treatment of OvCAR-3 cells with Valproic 
Acid (VPA) strongly optimized the potentiating effect of K12:TRAIL and anti-CD3:TRAIL on 







respectively (Fig. 12A-C). Interestingly, VPA enhanced the anti-tumor effect of K12:TRAIL, 
but not anti-CD3:TRAIL, towards two patient-derived tumor samples (Fig. 12D).
Various other strategies have been developed to selectively enhance GVT or ameliorate 
GVHD without affecting GVT. These strategies include the selective depletion of a popu-
lation of alloreactive CD69high T-cells before infusion (20), or selectively transferring only 
CD4+, CD8+ or CD25+ cells (21). K12:TRAIL and anti-CD3:TRAIL potentiated the tumoricid-
al activity of isolated CD69low, CD69medium, or CD69high T-cell populations to a similar degree 
(Fig. 12F). Similarly, K12:TRAIL and anti-CD3:TRAIL potentiated the tumoricidal activity of 
sorted CD4+ and CD8+ T-cells to a level similar to that observed in non-sorted T-cells (Fig. 
12G). Therefore, K12:TRAIL and anti-CD3:TRAIL appear suitable for integration in existing 























Figure 11. K12:TRAIL and anti-CD3:TRAIL inhibit growth of colorectal carcinoma in vivo. Male 
athymic mice were injected i.p. with 1 x 106 HCT-116-luc cells followed by i.p. injection with either 
saline, activated T-cells (1 x 106),  activated T-cells+K12:TRAIL (0.25 mg/kg) or activated T-cells+anti-
CD3:TRAIL (0.25 mg/kg).  T-cell localization was subsequently monitored at the indicated time-points 
using fluorescence together with tumor localization using bioluminescence.
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Figure 12. K12:TRAIL and anti-CD3:TRAIL are compatible with experimental strategies to ame-
liorate GvHD and optimize GvT. OvCAR-3 cells were pre-treated with VPA (1 nM) for 1day and 
subsequently treated for 16h with A activated T-cells B K12:TRAIL-armed T-cells (50 pg/T-cell) or C 
anti-CD3:TRAIL-armed T-cells (50 pg/T-cell) at the indicated E:T ratios. D Primary cancer cells (n=2) 
were pre-treated with VPA (1 nM) for 1day and subsequently treated for 16h with activated T-cells 
or K12:TRAIL/anti-CD3:TRAIL-armed T-cells (50 pg/T-cell) at an E:T ratio of 5:1. E Activated T-cells 
were double-stained for CD3 and CD69, whereupon CD69low, CD69medium and CD69high populations 
were sorted from the CD3-positive cells. F OvCAR-3 cells were treated with CD69low, CD69medium and 
CD69high in the presence or abscence of K12:TRAIL/anti-CD3:TRAIL (50 pg/T-cell) for 16h at an E:T 
ratio of 1:1. G OvCAR-3 cells were treated with CD4+ or CD8+ T-cell populations and K12:TRAIL/anti-









Here we report on the preclinical evaluation of a new strategy designed to deliver high 
levels of the pro-apoptotic effector molecule TRAIL to the surface of T-cells and thereby 
safely augment anti-tumor T-cell activity. Arming T-cells with anti-CD3:TRAIL or K12:TRAIL 
resulted in an >500-fold increase in tumoricidal activity towards both cancer cell lines and 
primary patient-derived malignant cells. In addition, co-treatment with K12:TRAIL and T-
cells significantly prolonged survival time of xenografted mice.
K12:TRAIL enhanced the tumoricidal activity of T-cells by activation of pro-apoptotic TRAIL-
receptor signaling in tumor cells. Surprisingly, the potentiating activity of anti-CD3:TRAIL 
was found to be predominantly due to granzyme/perforin signaling, analogous to the activ-
ity of T-cell redirecting bispecific antibodies. In line with this mechanism of redirected lysis 
anti-CD3:TRAIL triggered CD3-mediated Ca-flux due to mechanical stress acting on the 
anti-CD3:TRAIL-CD3 complex. These findings corroborate with a recent report that sug-
gest that CD3 in the T-cell Receptor Complex functions as a mechanoreceptor translating 
shear stresses into signaling (15;22). In this way, the function of anti-CD3:TRAIL appears 
analogous to artificial antigen-presenting complexes or native MHC-molecules. In view 
of these activating properties, anti-CD3:TRAIL may be particularly suited for e.g. ex vivo 
tumor cell purging of bone marrow. In addition, anti-CD3:TRAIL may be used in patients 
that suffer from malignant disease that is restricted to an anatomically confined region. Of 
interest in this respect are peritonitis carcinomatosis patients that undergo Heated Intra-
Peritoneal Chemotherapy (HIPEC), an operation in which anti-CD3:TRAIL may easily be 
incorporated. 
Applicability of K12:TRAIL is likely not limited to a specific kind of T-cell immunotherapy, 
but may be applied to e.g. ex vivo expanded tumor infiltrating lymphocytes, engineered 
T-cells, T-cell bodies, as well as in Graft-versus-Tumor (GVT) activity during allogeneic 
hematopoietic cell transplantation (AHCT). Indeed, perhaps the most obvious application 
of T-cell specific delivery of TRAIL using K12:TRAIL would be in the context of AHCT. Al-
loreactive donor T-cells are the primary mediators of GVT activity as well as graft-versus-
host disease (GVHD). Earlier studies have shown that TRAIL-expression on T-cells was 
required for optimal GVT, whereas TRAIL did not contribute to GVHD (10). Although not 
investigated here, the data of the current study suggest that targeted delivery of TRAIL to 
donor T-cells using K12:TRAIL may be of value to selectively enhance GVT. Interestingly, 
novel GVHD-inhibitors like Histone deacytelase inhibitors (HDACi) (16;17) or rapamycin 
(23) are also known to sensitize cancer cells to TRAIL-induced apoptosis (18;19). In line 
with this, our experiments demonstrate further optimization of the potentiating effect of 
K12:TRAIL by pre-treatment of tumor cells with the HDACi Valproic Acid. Thus, rationally 
designed combinatorial strategies that include K12:TRAIL may well yield optimal GvT activ-
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ity with no/minimal GvHD.
The here described immunotherapeutic approach to optimize T-cell immunotherapy may 
be further explored using TRAIL fusion proteins that incorporate other immunomodulatory 
scFvs or ligands that would simultaneously provide stimulatory signals to T-cells and add 
TRAIL signaling to the T-cell armamentarium. Likely combinations to this effect include 
stimulatory anti-CD28 scFvs (24) or inhibitory scFvs directed against Cytotoxic T-Lympho-
cyte Antigen 4 (CTLA-4) (25). In this respect, targeted activation of CTLA-4 signaling using 
a fusion protein CTLA-4:TRAIL fusion protein has been shown to limit T-cell activity and 
ameliorate autoimmunity in preclinical models (26). Reversely, inhibition of CTLA-4 signal-
ing may potentiate anti-tumor T-cell activity.
In conclusion, cell surface delivery of TRAIL to T-cells potently augments the anti-tumor 
activity of T-cells in vitro and in vivo and might be widely applicable in current/experimental 
T-cell-based strategies to optimize anti-cancer efficacy.
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Calreticulin is an apoptotic recognition phagocytic receptor that plays an im-
portant role in both autoimmune disease and cancer. Interestingly, previously 
calreticulin was shown to directly interact with TNF-family members FasL and 
TRAIL in an in vitro immunoassay. Furthermore, we have demonstrated that 
the interaction of calreticulin with FasL inhibits FasL-induced apoptosis in T-
cells. Here, we investigated calreticulin - TRAIL/TRAIL-receptors interaction on 
cancer cells and the effect this association had on TRAIL-induced apoptosis in 
tumor cells. Our results indicate that calreticulin is recruited with TRAIL to the 
Death Inducing Signaling Complex of the TRAIL-Receptor, but does not inhibit 
or augment TRAIL-induced apoptosis. Of note, the interaction of calreticulin and 
TRAIL is time-dependent, peaks after ~30-60 minutes of TRAIL treatment and 
then subsides again. Interestingly, whereas calreticulin was associated with the 
anti-phagocytic receptor CD47 in control conditions, treatment with TRAIL trig-
gered dissociation of calreticulin from CD47. Taken together, these data suggest 
that treatment of tumor cells with TRAIL leads to the recruitment of calreticulin 
towards the TRAIL apoptotic complex. Further elucidation of the role of calreti-
culin in TRAIL-signaling may help to pinpoint the immunological mechanisms of 
apoptotic cell recognition and removal upon TRAIL treatment.
 
Introduction
The endoplasmic reticulum chaperone calreticulin (CRT) is a pro-phagocytic ligand 
with roles in autoimmune disease and cancer (1). Normally, CRT is retained in the 
lumen of the endoplasmic reticulum (ER) (2;3), but CRT can also be excreted or dis-
played on the cell surface in association with other ER proteins (4-6). Interestingly, sur-
face and/or soluble CRT appears to modulate signaling by TNF-family members and/
or their receptors. For instance, binding of N-acetylmuramyl-L-alanyl-D-isoglutamine 
(L,D-MDP) to cell surface CRT (csCRT) induces activation of the pro-apoptotic TNFR1 
pathway in RK13 cells (7). In contrast, soluble CRT (sCRT) inhibits apoptosis induced 
by Fas-ligand (FasL) in T-cells (8). This inhibition of FasL-mediated apoptosis in T-cells 
was a result of direct interaction between CRT and FasL (8). Interestingly, CRT was 
reported to not only bind to FasL, but also to the TNF-related apoptosis inducing ligand 
(TRAIL) in an ELISA type assay (9). The biochemical implications of CRT interaction 
with TNF-family members that are associated with regulating apoptosis have not been 
fully elucidated, but CRT may interact with these cell surface cell death regulators in 
different ways.
TRAIL is a member of the TNF family with pro-apoptotic activity towards malignant 







considerable interest for the treatment of cancer. TRAIL induces apoptosis via two agonis-
tic receptors, TRAILR1 and TRAILR2, that both transmit apoptotic signals via the so-called 
Death Inducing Signaling Complex (DISC). The DISC contains the adaptor molecule Fas-
Associated protein with Death Domain (FADD) and the pro-form of initiator caspase-8, 
and assembly of this complex leads to proximity-induced activation of the latter (10). Con-
comitantly, an intracellular proteolytic caspase cascade ensues that ultimately leads to the 
execution of apoptosis (reviewed in (11;12)). 
Pro-apoptotic signaling via TRAILR1 and TRAILR2 may be competitively inhibited by two 
cell-surface expressed decoy receptors, TRAILR3 and TRAILR4. TRAILR3 is a phospholip-
id-anchored receptor that lacks a cytoplasmic domain (13), whereas TRAILR4 only retains 
a truncated intracellular domain that is incapable of apoptotic signaling (14). Therefore, 
both receptors are thought to function as decoy receptors for TRAIL (reviewed in (15)). 
Apoptotic signaling of the DISC can also be inhibited by recruitment of additional compo-
nents, such as cFLIP isoforms (16). These proteins are structurally related to caspase-8, 
lack enzymatic activity and inhibit DISC-associated activation and processing of caspase-8 
(for review see (17)).
Given the recent evidence that cell surface associated CRT can act as a cell death as-
sociated molecule and appears to enhance tumor recognition by the immune system (for 
review see (18)), we evaluated whether calreticulin might play a role in TRAIL-mediated 
apoptotic cell death of malignant cells. As cell surface CRT has previously been detected 
in melanoma cells (19) we focused on CRT interaction with TRAIL on the cell surface of 
melanoma cells using biochemical analyses. In addition, we evaluated whether calreticulin 




Anti-CRT mAbs (Ab2907, Ab39818, Ab4 and Ab22684 [FMC 75]) were purchased from Ab-
cam. CRT competing peptide Ab39895 is the peptide fragment used to generate Ab39818 
in mice and was purchased from Abcam. Anti-CD47 antibody (B6H12.2) was purchased 
from Abcam. Anti-TRAIL mAb (B-S23) was purchased from Diaclone SAS. Anti-TRAILR2 
mAb (HS-202) was purchased from Alexis. Chicken-anti-mouse-AlexaFluor596, Goat-
anti-rabbit-AlexaFluor488 and Goat-anti-mouse-AlexaFluor488 were purchased from In-
vitrogen. PE-labeled anti-TRAIL mAb (B-S23) was purchased from Diaclone SAS. Anti-
HA-Peroxidase mAb (3F10) and anti-HA sepharose beads (3F10) were purchased from 
Roche. Anti-FADD mAb (2782S) and anti-caspase8 mAb (18C8) were purchased from 
Cell signaling. Protein G-sepharose beads were purchased from GE Healthcare. CellEvent 
Caspase-3/-7 detection reagent was purchased from Invitrogen. Duolink proximity ligation 
assay was purchased from Olink Bioscience. Protease inhibitor cocktail was purchased 




from Sigma-Aldrich. Soluble FasL was purchased from Enzo Life Sciences. Native hu-
man calreticulin was purified from Jurkat cells using a method as previously described (8). 
RhTRAIL was purchased from R&D systems.
Production of HA-TRAIL
HA-TRAIL was constructed by cloning the cDNA of HA-tagged TRAIL in frame into previ-
ously described vector pEE14, yielding plasmid pEE14-HA-TRAIL. HA-TRAIL was pro-
duced in CHO-K1 cells essentially using previously described methods (20;21). Culture 
medium containing HA-TRAIL was cleared by centrifugation (10.000 g, 10 min), filter steril-
ized, and stored at -80°C until further use. HA-TRAIL was purified via the N-terminal He-
magglutinin (HA)-tag using anti-HA affinity chromatography.
Cell lines 
A375M was obtained from the American Tissue Culture Collection (ATCC) and character-
ized by short tandem repeat profiling, karyotyping and isoenzyme analysis. A375M.FADD-
DED cells were generated by transfection of parental A375M cells using Fugene (Roche 
BV, Woerden, The Netherlands). Ramos, Ramos.cFLIPL, Ramos.cFLIPS, Ramos.FERM 
and Ramos.Ezrin were a kind gift from Dr. B.J. Kroesen (UMCG, the Netherlands). A375M 
and Ramos were cultured in RPMI1640 medium supplemented with 10% fetal calf serum. 
A375M.FADD-DED, Ramos.cFLIPL, Ramos.cFLIPS, Ramos.FERM and Ramos.Ezrin cells 
were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum and 500 μg/
ml Geneticin.
Analysis of TRAIL binding to calreticulin
Native calreticulin (1 µg in 100 μL; 21 µM) in NaCO3 buffer (pH 9.6) was added to each well 
of a 96-well Nunc Maxisorp plate (Fisher Scientific). The plate was incubated overnight at 
4°C and then washed with PBST. Aspecific binding was blocked with 3% w/v bovine serum 
albumin (BSA) in PBST for 1 hour at 37°C. Plates were then washed as described above. 
Increasing concentrations of rhTRAIL were then diluted in 3% w/v BSA in PBST and added 
to triplicate wells and incubated for 1 hour at 37°C. The plates were again washed as 
described above. Binding of TRAIL to calreticulin was detected by adding PE-conjugated 
anti-TRAIL antibody and incubating the plate for 1 hour at 4°C. The wells were washed as 
described before and the plates were read on an ELISA plate reader at 565 nm.
Microscopy
A375M melanoma cells were treated with rhTRAIL (100ng/mL; 5.1 nM) for 1h at 37°C, 
washed three times with PBS and fixed using 4% v/v PFA. Cells were subsequently washed 







4°C for 1h. Cells were then washed three times with PBS, probed with secondary antibody 
and DAPI at 4°C for another 1h and washed three more times with PBS prior to examina-
tion. Confocal microscopy was performed on a Solamere Nipkow Disk CLSM equipped 
with temperature/CO2 controlled cabinet and multi-cell track table.
Proximity ligation assay
To determine direct CRT – TRAIL protein interaction, a proximity ligase assay (PLA) was 
employed. Aliquots of A375M cells, 4.5 x 103 in each chamber were cultured in permanox 
chamber slides. Cells were treated with 100ng/ml rhTRAIL as indicated, and subsequently 
fixed with 4% v/v PFA. Protein proximity was subsequently determined using the Duolink II 
Fluorescence assay according to the manufacturer’s instructions (Olink Bioscience, Upp-
sala, Sweden). Briefly, after blocking non-specific binding sites with BSA, cells were incu-
bated with anti-CRT (ab2907), anti-TRAIL (B-S23), anti-TRAILR2 (Hs201) or anti-CD47 
(B6H12.2) for 1 hour at 22°C. Cells were subsequently washed and incubated with the 
Duolink plus and minus PLA-probes, followed by a ligation step to hybridize the probes. 
Next, the fluorescent signal was enhanced by rolling circle amplification, and nuclei were 
stained with DAPI mounting medium. Fluorescent signal was examined using an EVOS fl 
fluorescent microscopy (Advanced Microscopy Group, Bothell, USA).
Immunoprecipitation 
For TRAIL immunoprecipitation, 15 x 106 cells were stimulated with 100 ng/mL of HA-TRAIL 
in 7.5 mL medium for the indicated times at either 4°C or 37°C. Cells were then washed 
three times with cold PBS and lysed in 1 ml lysis buffer (1% Triton, 20 mM of Tris-HCl 
(pH 7.5), 150 mM of NaCl, 1 mM of CaCl, 1 mM of MgCl and Protease inhibitor cocktail). 
Lysates were pre-cleared with Protein G-sepharose and immunoprecipitated overnight 
at 4°C with anti-HA sepharose beads. For CRT or TRAIL receptor immunoprecipitations, 
cells were stimulated with 100 ng/mL HA-TRAIL as described above, washed and lysed in 
Triton-containing lysis buffer. Lysates were pre-cleared as described and 10 µg of immuno-
precipitating antibody (anti-CRT - Ab39818 or anti-TRAILR2 - HS-202) was added. In both 
cases, beads were then washed four times with lysis buffer and immunoprecipitates were 
eluted in SDS-sample buffer prior to being used in immunobloting. 
Western blotting
Human melanoma cell lysates were resolved by SDS-polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes. Nonspecific binding was blocked by incuba-
tion in PBS containing 0.05% Tween-20 and 5% w/v powdered milk. Immunoblots were 
subsequently incubated with specific primary antibodies, followed by horseradish peroxi-
dase-conjugated secondary antibody, and were developed by Super signal west dura ac-




cording to the manufacturer’s protocol (Thermo Scientific). 
Analysis of cell death
For cell death assays, melanoma cancer cells were treated for 16 hours with rhTRAIL 
(100ng/mL) in the presence or absence of soluble CRT as indicated, after which apoptosis 
was assessed in tumor cells by loss of mitochondrial membrane potential (∆Ψ) as previ-
ously described (22), using an Accuri C6 flow cytometer. For inhibition of apoptosis using 
sCRT cells were treated using rhTRAIL and sCRT essentially as described before for FasL 
(8).
Statistical analysis
Data reported are mean values±SD of three independent experiments. Data was analyzed 
by one-way ANOVA followed by Tukey-Kramer post test or, where appropriate, by two-
sided unpaired Student’s t-test. Where indicated * = p<0.05; ** = p<0.01; *** = p<0.001.
 
Results
Calreticulin directly binds to TRAIL and co-localizes with TRAILR2 on melanoma cells
To confirm the initial reports on the direct interaction of CRT with TRAIL, a catching type 
ELISA was performed with TRAIL on CRT coated plates. As anticipated, addition of TRAIL 
to CRT-coated ELISA plates resulted in the specific and dose-dependent interaction of 
TRAIL with CRT (Fig.1A). To confirm that this interaction also occurred on the cell surface 
of cells, A375M melanoma cells were treated for 3h with TRAIL. A375M cells were cho-
sen because they express only TRAILR2 on their cell surface. Using fluorescent micros-
copy, no CRT signal was detected on the cell surface of untreated A375M cells (Fig. 1B). 
However, treatment with TRAIL resulted in the presence of a clear patched pattern of cell 
surface CRT (Fig. 1B). This CRT staining partly overlapped with cell surface expressed 
TRAILR2 (Fig. 1B). These results were confirmed using confocal microscopy, where again 
cell surface staining of CRT on untreated control cells was not detectable (data not shown). 
In contrast, in TRAIL-treated A375M cells, a clear punctuate cell surface expression of CRT 
was visible (Fig. 1C). The majority of this cell surface expressed CRT was co-localized 
with TRAILR2 (Fig. 1C). Reversely, only part of cell surface expressed TRAILR2 was co-
localized with CRT (Fig. 1C). Importantly, PLA further confirmed that CRT and TRAIL (Fig. 
2A), as well as CRT and TRAILR2 (Fig. 2B), were in close proximity (<40nm or ~4-12 pro-
teins) after treatment with TRAIL. Furthermore, the PLA staining indicates that CRT forms 
complexes with both TRAIL and TRAILR2 on the cell surface of A375M cells. Interestingly, 
CRT dissociated from CD47, a known CRT binding partner (Fig. 2C). Together these data 
clearly establish the co-localization of CRT with TRAIL on the cell surface of TRAIL-treated, 







Calreticulin associates with the TRAILR2-DISC via TRAIL
Since CRT co-localized with TRAILR2 only after treatment of melanoma cells with TRAIL, 
we next evaluated whether TRAIL-treatment resulted in the formation of a DISC to which 
CRT might be recruited. Indeed, immunoprecipitation of HA-tagged TRAIL after 15 and 180 
minutes of treatment with TRAIL at 37°C co-immunoprecipitated a complex that included 
CRT, FADD, and pro-caspase-8 (Fig.3A). Of note, caspase-8 was predominantly present 
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Figure 1. Calreticulin binds to TRAIL and associates with TRAILR2. A Calreticulin was coated and 
binding of increasing concentrations of TRAIL were assessed in a catch-type ELISA. B A375M mela-
noma cells were treated with 100 ng/mL rhTRAIL for 1h, double stained for CRT (red) and TRAILR2 
(green) and analyzed using fluorescent microscopy. C A375M cells were treated with 100 ng/mL 
rhTRAIL for 1h, double stained for CRT (red) and TRAILR2 (green) and analyzed using confocal 
microscopy.




in its full-length pro-enzyme (p54) form after 15 min. of treatment, but was also found in its 
intermediate processed p41/43 form (Fig.3A). This p41/43 was further increased after 3h 
of treatment (Fig. 3A). Treatment on ice also resulted in the formation of the TRAIL-associ-
ated complex comprised of typical DISC components and CRT (Fig.3A). However, partial 
caspase-8 processing on ice was only detected after 3h of treatment with TRAIL (Fig.3A).
To further confirm these data we performed a reciprocal CRT-immunoprecipitation. Four 
different anti-CRT antibodies were evaluated for their ability to co-immunoprecipitate 
TRAIL in TRAIL-treated A375M cells. Of these four antibodies, IP with Ab39818 resulted in 
the highest amount of TRAIL co-precipitated with CRT (data not shown). Thus, further IP 
experiments were performed with Ab39818. After 3h of treatment with recombinant TRAIL, 
immunoprecipitation with Ab39818 resulted in the co-precipitation of TRAIL, TRAILR2, as 
well as initiator caspase-8 (Fig.3B). Of note, 3h treatment with TRAIL at 0˚C co-precipitated 
mainly the full-length p54 form of caspase-8, whereas treatment with TRAIL for 180 min. at 
Figure 2. Calreticulin associates with TRAIL and TRAILR2. A375M melanoma cells were treated 
with 100 ng/mL rhTRAIL for 1h, incubated with mAbs directed against CRT and A TRAIL, B TRAILR2 
or C CD47 and subsequently used for proximal ligation assay (PLA).
A
B PLA αTRAILR2/αCRT
rhTRAIL (100ng/ml, 1h) isotype controlmedium 
PLA αTRAIL/αCRT
rhTRAIL (100ng/ml, 1h)medium isotype control
C PLA αCRT/αCD47







37˚C mainly precipitated the p41/43 form of caspase-8 (Fig. 3B).
Subsequently, TRAILR2 was precipitated to identify whether CRT and TRAIL associated 

























































































Figure 3. Calreticulin is recruited with TRAIL to the TRAILR DISC. A A375M cells were treated 
with HA-TRAIL for 15 or 180 min. at the indicated temperatures. Cells were subsequently lysed and 
HA-TRAIL was precipitated via affinity tag purification. Precipitates were subsequently probed for the 
presence of HA, CRT, TRAILR2, FADD and caspase-8. B A375M melanoma cells were treated with 
HA-TRAIL for 180 min. at the indicated temperatures. Cells were subsequently lysed and CRT was 
precipitated using anti-CRT Ab39818. Precipitates were subsequently probed for the presence of CRT, 
HA and caspase-8. C (Upper panel) A375M melanoma cells were treated with HA-TRAIL for 180 
min. at the indicated temperatures. Cells were subsequently lysed and TRAILR2 was precipitated 
using anti-TRAILR2 mAb HS-202. Precipitates were subsequently probed for the presence of HA and 
CRT. (lower panel) A375M melanoma cells were treated with HA-TRAIL or FasL for 180 min. at 37°C. 
Cells were subsequently lysed and CRT was precipitated using anti-CRT Ab39818. Precipitates were 
subsequently probed for the presence of TRAILR2. D A375M melanoma cells were treated with HA-
TRAIL or agonistic TRAIL mAb for 60 min. at 37°C. Cells were subsequently lysed and TRAILR2 was 
precipitated using the agonistic TRAIL mAb. Precipitates were subsequently probed for the presence 
of HA, CRT, TRAILR2 and caspase-8.




resulted in the co-precipitation of TRAIL (Fig. 3C). In addition, TRAILR2 immunoprecipita-
tion also resulted in the co-precipitation of CRT (Fig. 3C), which suggests that CRT as-
sociated with TRAIL and TRAILR2 in one complex. To exclude that CRT interacted with 
TRAILR2 in the absence of TRAIL, CRT was immunoprecipitated from untreated cells, 
TRAIL-treated cells and control FasL-treated cells. Importantly, TRAILR2 was only co-
precipitated in TRAIL-treated cells (Fig. 3C). To further confirm that the interaction of CRT 
with TRAIL was necessary for its association with TRAILR2, A375M cells were treated with 
TRAIL or agonistic anti-TRAILR2 antibody. Subsequent IP of TRAILR2 only resulted in the 
co-immunoprecipitation of CRT after treatment with TRAIL and not with agonistic TRAILR2 
antibody, whereas caspase-8 was detected in cells treated either with TRAIL or agonistic 
TRAILR2 antibody (Fig. 3D).
Calreticulin association with the TRAILR2-DISC is time-dependent
Since CRT associated with TRAIL in A375M cells, we next investigated whether this inter-
action was constant or transient. To this end, A375M cells were treated with TRAIL for vari-
ous time-points, after which TRAIL was immunoprecipitated. In these time-course experi-
ments, IP of TRAIL resulted in the co-precipitation of CRT. However, CRT association was 
minimal at early time-points, increased to a maximum association after ~1h and appeared 
to reach a stable level after 2 and 3 hours of treatment (Fig. 4A). IP of CRT in an analogous 
time-course confirmed a peak of interaction with TRAIL at 1h followed by a decrease to 
stable levels of CRT/TRAIL interaction after 2-3 h (Fig. 4B). Of note, association of CRT 
with the pro-form of caspase-8 rapidly reached a maximum at initial time-points of 5 and 15 
minutes after which association started to steadily decrease in time (Fig. 4C). At the same 
time, the association of the processed form of caspase-8 increased in time until 1h of treat-
ment and then declined to constant level at 2-3 hours of treatment (Fig. 4C). This maximal 
processing of caspase-8 was in time followed by the activation of effector caspase-3 as 
determined by fluorescent activity assay (Fig. 4D). These data were confirmed using PLA 
analysis that demonstrated a time-dependent increase in TRAILR2-CRT proximity with a 
maximum association after ~1h of treatment (Fig. 5).
Calreticulin association with the TRAILR-DISC is independent of execution of apoptosis
Next we determined whether the association of CRT with TRAIL was dependent on TRAIL-
induced apoptosis. To this end, Ramos B-cells overexpressing the anti-apoptotic DISC 
component cFLIP (Ramos.cFLIPL and Ramos.cFLIPs) were treated with TRAIL. Interest-
ingly, IP of TRAIL resulted in the co-precipitation of CRT in Ramos cells, but also in Ra-
mos.cFLIPL and Ramos.cFLIPs, indicating that activation of caspases was not required for 
the association of CRT with TRAIL (Fig. 6A). Similarly, treatment of A375M cells with pan 
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Figure 4. Calreticulin association with the TRAILR-DISC is time-dependent. A A375M cells were 
treated with HA-TRAIL at 37°C for the indicated time-points. Cells were subsequently lysed and HA-
TRAIL was precipitated via affinity tag purification. Precipitates were subsequently probed for the 
presence of CRT. B A375M cells were treated with HA-TRAIL at 37°C for the indicated time-points. 
CRT was precipitated using anti-CRT Ab39818. Precipitates were subsequently probed for the pres-
ence of HA. C A375M cells were treated with HA-TRAIL at 37°C for the indicated time-points. CRT 
was precipitated using anti-CRT Ab39818. Precipitates were subsequently probed for the presence of 
caspase-8. D A375M melanoma cells were treated with HA-TRAIL at 37°C for the indicated time-points 
and caspase-3 activity was assessed.




more, A375M cells overexpressing a dominant negative mutant of FADD (FADD-DED) that 
is unable to signal apoptosis still showed TRAIL/CRT co-localization after TRAIL treatment 
(data not shown).
Next, we assessed whether cytoskeletal reorganization might be required for the CRT/
TRAIL association. In Ramos.Ezrin cells that overexpress a dominant negative form of 
Ezrin, whereby cytoskeletal reorganization is blocked, TRAIL was not co-precipitated with 
CRT (Fig. 6A).
Taken together, these data indicate that whereas CRT association is independent of the 
execution of TRAIL-mediated apoptosis, the reorganization of the cytoskeleton is required 
for CRT/TRAIL association.
Calreticulin does not influence the apoptotic activity of TRAIL
Since the association of TRAIL with CRT occurred independently of caspase activation, we 
speculated that CRT might modulate TRAIL induced apoptosis at the cell surface. As ex-
pected, treatment of Ramos, Ramos.cFLIPL, Ramos.cFLIPs and Ramos.Ezrin with TRAIL 
t=0 t=5 min t=10 min
t=15 min t=30 min t=45 min
t=60 min t=150 min
Figure 5. Calreticulin association with the TRAILR-DISC is time-dependent. A375M melanoma 
cells were treated with 100 ng/mL rhTRAIL at 37°C for the indicated time-points, incubated with mAbs 













































































































Figure 6. Calreticulin association with the TRAILR-DISC is time-dependent. A Ramos, Ramos.
cFLIPL, Ramos.cFLIPS, Ramos.FERM and Ramos.Ezrin cells were treated with HA-TRAIL for 1h 
at 37°C. Cells were subsequently lysed and HA-TRAIL was precipitated via affinity tag purification. 
Precipitates were subsequently probed for the presence of CRT. B A375M cells were treated with 
HA-TRAIL in the presence or abscence of zVAD-fmk. Cells were lysed at the time points indicated 
and  CRT was precipitated. Precipitates were subsequently proped for HA-TRAIL. C Ramos, Ramos.
cFLIPL, Ramos.cFLIPS and Ramos.Ezrin cells were treated with rhTRAIL for 16h and apoptosis was 
assessed. D Ramos and Ramos.Ezrin cells were treated with rhTRAIL in the presence or absence of 
CRT or CRT-neutralizing antibody for 16h and apoptosis was assessed.




triggered apoptosis in Ramos, but not in Ramos.cFLIPL and Ramos.cFLIPs (Fig.6C). In 
contrast, Ramos.Ezrin cells, where CRT/TRAIL association does not occur, were slightly 
more sensitive to TRAIL-induced apoptosis then wild-type Ramos cells. However, treat-
ment with exogenous CRT or an anti-CRT polyclonal antibody that is known to neutralize 
CRT activity in phagocytosis assays had no effect on apoptosis induced by TRAIL in either 
Ramos or Ramos.Ezrin (Fig. 6D), indicating that the increased sensitivity of Ramos.Ezrin 




In many cell types, but particularly in tumor cells, the trafficking of CRT from the ER to 
the cell surface in association with other ER proteins (23) and interaction with apoptotic 
regulation proteins has been described (6). A previous study has reported the interaction 
of CRT with TRAIL in vitro (9). Here we report on the cell-surface interaction of the pro-
phagocytic molecule CRT with the pro-apoptotic TNF-family member TRAIL. In addition, 
our data establish that calreticulin transiently associated with the TRAILR Death DISC in 
A375M melanoma and leukemic Ramos B-cells.
Treatment of cells with TRAIL induced a rapid (<5min.) recruitment of CRT towards the 
TRAILR DISC independent of proximal caspase signaling, suggesting this was a pre-apop-
totic event. Furthermore, recruitment of CRT to the TRAILR DISC was contingent on the 
presence of TRAIL and did not occur upon treatment with FasL or an agonistic TRAILR2 
mAb. Together, these data indicate that the physical interaction of TRAIL and CRT me-
diates recruitment of CRT to TRAILR2. However, our data do not exclude simultaneous 
binding of CRT to both TRAIL and TRAILR2. This translocation of CRT to TRAILR2 was 
dependent on cytoskeletal rearrangements since overexpression of a double negative Ez-
rin mutant (DN-Ezrin), incapable of binding to actin, abolished the interaction. Interestingly, 
these Ramos.Ezrin cells were more sensitive to TRAIL-mediated apoptosis, with ~20% 
more cell death in Ramos.Ezrin compared to Ramos. However, addition of exogenous 
CRT had no effect on this differential induction of apoptosis by TRAIL, indicating that these 
effects were likely CRT-independent. In line with this, a recent report indicates that Ezrin 
functions as a negative regulator of both FasL and TRAIL mediated apoptosis in T-cells 
and functional inhibition of Ezrin, either by siRNA or expression of DN-ezrin, accelerates 
induction of apoptosis by TRAIL (24).
Our immunohistochemical data indicate changes in the cell surface distribution of CRT on 
TRAIL-treated cells. Such changes in CRT-localization on apoptotic cells have previously 
been reported for UV-irradiated cells and appear to reflect changes towards a more pro-
phagocytic phenotype (25). Indeed, CRT is released from anti-phagocytic binding partner 







rich in phosphatidyl serine (PS), another pro-phagocytic signaling molecule. Not surpris-
ingly, this reorganization enhances uptake of apoptotic cells by phagocytes (25). In this cur-
rent study, the proximal ligation studies also identified a reduced co-localization of CRT and 
CD47 in A375M cells undergoing TRAIL-induced apoptosis. These data support a model 
of CRT release from CD47 on cells undergoing apoptosis and indicate that treatment with 
TRAIL might function similar to UV-radiation in releasing CRT from an anti-phagocytic com-
plex.
Although involved in enhancing phagocytosis, CRT is also a key determinant of whether 
cell death provokes an immune response. Chemotherapeutic agents that simultaneously 
induce apoptosis and elicit the translocation of CRT from the ER to the cell surface are 
more immunogenic in mouse models when compared to agents that do not induce CRT 
exposure (4). Moreover, primary patient-derived human cancer cells treated with CRT-
exposing agents (anthracylins) display enhanced uptake by immature DCs and subse-
quent DC maturation (26).  Interestingly, TRAIL was also recently found to induce this 
CRT exposure in a caspase-independent manner (27). These findings are similar to the 
caspase-independent recruitment of CRT to the TRAILR2 complex reported here by us. As 
such, it is tempting to speculate that while TRAIL might initially induce immunogenic CRT 
exposure or re-localization, the association with the TRAIL might render CRT unable to af-
fect an immune response.
In conclusion, we provide evidence that calreticulin associates in a caspase-independent 
manner with the pro-apoptotic TRAILR2 DISC in melanoma and leukemia cells, but does 
not affect the induction of apoptosis by TRAIL. Therefore the role of calreticulin differs from 
the FasL and L,D-MDP-induced apoptosis, which appears to be regulated to some extent 
by association with CRT. Further studies are required to fully elucidate the role of CRT with 
TRAIL and TRAILR2 DISC. 
Acknowledgements
This work was supported by Dutch Cancer Society grants RUG 2009-4355 (EB), RUG2009-
4542 (to E.B/W.H.) and RUG2007-3784 (to W.H.), the Netherlands Organization for Sci-
entific Research (E.B.), the Melanoma Research Alliance (E.B.), the Alexander von Hum-
boldt Foundation (E.B) and the European Community’s Seventh Framework Programme 




Gold, L. I., Eggleton, P., Sweetwyne, M. T., Van Duyn, L. B., Greives, M. R., Naylor, S. M., Michalak, M., and 
Murphy-Ullrich, J. E. (2010) FASEB J. 24, 665-683
Del, C. N., Jeffery, E., Rizvi, S. M., Stamper, E., Peters, L. R., Brown, W. C., Provoda, C., and Raghavan, M. 
(2010) J. Biol. Chem. 285, 4520-4535




Michalak, M., Groenendyk, J., Szabo, E., Gold, L. I., and Opas, M. (2009) Biochem. J. 417, 651-666
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J. L., Castedo, M., Mignot, G., 
Panaretakis, T., Casares, N., Metivier, D., Larochette, N., van, E. P., Ciccosanti, F., Piacentini, M., Zitvogel, L., 
and Kroemer, G. (2007) Nat Med. 13, 54-61
Tarr, J. M., Young, P. J., Morse, R., Shaw, D. J., Haigh, R., Petrov, P. G., Johnson, S. J., Winyard, P. G., and 
Eggleton, P. (2010) J. Mol Biol. 401, 799-812
Kepp, O., Gdoura, A., Martins, I., Panaretakis, T., Schlemmer, F., Tesniere, A., Fimia, G. M., Ciccosanti, F., 
Burgevin, A., Piacentini, M., Eggleton, P., Young, P. J., Zitvogel, L., van, E. P., and Kroemer, G. (2010) Cell 
Cycle 9, 3072-3077
Chen, D., Texada, D. E., Duggan, C., Liang, C., Reden, T. B., Kooragayala, L. M., and Langford, M. P. (2005) 
J. Biol. Chem. 280, 22425-22436
Tarr, J. M., Winyard, P. G., Ryan, B., Harries, L. W., Haigh, R., Viner, N., and Eggleton, P. (2010) Arthritis 
Rheum. 62, 2919-2929
Duus, K., Pagh, R. T., Holmskov, U., Hojrup, P., Skov, S., and Houen, G. (2007) Scand. J. Immunol. 66, 501-
507
Wajant, H., Johannes, F. J., Haas, E., Siemienski, K., Schwenzer, R., Schubert, G., Weiss, T., Grell, M., and 
Scheurich, P. (1998) Curr. Biol. 8, 113-116
Ashkenazi, A. (2002) Nat Rev Cancer 2, 420-430
de Bruyn, M., Bremer, E., and Helfrich, W. (2011) Cancer Lett.
MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., and Alnemri, E. S. (1997) 
J. Biol. Chem. 272, 25417-25420
gli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., and Goodwin, R. G. (1997) Im-
munity. 7, 813-820
Falschlehner, C., Emmerich, C. H., Gerlach, B., and Walczak, H. (2007) Int. J. Biochem. Cell Biol. 39, 1462-
1475
Haag, C., Stadel, D., Zhou, S., Bachem, M. G., Moller, P., Debatin, K. M., and Fulda, S. (2011) Gut 60, 225-
237
Budd, R. C., Yeh, W. C., and Tschopp, J. (2006) Nat Rev Immunol. 6, 196-204
Kepp, O., Tesniere, A., Schlemmer, F., Michaud, M., Senovilla, L., Zitvogel, L., and Kroemer, G. (2009) Apop-
tosis. 14, 364-375
























de Bruyn, M., Rybczynska, A. A., Wei, Y., Schwenkert, M., Fey, G. H., Dierckx, R. A., van, W. A., Helfrich, W., 
and Bremer, E. (2010) Mol Cancer 9, 301
Bremer, E., Abdulahad, W. H., de, B. M., Samplonius, D. F., Kallenberg, C. G., Armbrust, W., Brouwers, E., 
Wajant, H., and Helfrich, W. (2011) Immunol. Lett. 138, 161-168
de Bruyn, M., Wei, Y., Wiersma, V. R., Samplonius, D. F., Klip, H. G., van der Zee, A. G., Yang, B., Helfrich, W., 
and Bremer, E. (2011) Clin. Cancer Res. 17, 5626-5637
Obeid, M. (2008) J. Immunol. 181, 2533-2543
Kuo, W. C., Yang, K. T., Hsieh, S. L., and Lai, M. Z. (2010) Oncogene 29, 1374-1383
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., 
Oldenborg, P. A., Michalak, M., and Henson, P. M. (2005) Cell 123, 321-334
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., and Spisek, R. (2011) Cancer Res. 
71, 4821-4833
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A. C., Chapman, D. C., Durchschlag, M., 
Joza, N., Pierron, G., van, E. P., Yuan, J., Zitvogel, L., Madeo, F., Williams, D. B., and Kroemer, G. (2009) 











Chapter 8: Summary and perspectives
C
hapter 8
The research reported on in this thesis is dedicated to the preclinical development of im-
munotherapeutic strategies against cancer using the tumoricidal protein TRAIL. TRAIL is 
considered to be a promising therapeutic agent due to its prominent apoptotic activity to-
wards many different types of cancer and its apparent lack of toxicity towards normal hu-
man cells. As such, a recombinant form of soluble TRAIL (sTRAIL) is currently undergoing 
early phase clinical evaluation in cancer patients. However, (pre-) clinical research has 
identified several features of the TRAIL/TRAIL-receptor biology that might limit the efficacy 
of recombinant sTRAIL in patients. These include the ubiquitous expression of TRAIL-
receptors (TRAILR) throughout the human body, and the short serum half life (~ 30 min.) 
of TRAIL. In addition, recombinant sTRAIL is less efficient at inducing apoptosis in cancer 
cells than the full-length membrane-bound form of TRAIL.
To overcome these potential drawbacks, we have pursued a TRAIL-based therapeutic ap-
proach in which recombinant soluble TRAIL is genetically fused to a cancer cell surface 
targeting domain. Typically, the targeting domain is a so-called antibody fragment (scFv), 
directed against a pre-defined tumour-associated cell surface antigen. As detailed in chap-
ter 2, this targeting domain ensures selective delivery of high levels of sTRAIL at the cell 
surface of tumour cells. Once bound via the targeting domain, sTRAIL is converted to a 
membrane-bound form of TRAIL and regains its full tumoricidal activity. In earlier studies, 
the feasibility and efficacy of this immunotherapeutic strategy has been evaluated for vari-
ous types of cancer, including solid cancers and haematological malignancies. 
In this thesis, the concept of tumour-targeted delivery of sTRAIL was further developed in 
preclinical studies with an emphasis on eliminating metastasis and disseminated disease 
(chapters 3 to 5). In addition, this tumour cell-targeted approach was adapted to an im-
mune cell-targeted approach with the goal of augmenting anti-tumour activity of T-cells. As 
demonstrated in chapter 6, selective delivery of high levels of TRAIL to the cell surface 
of T-cells, a key tumoricidal immune effector cell population, strongly augments their anti-
tumour activity. This novel approach proved to be highly effective towards a host of differ-
ent tumour cell types, including ovarian cancer and melanoma. The respective research 
chapters of this thesis are discussed in more detail below and perspectives for further (pre)
clinical development are provided.
Epidermal Growth Factor Receptor (EGFR)-targeted TRAIL-based immunotherapy
In chapters 3 and 4, the therapeutic potential of delivering sTRAIL to the Epidermal Growth 
Factor Receptor (EGFR) was investigated. EGFR is an oncogenic growth factor that is over 
expressed on many carcinomas and is a well-established target for immunotherapy [1]. 
Inhibition of EGFR-signalling using antagonistic antibodies or small molecule inhibitors has 
already shown promising clinical efficacy [1,2]. Previously, we incorporated both of these 







fusion protein comprised of an antagonistic anti-EGFR antibody fragment (scFv425) and 
sTRAIL. After binding to cancer cell-expressed EGFR, the anti-EGFR antibody fragment 
inhibited mitogenic signalling by EGFR, thereby sensitizing cells to TRAIL-induced apopto-
sis. At the same time, cell surface delivery of sTRAIL converts sTRAIL to membrane-bound 
TRAIL, yielding potent activation of TRAILR apoptotic signalling [3]. As described in chapter 
3, scFv425:sTRAIL successfully eradicated disseminated EGFR-positive tumours in mice, 
yielding in vivo proof of concept for the tumoricidal activity of scFv425:sTRAIL. For this 
study, we used a gene therapeutic strategy (based on a replication-deficient adenovirus) to 
ensure the continuous in vivo production of scFv425:sTRAIL over extended periods of time 
(>30 days). At high serum levels (>10 µg/mL), scFv425:sTRAIL successfully eradicated 
established tumours. Importantly, scFv425:sTRAIL also significantly halted tumour growth 
at scFv425:sTRAIL serum levels as low as 60 ng/ml. We conclude that EGFR-targeted pro-
apoptotic therapy using scFv425:sTRAIL may hold considerable promise for the treatment 
of malignant disease with intraperitoneal dissemination, such as ovarian cancer. 
In chapter 3, the natural tropism of adenoviral particles for the liver was utilized to ensure 
continues production of circulating scFv425:sTRAIL in mice. However, for gene therapeutic 
purposes, several other modifications may be applied to enhance both anti-tumour activity 
as well as anti-tumour selectivity. 
Adenoviral particles consist of a capsid core with extending fibers ending in so-called knob 
domains. Therefore, strategies to selectively retarget adenoviral particles to tumour cells 
generally focus on the modification of one of these structures (reviewed in [4]). First, aden-
oviral particles might be retargeted to tumour cells using bi-specific ligands that bind to the 
viral fiber knob domain and simultaneously to a tumour-associated antigen. Furthermore, 
adenoviral particles can be retargeted by incorporating targeting ligands into the adenoviral 
capsid proteins. In addition, fiber/knob chimeras have been generated in which the adeno-
virus knob is replaced by a knob from another virus, or alternatively, in which the entire 
adenovirus fiber is replaced with an artificial fiber. Adenoviral particles have also been 
modified by using so-called RGD-fibers. These RGD-fiber modified adenoviral particles 
display an enhanced infection activity of e.g. ovarian carcinoma cells [5]. 
Adenoviruses have also been engineered that are conditionally replicative (CRAd) (re-
viewed in [6]). These CRAd are designed to specifically infect cancer cells, replicate se-
lectively, and then to spread to other cancer cells, without damaging untransformed cells. 
This has been achieved by deleting part of the viral genome to prevent replication in normal 
cells, but allow replication in tumour cells with genetic defects that complement the deleted 
viral genome functions. For instance, a 24 base pair deletion in the adenoviral gene E1A 
(dl922–947) results in an E1A viral protein that is unable to bind and inactivate the retino-
blastoma tumour suppressor/cell cycle regulator protein preventing efficient viral replica-
tion in cells with an intact G1/S phase checkpoint.
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In addition, viral replication and/or expression of the tumoricidal payload can be placed 
under the control of a tumour-specific or tumour-associated promoter (TSP), thereby re-
stricting viral replication and toxicity to tumour cells. In one example, viral particles were 
generated in which a suicide gene was placed under the control of the promoter for Ep-
CAM. EpCAM is a cell-surface molecule and is frequently over expressed on a host of car-
cinomas, including ovarian cancer. These adenoviral particles demonstrated a significantly 
reduced expression of the suicide gene in the liver and possessed enhanced tumoricidal 
activity [7].
Chapter 3 highlights a considerable promise of scFv425:sTRAIL for immunotherapy of can-
cer. However, the efficacy of the soluble TRAIL domain may be further optimized by using 
rationally designed sTRAIL variants. TRAIL has an intricate receptor system, comprising 5 
different receptors, of which only TRAILR1 and TRAILR2 can transmit the apoptotic signal. 
The other three receptors, TRAILR3, TRAILR4 and osteoprotegerin (OPG), are so-called 
decoy receptors that are unable to convey apoptotic signalling. Interestingly, the expres-
sion of the various TRAIL receptors per se does not have a reliable predictive value with 
regard to sensitivity to TRAIL-induced cell death. 
To enhance the selectivity of sTRAIL for one or both agonistic TRAIL-receptors and to 
reduce binding affinity for the antagonistic receptors, various research laboratories have 
generated variants of sTRAIL with one or more amino acid substitutions. In chapter 4, we 
evaluated the therapeutic potential of EGFR-targeted delivery of one of the reported vari-
ants of sTRAIL, sTRAILmR1-5, that was shown to have increased affinity for TRAILR1 and 
reduced affinity for TRAIL decoy receptors [8]. Indeed, scFv425:sTRAILmR1-5 had superior 
anti-cancer activity compared to the wild type scFv425:sTRAIL in ~50% of cell lines tested. 
Interestingly, although this TRAIL mutant was reported to only signal via TRAILR1, our data 
clearly indicate that upon EGFR-targeted delivery TRAILmR1-5 also efficiently triggers 
TRAILR2 apoptotic signalling. We conclude that fusion protein, anti-EGFR:TRAILmR1-5 
has superior anti-tumour activity and may be an excellent candidate for further (pre-) clini-
cal development. 
Similarly, several lines of evidence suggest that incorporating a TRAILR2-selective sTRAIL 
mutant into our scFv:sTRAIL fusion protein format may yield novel therapeutics with unique 
anti-tumour activity. First, TRAILR2 is often over expressed compared to TRAILR1 in tu-
mour cells. Second and as also described above, TRAILR2 signalling is only efficiently trig-
gered in the context of membrane-bound TRAIL whereas TRAILR1 signalling can also be 
efficiently triggered by sTRAIL. As such, a scFv:TRAILR2-selective mutant fusion protein 
would only gain full fledged TRAILR2-mediated apoptotic activity once bound to the target 
TRAILR2-positive cell, yet remain inactive towards TRAILR1 while “en route”. This un-







proof to be beneficial in terms of unwanted toxicity. Of note, studies on cynomolgus monkey 
hepatocytes indicate that a TRAILR2 selective mutant only induces hepatocyte toxicity 
after antibody-mediated crosslinking [9]. Therefore, selective delivery of a scFv:TRAILR2-
selective mutant to a tumour cell surface antigen not expressed on hepatocytes could 
further preclude unwanted toxicity towards untransformed cells.
Obviously, rational combinatorial delivery of TRAILR1 and TRAILR2 selective mutants to 
different tumour cell surface antigens may enhance tumour-selective induction of apoptosis 
even further. 
Bi-functional scFv:sTRAIL fusion proteins combining anti-metastatic and pro-apop-
totic activity
It is well-established that the efficacy of protein-based therapeutics may be hampered by 
the inherent limited diffusion rate of macromolecules over multiple cell layers. In the case of 
solid cancers, tumour penetration is further limited by high intra-tumoural pressure. There-
fore, the most straight-forward anti-cancer application of TRAIL-based immunotherapy as 
described in this thesis is after (or possibly during) cytoreductive intervention, such as sur-
gical debulking and/or chemo/radiotherapy. After cytoreductive intervention, a particularly 
important and as of yet unsolved problem is the potential presence of circulating cancer 
cells that, after period of minimal residual disease (MRD), ultimately trigger formation of 
local and/or distant metastasis. Prevention and/or inhibition of metastases formation by 
circulating or occult cancer cells is therefore paramount to achieving curative treatment. To 
evaluate the utility of our immunotherapeutic approach towards such circulating/metastatic 
cancer cells, we constructed and evaluated the melanoma-targeted TRAIL fusion protein 
anti-MCSP:TRAIL (chapter 5). Melanoma was chosen in this study as it is a prime example 
of metastatic disease. This is exemplified by the fact that surgical resection of localized 
primary melanomas often yields curative treatment, yet metastatic melanoma has a very 
dismal prognosis (survival rate of <9 months) and is essentially incurable. The melanoma 
chondroitin sulphate proteoglycan (MCSP) was chosen as a suitable target antigen, not 
only based on its high expression on metastatic melanoma cells, but also since MCSP is 
thought to contribute to the metastatic potential of melanoma cells. Therefore, fusion protein 
anti-MCSP:TRAIL was designed to inhibit MCSP-mediated pro-metastatic signalling, while 
simultaneously triggering TRAIL-mediated apoptotic cell death. Indeed, anti-MCSP:TRAIL 
demonstrated strong apoptotic activity towards a panel of melanoma cell lines in vitro. Im-
portantly, treatment with anti-MCSP:TRAIL strongly inhibited growth of human melanoma 
xenografts in mice. Intriguingly, in vitro analysis indicated that anti-MCSP:TRAIL was over 
100-fold more effective in eliminating melanoma cells in metastatic settings (3D colony 
forming cultures) than in adherent 2D cultures. This potent activity against colony forming 
cells was found to be the result of combined inhibition of tumorigenic MCSP-signalling and 
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induction of apoptosis by TRAIL. Therefore, anti-MCSP:TRAIL holds considerable promise 
for the treatment of MRD and elimination of metastatic melanoma cells.
Of note, tumorigenic signalling has also recently been reported for the target antigen Ep-
CAM [10]. Upon cell-cell contact between neighbouring cells, the intracellular region of Ep-
CAM (EpCAM IntraCellular Domain; EPICD), was found to be cleaved from the membrane 
upon which it translocated to a transcription factor complex in the nucleus. In the nucleus, 
EPICD activated the proto-oncogene c-Myc resulting in pro-mitogenic signalling. In light of 
this, we speculated that the potent anti-tumour activity we have previously found for the 
EpCAM-specific fusion protein scFvC54:sTRAIL may have been partly related to inhibition 
of EpCAM processing and concomitant inhibition of mitogenic cell signalling pathways. 
Therefore, we recently examined whether treatment of HEK293 cells stably expressing 
EpCAM-YFP (where the YFP tag is located on the EPICD domain) with scFvC54:sTRAIL 
could abrogate EpCAM cleavage and translocation of EPICD. Interestingly, treatment of 
these cells with scFvC54:sTRAIL blocked EpCAM cleavage induced by homotypic interac-
tion with soluble EpCAM and prevented intracellular translocation of EPICD (Fig. 1). Cur-
rently, further studies into these anti-tumour effects of scFvC54:sTRAIL in the context of 
MRD are ongoing.
Enhancing the anti-tumour activity of immune effector cells by targeted delivery of 
TRAIL
TRAIL is an integral part of the immune system and in this capacity serves to prevent and 
control the development and progression of malignant cells. Most notably, transmembrane 
TRAIL appears to be the main immune effector mechanism by which resident natural killer 
(NK) cells prevent circulating tumour cells to invade the liver [11]. Thus, a clear rationale 
exists for ensuring that immune effector cells have high levels of tumoricidal TRAIL on 
their surface. In chapter 6, TRAIL was selectively delivered to the cell surface of T-cells 
and antitumor activity of such TRAIL-“armed” T-cells was evaluated. T-cells were chosen 
for several reasons. First of all, there is a window of opportunity for displaying TRAIL on 
T-cells, since these cells normally do not or only minimally express TRAIL on the cell sur-
face. Second, large infiltrates of T-cells can be detected in many tumours and the presence 
of such tumour infiltrated T-cells (TILs) is often associated with a better prognosis for the 
patient [12]. Apparently, TILs are able to (temporarily) control tumour growth. Finally, T-cells 
already exert a strong intrinsic anti-tumour activity that relies on immune effector molecules 
other then TRAIL.
As described in chapter 6, TRAIL was selectively delivered to the cell surface of T-cells us-
ing an anti-CD3 antibody fragment (anti-CD3) or the CD7 ligand K12. The resultant fusion 
proteins, anti-CD3:TRAIL and K12:TRAIL, proved to significantly enhance the anti-cancer 







activity of T-cells by activation of pro-apoptotic TRAIL-receptor signalling in tumour cells. 
Surprisingly, the potentiating activity of anti-CD3:TRAIL was found to be predominantly 
due to activation of intrinsic T-cell mediated cytotoxicity (e.g. granzyme/perforin signalling). 
CD3 is a major signalling component of the T-cell receptor (TCR) complex and, as such, 
can induce T-cell activation after binding of antibodies or antibody fragments. Intriguingly, 
our data indicate that binding of the anti-CD3 domain of anti-CD3:TRAIL induces T-cell 
activation only after crosslinking via TRAILR2 on the tumour cell surface. Thus, depend-
ing on the target antigen of choice, a TRAIL fusion protein can have a strikingly different 
activity profile.
The anti-tumour activity of anti-CD3:TRAIL is reminiscent of so-called T-cell redirecting 
bi-specific antibodies. These antibodies bind to an antigen on the T-cell (for instance CD3) 
and an antigen on the tumour cell (for instance EpCAM). As a result of CD3 signalling, 
T-cells become activated. Subsequently, binding of the bi-specific antibody to EpCAM in-
duces proximity-induced release of granzymes/perforins and subsequent elimination of 
EpCAM-positive tumour cells (Figure 2). Of note, combination of a bi-specific anti-CD3x-
anti-EpCAM antibody with K12:TRAIL synergistically enhanced the anti-tumour activity of 
T-cells (unpublished data).
The concept of bi-specific antibodies has also been extended to so-called tri-bodies. Here, 
three distinct single-chain antibody fragments (scFvs) are genetically linked to enhance the 
avidity of the T-cell to the tumour cells. For instance, a tri-body directed against CD3, Ep-
CAM and EGFR simultaneously binds T-cells via CD3 and tumour cells via EpCAM and/or 
EGFR. Therefore, such a tri-specific antibody can redirect T-cells to tumour cells express-
ing both EpCAM and EGFR, but also to tumour cells expressing either EpCAM or EGFR 
medium +sEpCAM +sEpCAM+scFvC54:sTRAIL
Figure 1. ScFvC54:sTRAIL inhibits sEpCAM-mediated cleavage of EpCAM and intrecellular 
translocation of EpICD. HEK293.EpCAM-YFP cells were treated with sEpCAM to induce EpICD 
cleavage in the presence or abscence of scFvC54:sTRAIL. Cells were subsequently counter-stained 
for membrane-localized EpCAM using anti-EpCAM antibody Moc31-PE and EpICD-YFP translocation 
was visualized using confocal microscopy.
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alone. However, T-cells will preferentially bind tumour cells expressing both antigens simul-
taneously. As a result, off-target toxicity to untransformed cells expressing only EGFR or 
EpCAM is reduced. Based on the synergy between K12:TRAIL and bi-specific antibodies, 
TRAIL might be incorporated into such a tri-body approach. The resultant fusion protein, 
for instance anti-EpCAM:anti-CD3:TRAIL would redirect T-cells to the tumour cells while 
simultaneously “arming” T-cells with TRAIL (see Fig. 2).
However, the tumour micro-environment often contains immune-inhibitory molecules that 
appear to induce an anergic state in T-cells, preventing them from eliminating the can-
cer cells (reviewed in [13]). Indeed, both tumour-derived and tumour-induced molecules 
have been reported to induce anergy in TILs, which may serve to hamper the efficacy 
of K12:TRAIL/anti-CD3:TRAIL such as reported in chapter 6. Therefore, incorporation of 
antibody-based approaches that block these inhibitory factors into our strategy is war-
ranted. Of particular interest in this respect is the use of a blocking anti-CTLA-4 antibody 
fragment. CTLA-4 is a T-cell inhibitory molecule triggered by members of the B-7 family, 
B7.1 and B7.2 (CD80 and CD86, respectively). Anti-CTLA-4 antibodies prevent binding of 
B7.1 and B7.2 to CTLA-4 and enhance T-cell mediated immune responses [14]. One such 
anti-CTLA-4 antibody, Ipilimumab was recently approved by the FDA for the treatment of 
advanced melanoma. In clinical trials, ipilimumab restored anti-melanoma T-cell activity, re-






Figure 2. Mode of action for a 
bi-specific:TRAIL fusion pro-
tein. A bi-specific anti-CD3:anti-
EpCAM antibody functions by 
binding to T-cell marker CD3 
and tumour cell marker Ep-
CAM, thereby redirecting T-
cells to EpCAM+ tumour cells. 
Fusion protein anti-CD3:anti-
EpCAM:TRAIL would selective-
ly redirect T-cells to EpCAM+ 
tumour cells by binding to T-cell 
marker CD3 and tumour cell 
marker EpCAM. Tumoricidal ac-
tivity of T-cells should be further 
augmented by virtue of TRAIL-
TRAILR receptor mediated sig-







subgroup of patients developed stable disease [14]. The use of an anti-CTLA-4 antibody 
fragment in the TRAIL fusion protein concept would exploit the dual-signalling concept by 
simultaneously inhibiting inhibitory T-cell signalling and enhancing the anti-tumour activity 
of T-cells. In this manner, a T-cell inhibitory signal would in essence be converted into a 
pro-apoptotic anti-tumour “weapon”.
In addition to blocking inhibitory signals, antibody fragment that activate co-stimulatory sig-
nals on T-cells can also be incorporated into the TRAIL-based therapeutic strategy. Likely 
targets to this effect include 4-1BB, CD28 and inducible co-stimulator (ICOS). Indeed, an-
tibodies that target these molecules have been shown to augment anti-tumour activity of 
T-cells in several preclinical studies [15-17]. 
An alternative way of enhancing this immunotherapeutic strategy is the use of the above 
highlighted TRAILR-selective TRAIL variants. For instance, T-cell activation and anti-tu-
mour effects of anti-CD3:TRAIL depended on TRAILR2 binding/cross-linking. Therefore, it 
is tempting to speculate that the anti-tumour activity of the anti-CD3:TRAIL will be enhanced 
by genetically fusing a TRAILR2-selective mutant to anti-CD3 (anti-CD3:TRAILmR2). This 
fusion protein could induce maximal activation and tumoricidal potential of T-cells via cross-
linking of CD3.
Several immunotherapeutic protocols have been developed that aim to redirect T-cells to 
engage and eliminate tumour cells. Mostly, these protocols rely on the viral transduction 
of T-cells with engineered T-cell receptors (eTCRs) (reviewed in [18]). These eTCRs en-
able T-cells to specifically recognize and activate upon encounter with tumour-associated 
cell surface molecules such as EpCAM. However, tumoricidal activity of such redirected 
T-cells may still be hindered by cancer cell resistant to T-cell effector mechanisms and/
or tumour microenvironment-induced anergy of T-cells. Here, incorporation of TRAIL into 
viral transduction strategies might provide additional therapeutic benefits. This could be 
achieved by the transduction of T-cells with transmembrane TRAIL, or by transducing T-
cells to produce a TRAIL fusion protein. The latter strategy is reminiscent of that presented 
in chapter 3 on the use of Ad-scFv425:sTRAIL. While adenoviruses cannot normally infect 
T-cells, bi-specific antibodies or viral fiber/knob modifications thereof might be used to 
redirect adenoviral particles towards T-cells [19]. Alternatively, viral vectors with an innate 
T-cell tropism such as lentiviruses could be exploited. In this respect, lentiviral particles 
have already been extensively used to deliver modified eTCR into T-cells (reviewed in 
[20]). A recent paper reported on the induction of immune response and ongoing remission 
10 months after adoptive transfer of lentivirally transduced designer T-cells containing a 
chimeric eTCR [21]. Inclusion of lentiviral TRAIL fusion protein vectors might therefore be 
suitable for integration into these strategies. 
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The delivery of TRAIL to the cell surface of T-cells (chapter 6) can be readily incorporated 
into existing cancer immunotherapies and may therefore move rapidly into clinical evalua-
tion. Pre-clinical side-by-side comparison of the above-described strategies will help iden-
tify the optimal form of targeted TRAIL for future clinical evaluation.
TRAIL in tumour immunogenicity
TNF-family members such as TRAIL are integral parts of the immune system and trigger 
cell death in target cells. Upon induction of apoptotic cell death, cancer cells are rapidly 
removed by phagocytosis. Typically, phagocytosis occurs in a non-immunogenic fashion, 
leading to the quiet removal of superfluous cells. However, recent studies highlight that 
anti-cancer therapies can also trigger immunogenic phagocytosis, which to a large degree 
depends on the pro-phagocytic receptor calreticulin (CRT).
CRT is an ER-resident protein involved in Ca2+ signalling and protein folding. However, 
treatment with certain apoptotic stimuli, including TRAIL, triggers translocation of CRT to 
the tumour cell surface. Here, CRT serves as an ‘eat me’ signal for phagocytes. Although 
normally non-immunogenic, the phagocytosis of pre-apoptotic cells with cell surface ex-
posed CRT may lead to the induction of an anti-tumour immune response. Furthermore, 
CRT needs to dissociate from its binding partner CD47 on apoptotic cells in order for them 
to be effectively phagocytosed. 
Based on these studies, and the recent finding that CRT can directly interact with TRAIL 
in an ELISA-type assay, we evaluated whether CRT may be involved in TRAIL/TRAIL-
receptor mediated apoptotic cell removal. The data in chapter 7 indicate that treatment 
of tumour cells with TRAIL induced the rapid pre-apoptotic association of CRT with TRAIL 
and TRAILR2. This association occurred during TRAIL-mediated DISC formation and acti-
vation of caspase-8, but preceded activation of caspase-3. Furthermore, CRT associated 
with the TRAILR DISC only in the presence of sTRAIL, but not when cells were treated 
with an agonistic TRAILR antibody. Therefore, association of CRT with the TRAILR DISC 
is likely mediated via sTRAIL. Concurrently to the association of CRT with TRAILR, CRT 
dissociated from CD47. Of note, dissociation of CD47 from CRT has been reported for cells 
undergoing apoptosis after exposure to UV-C radiation, and resulted in an enhanced clear-
ance of apoptotic cells by phagocytes. Together, this indicates that TRAIL-induced apop-
tosis in tumour cells may promote tumour immunogenicity. However, TRAIL is generally 
considered to be a non-immunogenic inducer of apoptosis. Therefore, the pre-apoptotic 
association of CRT with TRAIL might also serve to prevent an immune response. Although 
further studies are needed to clarify this important point, it is tempting to speculate that 
modulating the interaction between TRAIL and CRT might be used to enhance the induc-







it is worth mentioning a recently reported cell penetrating peptide that induces a marked 
translocation of CRT to the cell surface [22]. In addition, recombinant CRT can be used to 
adsorb to apoptotic cells and increase cell surface levels of CRT [23]. 
In conclusion, we demonstrate here that the targeted delivery of TRAIL to either the tu-
mour or T-cell surface can potently inhibit the growth of metastatic or disseminated cancer. 
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Per jaar overlijden er wereldwijd ongeveer acht miljoen mensen aan de gevolgen van 
kanker. Ondanks verbeterde behandelingsmethodes wordt er verwacht dat dit aantal de 
komende jaren helaas nog verder zal toenemen. Er wordt daarom intensief gezocht naar 
nieuwe methodes om kanker te voorkomen en beter te behandelen. 
In grote lijnen valt kanker onder te verdelen in solide kanker (tumoren) en bloedkanker 
(leukemie/lymfomen). Bij solide kanker wordt als behandeling vaak gekozen voor een radi-
cale chirurgische verwijdering van de tumor eventueel in combinatie met chemo en/of ra-
diotherapie. In veel gevallen slaat deze behandeling in eerste instantie goed aan. Helaas 
komt de ziekte vroeg of laat toch weer terug. Een in het oogspringend voorbeeld hiervan is 
eierstokkanker (ovarium carcinoom, hierna afgekort met OC). Patiënten met OC reageren 
in eerste instantie goed op een dergelijke behandeling en de ziekte lijkt te zijn overwonnen. 
Echter, na deze periode van zogeheten “minimal residual disease” komt de kanker vaak 
weer terug. Helaas is dat stadium de kanker vaak uitgezaaid en  resistent geworden voor 
verdere therapie. Er wordt gedacht dit het gevolg is van therapieresistente kankercellen die 
de eerste ronde van therapie om de een of andere reden hebben overleefd. Deze kanker-
cellen groeien vervolgens weer uit. Het is dan ook noodzakelijk om nieuwe complemen-
taire therapieën te ontwikkelen om ook deze therapieresistente kankercellen te kunnen 
elimineren. Een therapeutische aanpak die in dit opzicht veelbelovend lijkt is het gebruik 
van cellen of moleculen van het immuunsysteem.
Het immuunsysteem
Het immuunsysteem is het verdedigingsmechanisme van het lichaam tegen aanvallen 
(pathogenen) van buiten af, maar ook van binnen uit. Het immuunsysteem beschermt bi-
jvoorbeeld tegen virussen of bacteriën die het lichaam willen binnendringen. De verdedig-
ing door het immuunsysteem valt in principe te splitsen in het aangeboren en het verwor-
ven immuunsysteem.
Onder het aangeboren immuunsysteem vallen natuurlijke barrières zoals huid en slijmla-
gen, maar ook cellen zoals macrofagen en dendritische cellen (DCs). Het aangeboren im-
muunsysteem herkent algemene kenmerken van pathogene micro-organismen en vormt 
een eerste verdedigingslinie. Een binnengedrongen pathogene organisme wordt herkend 
en opgegeten door macrofagen/DCs (phagocytose). De macrofaag/DC doodt het  patho-
gene micro-organisme, breekt het vervolgens af en zorgt voor de activatie van andere im-
muuncellen (o.a. cellen van het verworven immuunsysteem). 
Het verworven immuunsysteem bestaat voornamelijk uit T-cellen en B-cellen die ontstaan 
uit voorlopercellen in het beenmerg. T voorloper cellen migreren vervolgens naar de Thy-
mus en ontwikkelen zich hier vervolgens verder tot volwassen T-cellen. Het rijpen van 







voor het tot stand komen van een adequate immuunrespons die specifiek gericht is te-
gen het herkende pathogene micro-organisme, maar doen dit op verschillende manier (zie 
voorbeeld hieronder). Zoals de naam al impliceert komt het verworven immuunsysteem 
tot stand door contact met allerlei antigenen. In vrijwel alle gevallen wordt het verworven 
immuunsysteem in eerste instantie geactiveerd door cellen van het aangeboren immuun-
systeem. 
Bijvoorbeeld: een cel die door een virus geïnfecteerd is breekt een deel van de virale eiwit-
ten af en presenteert vervolgens kleine eiwitfragmenten hiervan aan DCs. DCs phagocy-
teren deze eiwitfragmenten en presenteren deze weer aan T-cellen en B-cellen. T-cellen 
herkennen vervolgens de geïnfecteerde cellen, omdat deze dezelfde eiwitfragmenten pre-
senteren. Een deel van de T-cellen wordt nu zogeheten cytotoxische T-cellen. Na speci-
fieke herkenning vernietigen cytotoxische T-cellen de geïnfecteerde cellen door direct cel-
lulair contact. Een ander deel van de T-cellen (helper T-cellen) helpt (activeert) B-cellen 
om hun functie uit te voeren. Geactiveerde B-cellen ruimen niet direct de geïnfecteerde 
cellen op, maar produceren specifieke antilichamen die het betreffende antigen herkenen. 
Na binding aan een antigen fungeert een antilichaam als een herkenningsvlag voor andere 
cellen van het immuunsysteem (zie ook Figuur 1).
Het immuunsysteem en kanker
In het begin van de twintigste eeuw kwam Paul Erlich met de hypothese dat het immuunsys-
teem wellicht ook een belangrijke rol speelt bij het onderdrukken van kanker. Dit idee werd 
opnieuw opgepakt in de jaren 50 door Burnet en Thomas. Deze heren formuleerden toen 
de zogenaamde “immuun surveillance” theorie voor kanker. Volgens deze theorie ontstaan 
er voortdurend nieuwe kankercellen in het lichaam die worden herkend en opgeruimd door 
cellen van het immuunsysteem. Hierdoor zou het ontstaan van kanker in de meeste geval-
len vroegtijdig onderdrukt worden. Sindsdien zijn er een groot aantal wetenschappelijke 
publicaties geweest die deze theorie bevestigen en “immuun surveillance” aanmerken als 
een belangrijk beschermingsmechanisme tegen het ontstaan van tumoren.
Bij “immuun surveillance” wordt er gedacht dat het immuunsysteem reageert op antigenen 
die selectiever tot expressie komen op tumorcellen dan op normale cellen. Deze anti-
genen worden daarom ook wel tumor geassocieerde antigenen (TAAs) Genoemd. Zoals 
hierboven vermeld kunnen antigenen herkend worden door de bijbehorende antilichamen. 
Antilichamen die binden aan TAAs zullen dus preferentieel binden aan kankercellen. Deze 
eigenschap van TAA antilichamen is dan ook gebruikt om dergelijke antilichamen verder 
te ontwikkelen in kankertherapieën. Een voorbeeld hiervan is het gebruik van TAA antili-
chamen om selectief toxische lading (bijvoorbeeld bacteriële toxinen) af te leveren aan 
kankercellen. Dit kan door antilichamen of antilichaamfragmenten chemisch of genetisch 
te koppellen aan een toxische lading (Figuur 2). Echter, degelijke toxinen zijn meestal ook 
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giftig voor gezonde cellen. Omdat TAAs ook kunnen voorkomen op een gedeelte van de 
gezonde cellen zullen deze ook getroffen worden door het toxine. Een ideale lading voor 
antilichamen zou dan ook 1. alleen toxisch moeten zijn voor tumorcellen en 2. pas actief 
worden als het bindt aan tumorcellen. Een molecuul dat hier uitermate geschikt voor lijkt te 
zijn is “Tumor Necrosis Factor (TNF) Related Apoptosis Inducing Ligand” (TRAIL).
TRAIL is een zogeheten type II transmembraan eiwit dat voorkomt op het celoppervlak van 
bepaalde immuuncellen. TRAIL wordt door deze immuuncellen gebruikt om kankercellen 
te doden via een proces dat geprogrammeerde celdood (apoptose) heet. Apoptose wordt 
door het lichaam gebruikt om overvloedige of mogelijk gevaarlijk geworden snel en veilig 
op te ruimen. Een belangrijke eigenschap van TRAIL voor kankertherapie is dat TRAIL 
alleen apoptose lijkt te induceren in cellen die kwaadaardig zijn en normale cellen volledig 


































Figuur 1. Een voorbeeld van een immuunreactie. Een lichaamscel die geïnfecteerd is door bijvoor-
beeld een virus breekt een deel van de virale eiwitten af en presenteert deze als eiwitfragmenten 
op het oppervlak van de cel. Een dendritische cel (DC) herkent deze fragmenten en phagocyteert 
een celfragment of de gehele cel. De DC verwerkt deze eiwitfragmenten verder en presenteert deze 
aan T-cellen. T-cellen worden hierdoor geactiveerd en kunnen hierna specifiek de eiwitfragmenten 
herkennen op het oppervlak van geïnfecteerde cellen. Cytotoxische T-cellen kunnen hierna direct 
geïnfecteerde cellen doden, terwijl helper T-cellen de B-cellen activeren. B-cellen produceren vervol-
gens antilichamen die specifiek de eiwitfragmenten (antigenen) herkennen. Deze herkenning maakt 
de geïnfecteerde cellen als het ware zichtbaar voor de rest van het immuunsysteem. Dit resulteert 








Apoptose kan worden geïnduceerd door de zogeheten intrinsieke en extrinsieke routes 
(Figuur 3). De intrinsieke route wordt geactiveerd van binnen uit de cel, terwijl de extrin-
sieke route wordt geactiveerd door receptoren op de buitenkant van de cel. Dit laatste 
is het geval bij TRAIL. TRAIL induceert apoptose door te binden aan TRAIL-receptoren 
(TRAILRs) op het oppervlak van de cel. Er zijn vijf verschillende TRAILRs te ondersche-
iden en deze dragen verschillend bij aan de inductie van apoptose. TRAILR1 en TRAILR2 
induceren apoptose in cellen, terwijl er van TRAILR3 en TRAILR4 gedacht wordt dat deze 
fungeren als een soort van afleidingsreceptor. TRAIL kan wel aan TRAILR3 en TRAILR4 
binden, maar dit resulteert niet in apoptose (Figuur 4). Een andere variante TRAIL recep-
tor, OPG, komt niet op cellen voor, maar is oplosbaar. Ook TRAIL kan  in oplosbare vorm 
voorkomen (sTRAIL) in het lichaam. Dit sTRAIL is nagemaakt in laboratoria en heeft ook 
een antikanker werking. Echter, van sTRAIL is bekend dat dit veel minder goed in staat 
is om TRAILR2 te activeren. Hiermee lijkt sTRAIL dus ook grotendeels te voldoen aan de 
criteria voor een ideale lading voor aflevering aan kankercellen via antilichaamfragmenten. 
Namelijk: sTRAIL is niet toxisch voor gezonde cellen en induceert voornamelijk apoptose 
als het aan het oppervlak van kankercellen gebonden is.
anti-TAA antilichaam
Deel van het antilichaam













Figuur 2. Het maken van antikanker therapeutica gebaseerd op antilichamen. Een antilichaam 
herkent specifiek een bepaald tumor geassocieerd antigen (TAA). Deze herkenning vindt plaats via 
de zogeheten complementair herkennende regionen (CDRs; zie omlijning). Therapeutica kunnen dan 
ook gemaakt worden door het hele antilichaam te gebruiken (onderste lijn) , alleen de CDRs (boven-
ste lijn), of variaties hiervan. Antilichamen of antilichaamfragmenten kunnen chemisch of genetisch 
gekoppeld worden aan een toxine. Hierdoor ontstaat een anti-TAA:toxine fusie-eiwit dat specifiek een 
TAA op een kankercel kan herkennen. Hierdoor kunnen toxinen aan het oppervlak van kankercellen 
worden afgeleverd. Na aflevering worden de toxinen meestal opgenomen in de cel. Dit resulteert uit-
eindelijk dan in de dood van de kankercel.
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Dit in ogenschouw nemend hebben wij voorheen dan ook fusie eiwitten gemaakt waarin 
sTRAIL genetisch gekoppeld is aan antilichaamfragmenten die binden aan TAAs op het 
oppervlak van kankercellen (Figuur 5). In de volgende paragrafen wordt het onderzoek 
beschreven naar het gebruik van dergelijke fusie eiwitten bij het selectief en veilig doden 
van kankercellen.
Het selectief afleveren van TRAIL aan het oppervlak van kankercellen



















Extrinsieke route Intrinsieke route
Figuur 3. Inductie van apoptose. Geprogrammeerde celdood ofwel apoptose vindt plaats door een 
gecontroleerde afbraak van de cel van binnen uit. Deze afbraak is afhankelijk van zogeheten cellulaire 
proteasen genaamd caspases. Deze caspases knippen als het ware een cel van binnenuit op een 
gecontroleerde manier kapot. Dit resulteert uiteindelijk in de dood van de cel. Apoptose kan worden 
aangezet (geïnduceerd) via de zogeheten extrinsieke en intrinsieke routes. Bij de extrinsieke route 
bindt een eiwit zoals sTRAIL aan TRAIL receptoren (TRAILR) die zich op het oppervlak van de cel 
bevinden. Hierna ontstaat een ketting reactie die zorgt voor het activeren van de caspases en uitein-
delijk apoptotische celdood. Bij de intrinsieke route kunnen chemotherapeutica, toxinen, of andere 
cellulaire stressoren zorgen voor beschadiging van de mitochondriën. De mitochondriën zijn als het 
ware de energiefabrieken van de cel en als deze beschadigd raken wordt er een proces in gang gezet 
om de cel op een gecontroleerde manier via caspases een apoptotische celdood te laten ondergaan. 
sTRAIL=soluble TRAIL, TRAILR=TRAIL receptor, FADD=Fas associated death domain, Bid=BH3 in-
teraction death domain agonist, tBid= truncated Bid, Bcl-2= B-cell lymphoma 2, Bcl-XL= B-cell lym-







nu toe. Hierbij ligt de nadruk op het toepassing van het zogenaamde “dual signaling” con-
cept. Hierbij wordt er in een sTRAIL fusie-eiwit gebruik gemaakt van een antilichaamfrag-
ment dat van zichzelf ook een antikankerwerking heeft. Een belangrijk voorbeeld hiervan 
is het fusie eiwit scFv425:sTRAIL. In dit fusie-eiwit is het antilichaam fragment scFv425 
gekoppeld aan sTRAIL. ScFv425 bindt aan de Epidermale Groei Factor Receptor (EGFR) 
welke tot over-expressie komt op het oppervlak van tumorcellen van vele soorten solide 
tumoren. EGFR is de receptor voor de Epidermale Groei Factor (EGF), waarbij binding 
van EGF aan EGFR zorgt voor versnelde tumorgroei. Doordat scFv425 deze binding ver-
hindert, groeien de tumorcellen minder snel en worden ze tevens gevoeliger voor sTRAIL. 
Voorheen hebben wij laten zien dat scFv425:sTRAIL in staat is om in vitro (in cellen in het 
laboratorium) selectief EGFR-positieve kankercellen van verschillende oorsprong te doden. 
In hoofdstuk 3 hebben wij deze veelbelovende resultaten verder uitgebouwd door de anti-
tumoractiviteit van scFv425:sTRAIL te bepalen in vivo (in proefdieren). In deze proefdieren 
hebben wij gekozen voor een zogeheten intraperitoneaal (buikholte) tumormodel. Dit tu-
mormodel bootst de situatie na van patiënten met uitgezaaide kanker in de buikholte (zoals 
bij bijvoorbeeld OC en darmkanker). Om een adequate concentratie van scFv425:sTRAIL 
in de muis te garanderen hebben wij gebruik gemaakt van een recombinant adenovirus dat 
codeert voor dit fusie-eiwit (Ad-scFv425:sTRAIL). Na infectie van een proefdier infecteert 
Ad-scFv425:sTRAIL voornamelijk de lever van de muis, waarna de lever als het ware gaat 
fungeren als een fabriek voor de productie van scFv425:sTRAIL. Hierdoor wordt er een 
aanzienlijke en constante hoeveelheid  scFv425:sTRAIL door de muis zelf geproduceerd 
en komt scFv425:sTRAIL terecht in de bloedbaan. ScFv425:sTRAIL kan vervolgens bin-
den aan de tumorcellen in de buikholte van de muis en induceert selectief apoptose in deze 
kankercellen. Logischerwijs is de concentratie scFv425:sTRAIL in de bloedbaan afhankelijk 
van de hoeveelheid Ad-scFv425:sTRAIL (virus titer) die in eerste instantie wordt ingespo-







Figuur 4. TRAIL receptoren. TRAIL kan binden aan vier verschillende TRAIL receptoren. TRAILR1 
en TRAILR2 hebben een intracellulair domein waaraan FADD kan binden en apoptose kan worden 
geïnduceerd (zie ook Figuur 3). TRAILR3 en TRAILR4 hebben geen intracellulair domein waar FADD 
aan kan binden en kunnen dus ook geen apoptose induceren.
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titer) resulteerde dan ook in hoge niveaus van scFv425:sTRAIL in de bloedbaan, hetgeen 
leidde tot volledig elimineren van de aanwezige tumoren in de buikholte. Muizen die geïn-
jecteerd werden met een kleinere hoeveelheid Ad-scFv425:sTRAIL (lage titer) hadden in-
derdaad minder scFv425:sTRAIL in het bloed (<10 ng/ml), maar dit bleek wel voldoende 
om de groei van de tumoren volledig te remmen. Tezamen geven deze resultaten aan dat 
scFv425:sTRAIL veelbelovend is voor de behandeling van uitgezaaide kanker in de buik-
holte. Toepassing van deze benadering bij mensen ligt echter niet voor de hand vanwege 
allerlei praktische en principiële  bezwaren van gentherapie met adenovirussen.













Figuur 5. Het selectief afleveren van TRAIL aan het oppervlakte van kankercellen. Zoals ook in 
Figuur 2 is beschreven kan een toxische lading worden afgeleverd aan het oppervlak van kankercel-
len met behulp van een antilichaamfragment. Ditzelfde is mogelijk voor het selectief afleveren van 
TRAIL. In onze strategie is TRAIL genetisch gekoppeld aan een zogeheten scFv antilichaamfragment. 
Omdat TRAIL trimeer voorkomt (drie TRAIL moleculen vormen automatisch een trimeer molecuul) 
zullen er daarom ook drie scFv fragmenten binnen een TRAIL fusie-eiwit voorkomen. Een dergelijk 
scFv:sTRAIL fusie-eiwit kan vervolgens binden aan een doel antigen op het oppervlak van kanker-
cellen. Hiermee wordt het sTRAIL omgezet naar een membraan vorm van TRAIL en induceert het 
apoptose in de kankercellen. Dit kan plaatsvinden op een autocriene manier (binden en doden van 
dezelfde cel), maar ook paracrien (het over en weer doden van buurcellen). Een bijkomend voordeel 
van een dergelijk fusie-eiwit is dat het tevens apoptose induceert in “buur” kankercellen die dit antigen 







nog verder konden versterken door de binding van TRAIL aan de verschillende TRAIL re-
ceptoren te moduleren. Zoals vermeld zijn er vijf verschillende TRAIL receptoren, waarvan 
er vier op het oppervlak van cellen voorkomen en één een oplosbare receptor is. Van de 
vier celgebonden TRAIL receptoren induceren alleen receptor 1 (TRAILR1) en receptor 
2 (TRAILR2) apoptose. TRAILR3 en TRAILR4 binden wel aan TRAIL, maar induceren 
geen apoptose. Dit in ogenschouw nemende hebben verschillende onderzoeksgroepen 
varianten van sTRAIL gemaakt die meer binden aan TRAILR1 of TRAILR2 en minder aan 
TRAILR3 en TRAILR4. Van één van deze varianten (sTRAILmR1-5) is gepubliceerd dat 
deze voornamelijk bindt aan TRAILR1. Daarom was onze gedachtegang dat deze variant 
wellicht meer apoptose kan induceren in cellen die meer TRAILR1 tot expressie brengen 
vergeleken met TRAILR2. Om dit te onderzoeken hebben wij in hoofdstuk 4 een nieuw 













Figuur 6. Het bewap-
enen van T-cellen 
met behulp van 
TRAIL. Zoals ook in 
Figuur 5 is beschreven 
kan TRAIL selectief 
worden afgeleverd aan 
het oppervlak van cel-
len met behulp van een 
antilichaamfragment. 
Ditzelfde is mogelijk 
voor het afleveren van 
TRAIL aan het opper-
vlak van T-cellen. Als 
variatie hierop hebben 
wij echter in hoofdstuk 
6 ook gebruik gemaakt 
van een receptor-ligand 
in plaats van een scFv 
antilichaamfragment. 
Het principe is hier-
bij hetzelfde, maar er 
wordt gebruik gemaakt 
van een natuurlijke 
bindingspartner van 
een receptor op het op-
pervlak van T-cellen. In 
dit geval het K12-CD7 
ligand-receptor paar. 
Op het moment dat 
deze fusie-eiwitten anti-CD3:TRAIL of K12:TRAIL binden aan het oppervlak van de T-cel wordt de 
T-cel als het ware “bewapend” met een extra kankerdodend eiwit (TRAIL). Dit TRAIL gebruikt de T-cel 
vervolgens om de kankercellen te doden.
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scFv425:sTRAIL aan EGFR en induceert vervolgens selectief apoptose in tumorcellen die 
EGFR tot expressie brengen. Interessant genoeg induceerde scFv425:sTRAILmR1-5 zeer 
efficiënt apoptose in tumorcellen, ongeacht de expressie niveaus van de verschillende 
TRAIL receptoren. Hiernaast was de apoptotische activiteit van scFv425:sTRAILmR1-5 
ook sterker dan scFv425:sTRAIL wanneer deze gecombineerd werden met chemothera-
peutische behandelingen. Tezamen geeft dit aan dat het gebruik van sTRAIL varianten in 
het fusie-eiwit concept kan leiden tot verhoogde antikanker activiteit.
Kankerpatienten waarbij de kanker in een vroeg stadium wordt vastgesteld hebben mees-
tal een goede kans op genezing. Hiertegenover staat dat patiënten met uitgezaaide kanker 
uiteindelijk meestal overlijden aan de gevolgen van deze metastases. Een belangrijke fac-
tor hierbij zijn therapieresistente kankercellen die de eerste behandelingen overleven en 
vervolgens weer uitgroeien tot tumoren/metastases. Het is voor een genezende behandel-
ing van kanker dan ook van groot belang om te voorkomen dat tumoren metastases gaan 
vormen. Onze hypothese was dat het “dual signaling” concept van bepaalde fusie-eiwitten 
gebruikt zou kunnen worden om selectief de vorming van metastases te remmen en tegeli-
jkertijd apoptose te induceren via TRAIL. Hiertoe zou gebruik gemaakt kunnen worden van 
een scFv fragment dat van zichzelf een antimetastaserende werking heeft. In hoofdstuk 
5 hebben wij deze hypothese getest in het kader van melanoom, een kanker die geken-
merkt wordt door de snelle en uitgebreide vorming van metastases. Hiertoe hebben wij een 
nieuw fusie-eiwit ontwikkeld genaamd anti-MCSP:TRAIL. Het antilichaamfragment in anti-
MCSP:TRAIL is afkomstig uit een antilichaam dat bindt aan melanoomcellen, hetgeen een 
antimetastaserende werking blijkt te hebben. MCSP staat voor Melanoom Chondroitin Sul-
fate Proteoglycan en komt verhoogd tot expressie op melanoomcellen. Overexpressie van 
MCSP lijkt de vorming van metastases door melanoomcellen te bevorderen. Behandeling 
met Anti-MCSP:TRAIL bleek in staat om apoptose te induceren in een serie verschillende 
melanoomcellen en kon de groei remmen van melanoomcellen zowel in vitro als in vivo. 
Een interessant observatie die wij maakten was dat behandeling met Anti-MCSP:TRAIL 
zelfs de groei remde van TRAIL-resistente melanoom cellen. Daarom speculeerden wij 
dat het groeiremmende effecten van anti-MCSP:TRAIL wellicht een gevolg was van de 
remming van MCSP. Na verder onderzoek bleek inderdaad dat anti-MCSP:TRAIL een aan-
tal signaleringsroutes remde die belangrijk zijn voor metastasering van melanoomcellen. 
Hieruit concluderen wij dat anti-MCSP:TRAIL veelbelovende antimelanoom activiteit heeft 
die berust op de gelijktijdige remming van signalering die metastases bevordert en de 
inductie van apoptose. 
Het selectief afleveren van TRAIL aan het oppervlak van immuuncellen
Hierboven is beschreven hoe het selectief afleveren van TRAIL aan het oppervlak van 







wij vastgesteld dat het scFv:TRAIL concept: 1. in vivo antikanker activiteit voor tumoren 
in de buikholte, 2. versterkt kan worden door gebruik te maken van bepaalde TRAIL vari-
anten, 3. de groei van melanomen kan remmen en 4. geen of nauwelijks toxische effecten 
heeft ten opzichte van gezonde normale cellen. 
Vervolgens hebben wij dit concept van het selectief afleveren van TRAIL aangepast door 
TRAIL niet aan kankercellen, maar juist aan immuuncellen af te leveren. Het idee hier-
achter is dat hierdoor de antikankerwerking van deze immuuncellen versterkt zal worden. 
Zoals beschreven staat in hoofdstuk 2 van dit proefschrift komt TRAIL van nature voor op 
het celoppervlak van zogenaamde NK-cellen,  NK-cellen zijn onderdeel van het aange-
boren immuunsysteem en vervullen een rol die sterk  complementair is aan de rol van 
T-cellen. Namelijk, kwaadaardige cellen die MHC-klasse moleculen verlaagd, of geheel 
niet meer tot expressie te brengen, kunnen ontsnappen aan vernietiging door T-cellen. NK-
cellen herkennen en vernietigen echter cellen die geen of te weinig MHC-I tot expressie 
brengen. TRAIL speelt hierbij belangrijk rol. Het TRAIL op NK-cellen is dus ook belangrijk 
voor het vernietigen van b.v. metastaserende kankercellen. T-cellen brengen normaal veel 
minder TRAIL tot expressie op het oppervlak dan NK-cellen. Echter, onder bepaalde om-
standigheden kunnen T-cellen wel gestimuleerd worden om meer TRAIL op het oppervlak 
tot expressie te brengen en dit versterkt de antikankerwerking vervolgens enorm. Tezamen 
geeft dit aan dat het kunstmatig verhogen van de hoeveelheid TRAIL op het oppervlak van 
T-cellen de antikankerwerking van deze T-cellen aanzienlijk zou kunnen versterken. Dit zou 
kunnen worden bereikt door TRAIL selectief af te leveren aan het oppervlak van immuun-
cellen met behulp van scFv antilichaamfragmenten. Deze hypothese hebben wij in hoofd-
stuk 6 getest door TRAIL selectief af te leveren aan de T-cel oppervlaktemoleculen CD3 
en CD7, met behulp van respectievelijk de fusie-eiwitten anti-CD3:TRAIL en K12:TRAIL 
(Figuur 6). Beide fusie-eiwitten waren in staat om de antikankeractiviteit van T-cellen aan-
zienlijk (> 500-voudig) te versterken t.o.v. een grote verscheidenheid aan kankercellijnen. 
Daarnaast werd ook de antikankeractiviteit van T-cellen versterkt t.o.v. kankercellen die 
uit patiëntentumoren geïsoleerd waren. Hierop volgend hebben wij de activiteit van deze 
fusie-eiwitten getest in muizen met een tumor in de buikholte. Hieruit bleek dat beide fusie 
eiwitten in staat waren om de groei van dergelijke tumoren aanzienlijk te remmen. Teza-
men geeft dit aan dat selectieve aflevering van TRAIL aan het oppervlak van T-cellen de 
antikanker activiteit van deze cellen aanzienlijk kan versterken. Een dergelijke strategie 
zou relatief simpel toegepast kunnen worden in reeds bestaande immuuntherapieën voor 
kanker.
TRAIL en tumor immuniteit
Zoals hierboven beschreven kan TRAIL gebruikt worden om de antikankeractiviteit van im-
muuncellen te versterken. Ook zijn er aanwijzingen dat TRAIL nog andere immuunstimul-
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erende effecten zou kunnen hebben. Onlangs is gepubliceerd dat, voorafgaand aan apop-
tose in kankercellen, het intracellulaire eiwit calreticuline (CRT) zich naar het oppervlak 
van de cel verplaatst. Dit gebeurt ten gevolge van behandeling met bepaalde apoptose 
inducerende therapeutica, waaronder TRAIL. Eenmaal op het celoppervlak dient CRT als 
een herkenningsmolecuul voor DCs en bevordert de opname van apoptotische kankercel-
len. Opname door DCs is een belangrijke vereiste voor het ontstaan van een immuunre-
actie die specifiek is gericht tegen deze kanker. Opname van apoptotische kankercellen 
door andere immuuncellen, zoals macrofagen, leidt juist niet tot een immuunreactie en kan 
leiden tot de inductie van tolerantie. CRT is dus een belangrijke schakel om te bepalen of 
apoptotische cellen wel of geen immuunreactie induceren. Tevens kwam er onlangs ook 
bewijs naar voren dat TRAIL direct kon binden aan CRT. Daarom hebben wij in hoofdstuk 
7 gekeken naar de mogelijke rol van CRT bij de apoptose zoals die geïnduceerd wordt na 
behandeling met TRAIL. Wij ontdekten dat behandeling van kankercellen met TRAIL resul-
teerde in een snelle pre-apoptotische associatie van CRT met TRAIL en TRAILR2. Tegeli-
jkertijd liet CRT lost van zijn normale bindingspartner CD47. Van CD47 wordt gedacht dat 
het verhindert dat CRT bindt aan phagocyten. Wanneer op de celmembraan CRT vrijkomt 
van CD47, dan verhoogt dat de phagocytose van de betreffende cel door fagocyten. Ver-
der ontdekten wij dat de binding van CRT aan TRAIL geen invloed had op de inductie 
van apoptose door TRAIL. Concluderend, behandeling van kankercellen met TRAIL heeft 
direct invloed op CRT aan het celoppervlak van kankercellen. Deze bevinding kan wellicht 
verder implicaties hebben voor het ontwikkelen van een antikanker immuunreactie.
Conclusies
In dit proefschrift hebben wij laten zien dat het selectief afleveren van TRAIL, of rationeel 
ontworpen varianten van TRAIL, aan het oppervlak van kankercellen deze kankercellen 
kan doden. Ook hebben wij laten zien dat de antikanker activiteit van T-cellen versterkt kan 
worden door het selectief afleveren van TRAIL aan het oppervlak van deze cellen. Onze 
data toont verder aan dat scFv:TRAIL fusie eiwitten, die tevens gebruik maken van het 
zogenaamde ‘dual signalling concept’, de groei van kankercellen op meerdere manieren 
kunnen remmen en dat dit resulteert in een versterkte antikanker werking. De behaalde 






Geachte lezer, het is dan eindelijk zover. U bent aangekomen bij het laatste hoofdstuk van 
dit proefschrift. Voor degenen onder U die dit werk van begin tot eind hebben doorgelezen 
zal dit vast als een opluchting komen. Voor degenen die dit werk snel hebben doorgebla-
derd om er achter te komen of U wel of niet vermeld wordt in het dankwoord: ik hoop U niet 
teleur te stellen.
Allereerst zou ik graag mijn begeleider en co-promotor Wijnand Helfrich bedanken. Beste 
Wijnand, ongeveer vijf jaar geleden kwam ik naar je toe met het verzoek of ik in de groep 
Tumor Immunologie een klein stageproject kon lopen om de laatste benodigde studiepun-
ten van mijn opleiding Medische Biologie te behalen. De oorspronkelijke drie maanden zijn 
dankzij jouw inzet uiteindelijk veel langer geworden. Bedankt voor de kans om te werken 
aan dit leuke KWF project en voor alle gesprekken en discussies in de afgelopen vijf jaar. 
Ik kijk met veel genoegen op onze samenwerking terug!
Niet in mindere mate wil ik mijn andere co-promotor Edwin Bremer bedanken. Toen ik net 
aangesteld was als promovendus lag er een vriendelijk verzoek van een drietal reviewers 
om het manuscript behorende bij hoofdstuk 4 iets aan te passen. Ik hoor de woorden nog 
klinken: “dat kan Marco mooi doen”. Hiermee kreeg ik meteen een uitgelezen kans om mee 
te werken, en mee te schrijven aan mijn eerste wetenschappelijke artikel. Edwin, bedankt 
voor deze kans, voor onze vele brainstorm sessies, en voor alle kneepjes van het vak die 
ik in de afgelopen vijf jaar van jou heb geleerd!
Douwe Samplonius, zonder jouw inzet was dit proefschrift nooit tot stand gekomen. Jij hebt 
letterlijk bloed, zweet en tranen in dit werk gestopt. Okay, ik geef het toe, voor dat laatste 
moet je nog wel even een traantje wegpinken bij dit dankwoord. Beste Douwe, ik heb de 
afgelopen vijf jaar met ontzettend veel plezier met jou samengewerkt, samen gedacht, 
samen gebloed, samen gelachen, en af en toe ook samen flink gebaald. Ik hoop dat we in 
de toekomst nogmaals de kans zullen krijgen om samen te werken. Oh ja, en je bent me 
ook nog een draaiorgelconcert schuldig.
Bram ten Cate, toen ik net als promovendus begon was jij al een aardig eind op weg, en 
aan jou dus ook de taak om mij op het lab te begeleiden. Samen met Theo Bijma hebben 
jullie mij volledig wegwijs gemaakt en mij het hoe en wat van de belangrijkste experimen-
tele handelingen geleerd. Bram en Theo, bedankt hiervoor, en bedankt voor al het plezier 
dat we samen op het lab beleefd hebben. Theo, als je nog aanraders wilt voor slechte films 
hoor ik het graag.








rens, hoewel we niet heel erg lang hebben samengewerkt wil ik hier wel even stilstaan 
bij de bijdragen die jullie hebben geleverd aan het tot stand komen van dit proefschrift. 
Bedankt voor alle hulp, advies en experimenten die we samen hebben gedaan. Marleen, 
succes met het afronden van jouw eigen proefschrift de komende tijd.
Valerie Wiersma en Jurjen Gersen, nu ik op het punt sta te gaan promoveren staan jullie 
relatief gezien nog aan het begin van jullie KWF “reis”. Gelukkig hebben we al wel de kans 
gehad om succesvol samen te werken aan een aantal projecten. Ik wens jullie veel plezier 
en succes de komende jaren en ben er volledig van overtuigd dat jullie erin zullen slagen 
het project tot een goed einde te brengen.
Yunwei Wei, thank you for all the help and advice you gave me during the time we worked 
together. I hope to see you once again in the near future and wish you the best of luck with 
your own thesis.
Ate van der Zee en Lou de Leij, mijn promotoren, wil ik graag bedanken voor alle feedback 
en productieve gesprekken tijdens mijn promotie periode. Tevens wil ik hierbij graag de 
leden van de leescommissie, Hans Nijman, Steven de Jong en Wim Quax bedanken voor 
het kritisch doorlezen van het proefschrift.
Jelleke Dokter en Bart Jan Kroezen, wij hebben voornamelijk de kans gehad om samen te 
werken toen ik nog bij de Medische Biologie zat, maar ook na onze verhuizing waren jullie 
altijd bereid om me bij te staan met advies, reagentia en cellen. Bedankt voor alles wat ik 
van jullie geleerd heb en voor de altijd, leuke en vriendelijke gesprekken.
Mijn collegae van het chirurgisch onderzoekslaboratorium wil ik hierbij ook graag bedan-
ken voor alle hulp en plezier die ik de afgelopen twee jaar van jullie heb mogen ontvangen. 
Een speciale vermelding hierbij voor Jacco Zwaagstra. Beste Jacco, bij elk verzoek of 
probleem trad je snel, hulpvaardig en daadkrachtig op. Bedankt hiervoor.
Joan Vos en Niels Kouprie, jullie waren altijd bereid om de tijd te nemen voor het afnemen 
van een paar buisjes bloed. Zonder jullie hulp was het werk in hoofdstuk 6 niet mogelijk 
geweest. Bedankt hiervoor en voor de altijd gezellige gesprekken. 
Henk Moes en Geert Mesander, er zat geen saai bezoek aan het flow cytometrie centrum 





Klaas Sjollema, bedankt voor het nooit aflatend enthousiasme en alle hulp de afgelopen 
jaren bij het opzetten van “gekke” microscopie experimenten. Ik zal met veel plezier blijven 
terug kijken op het “aantikken” van T-cellen.
Tevens wil ik via deze weg alle medewerkers van de centrale dienst proefdieren, de animal 
welfare officers en de secretaris van de dierexperimentele commissie bedanken voor alle 
hulp bij het opzetten en uitvoeren van dierexperimenteel werk.
Mijn vrienden, Gabriela, Lisanne, Martijn, Rory en Steven. Ongelofelijk dat we elkaar nu al 
ongeveer 10 jaar kennen. Ik wil jullie hierbij van harte bedanken voor alle ontspanning en 
lol die ik de afgelopen vijf jaar met jullie heb gehad op, onder andere, onze vrijdagen. Ex-
cuus voor die keren dat ik er even een paar uurtjes tussen uit moest om nog wat te meten 
op het lab. Ik ben blij dat ik goede mensen zoals jullie tot mijn vrienden mag rekenen.
My “newer” friends, Daan en Magda. Since we met, we have shared three weddings, sev-
eral birthdays and even a Christmas together. Thank you for all the help and support you 
gave both me and Anna during our PhDs. I hope we can continue to remain good friends 
for years to come.
I would also like to thank my Polish family. Mirosławo, Andrzeju, Dawidzie i Klaudio, 
chciałbym Wam z całego serca podziekować za Wasze wsparcie. Dawidzie, mój bracie 
z innej matki, od czasu naszego pierwszego spotkania, utkwiły w mojej pamięci Twoje 
następujące słowa: “opiekuj się nią dobrze”. Mam nadzieję, że Cię nie zawiodłem. Moja 
nowa siostro, Klaudio, i Dawidzie, w przeciągu tych lat spedziliśmy razem tyle zabawnych 
momentów. Były one dla mnie zawsze źródłem wielkiego relaksu. Życzę Wam obojgu 
również powodzienia z kończeniem Waszych studiów. Mirko, zawsze wierzyłaś, że mogłem 
zajść tak dalego (nie w sensie, że „do Polski”) i chciałbym Ci za to serdecznie podziękować. 
Dziękuję Ci za miłe chwile spędzone w Twoim towarzystwie. Mam nadzieję, że rozciągną 
się one na wszystkie kolejne lata spędzone razem w Polce i w Holandii.
Mijn broer Paul, je hebt me tijdens mijn promotietraject altijd bijgestaan met raad en daad. 
Bedankt voor al je steun, het plezier dat we altijd samen hebben, je hulp bij het invriezen 
van een verlovingsring en het feit dat je bij twee huwelijken mijn getuige hebt willen zijn. 
Het duurt nu niet lang meer voordat je zelf gaat promoveren, dus alvast veel plezier en suc-
ces gewenst daarbij. Krisztina, in the time that we have known each other I have come to 
think of you as a sister. Thank you for all the fun times we have had in the last three years. 
I hope we will continue to do so in the future. Now on the eve of my thesis defense, I hope 








Mijn ouders, Meta en Henk, het zal geen verassing zijn als ik zeg dat zonder jullie dit proef-
schrift er niet geweest zou zijn. Jullie opvoeding en steun heeft mij grotendeels gevormd tot 
de persoon die ik vandaag de dag ben. Zelfs toen ik er niet in geloofde dat ik misschien ooit 
zo ver zou kunnen komen deden jullie dat wel. Bedankt voor alle steun die ik in mijn leven 
van jullie heb ontvangen. Ik had me geen betere ouders kunnen wensen.
Ania, moja żono, when we started our PhD adventure together we also started our per-
sonal adventure by living together. Over the past five years, we have grown both person-
ally and professionally. We even had the pleasure of combining a bit of both worlds at our 
wedding last year, with a large UMCG delegation present. You have stood by me through 
everything, all the time, and there are no words that can describe the joy and love that I 
have felt being with you. I am looking forward to spending the rest of my life with you. Fi-
nally, thank you for all the times you used your witchy powers to reassure me of my work. 
Kocham Cie bardzo, Sówka!
Als laatste wil ik hier verder iedereen bedanken die ik niet bij naam genoemd heb, maar 
die op de een of andere manier wel betrokken is geweest bij het tot stand komen van dit 
proefschrift. Zonder al jullie hulp was dit niet mogelijk geweest. Bedankt!
Ceterum autem censeo, Carthaginem delendam esse.
Marco
